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Summary 
Development of New Two-Component Alkyne Metathesis Catalysts 
The last couple of years have seen considerable progress in alkyne metathesis. This 
development led to catalysts with remarkable activity and functional-group tolerance as 
demonstrated in highly advanced applications.[1] However, substrates with (multiple) protic 
sites still cause problems. Therefore we submitted the current catalyst generation based on 
Mo-alkylidynes with monodentate siloxy ligands to an extensive screening. The acquired 
information was then used for the design of a new catalyst generation based on 
multidentate siloxy ligands. We have established an efficient, scalable method to form 
tridentate silanols of type 3 via hydrosilylation of triolefin precursors 1 with chlorosilanes 2 
and subsequent hydrolysis (Scheme 1). 
 
Scheme 1: General synthesis for tridentate silanol ligands 3. 
The catalysts are generated in situ from the known molybdenum alkylidyne[2] 4 and silanols 
3a-c by ligand exchange (Scheme 2). Gratifyingly they show excellent stability and tolerate 
substrates containing free alcohols and highly coordinating groups. Their potential was 
further underlined by the ring closing alkyne metathesis (RCAM) reaction of diynes with two 
protected or unprotected hydroxy groups in propargylic positions. Moreover, they enabled 
three natural product syntheses where other commonly used catalysts failed. 
 
Scheme 2: Metathesis reactions with new two-component catalyst systems. 
 
 
 
Stabilization of α-Helical Peptides Using RCAM 
Hydrocarbon-stapled peptides are a promising tool for targeting challenging protein-protein 
interactions, that are not accessible via classic small molecule approaches.[3] One way to 
enforce an α-helical conformation is the introduction of an all-hydrocarbon macrocyclic 
bridge connecting two turns of a helix (Scheme 3).[4] To accomplish this goal a hydrocarbon 
tether was introduced by RCAM using immobilized precursors 5. Impressingly all (protected) 
functionalities present in the 20 proteinogenic amino acids were tolerated. 
 
Scheme 3: RCAM approach to stabilize α-helical peptides. 
Additionally, we successfully accomplished the synthesis of adjacent and intertwined bicyclic 
peptides via tandem ring closing olefin metathesis (RCM) and RCAM reactions. In order to 
further functionalize the macrocyclic scaffolds the immobilized alkyne was submitted to 
hydration, dibromination and azide-alkyne cycloadditions, which allowed us to introduce 
sidechains containing biomolecules such as sugars or biotin.  
 
Formal Total Synthesis of (+)-Aspicilin 
We have demonstrated the feasibility of constructing an E,E-diene in a macrocyclic molecule 
within a formal synthesis (+)-Aspicilin (7). In this synthesis we found that the 18-membered 
macrocyclic core structure 9 could be achieved via RCAM at high reaction temperature and 
under strict control of the reaction time (Scheme 4). Furthermore, we applied a newly 
developed hydrostannylation methodology for the first time on a macrocyclic 1,3-enyne.[5] 
The formal synthesis of (+)-Aspicilin was completed in 14 steps with an overall yield of 10% 
for the longest linear sequence of ten steps. 
 
Scheme 4: Retrosynthetic analysis of (+)-Aspicilin 7. 
 
 
Zusammenfassung 
Entwicklung Neuer Zwei-Komponenten-Alkinmetathese-Katalysatoren 
In den letzten Jahren wurden beträchtliche Fortschritte auf dem Gebiet der Alkinmetathese 
erzielt, was zu Katalysatoren mit bemerkenswerter Aktivität und Toleranz gegenüber 
funktionellen Gruppen führte. Dies wurde in zahlreichen herausfordernden Anwendungen 
demonstriert.[1] Substrate mit einer oder mehreren protischen Funktionalitäten bleiben aber 
oft problematisch. Daher wurde die aktuelle Katalysatorgeneration einer erweiterten 
Substratkompatibilitätsprüfung unterzogen. Die so gewonnenen Informationen wurden in 
das Design neuer Katalysatoren einbezogen, welche auf multidentaten Siloxy Liganden 3 
basieren. Für diese haben wir einen effizienten und skalierbaren Zugang ausgehend von 
Triolefinen 1 durch Silylierung und Hydrolyse geschaffen (Schema 1). 
 
Schema 1: Generelle Synthese von tridentaten Silanolen 3. 
Die Katalysatoren wurden ausgehend vom Alkylidin 4 und dem jeweiligen Silanol 3a-c in situ 
durch Ligandenaustausch hergestellt (Schema 2). Sie zeigten eine herausragende Stabilität 
selbst unter verschärften Reaktionsbedingungen. Des Weiteren wurde eine verbesserte 
Toleranz gegenüber Substraten mit freien Alkoholen sowie stark koordinierenden Gruppen 
beobachtet. Diese Befunde konnten z.B. durch die Ringschluss-Alkinmetathese (RCAM) 
Reaktionen von Substraten mit zwei geschützten oder ungeschützten Hydroxy-Gruppen in 
propargylischer Position belegt werden. Ebenso konnten die neuen Katalysatoren in drei   
Totalsynthesen ihre Überlegenheit gegenüber den sonst üblichen Katalysatoren beweisen.  
 
 
Schema 2: Metathesereaktionen mit den neuen Zwei-Komponenten-Katalysatoren. 
 
 
Stabilisierung von α-Helikalen Peptiden durch RCAM 
Peptide, die über Kohlenwasserstoffbrücken stabilisiert sind, gelten als vielversprechendes 
Werkzeug um Protein-Protein-Interaktionen zu adressieren; dies ist durch kleine Moleküle 
oft nicht möglich.[3] Ein Weg zur Stabilisierung der α-helikalen Konformation ist die 
Einführung einer Kohlenwasserstoffbrücke[4], die zwei Windungen der Helix miteinander 
verbindet. Dies ist uns ausgehend vom festphasengebundenen Vorläufer 5 durch RCAM zu 6 
gelungen (Schema 3). Die Methodik tolerierte alle (geschützten) Funktionalitäten der 20 
proteinogenen Aminosäuren. 
 
Schema 3: RCAM zur Stabilisierung α-helikaler Peptide. 
Durch Kombination von Olefinmetathese und Alkinmetathese konnten bizyklische Peptide 
mit benachbarten oder sich überschneidenden Brücken erzeugt werden. Wir konnten 
weiterhin zeigen, dass sich die Alkine mittels Hydratisierung, Dibromierung oder Azid-Alkin-
Cycloaddition weiter funktionalisieren lassen. Letzteres ermöglichte die Einführung von 
Seitenketten mit Biomolekülen wie Biotin oder eines Zuckerderivates. 
 
Formale Totalsynthese von (+)-Aspicilin mittels RCAM und Hydrostannylierung 
Um die kürzlich erzielten Fortschritte in der Reaktionsführung von RCAM Reaktionen zu 
zeigen[6], wurde eine formale Totalsynthese von (+)-Aspicilin (7) durchgeführt. Der 18-
gliedrige Makrozyklus 9 wurde durch RCAM aufgebaut, was nur unter strikter Kontrolle von 
Reaktionszeit und Temperatur selektiv möglich war (Schema 4). Zudem wendeten wir 
erstmalig die neu entwickelte Hydrostannylierung auf ein makrozyklisches Enin an.[5] Die 
formale Synthese von (+)-Aspicilin gelang in 14 Stufen mit einer Ausbeute von 10% in der 
längsten linearen Sequenz von zehn Stufen. 
 
Schema 4: Schlüsselschritte in der formalen Totalsynthese von (+)-Aspicilin. 
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1 Introduction 
1.1 Fundamentals of Alkyne Metathesis 
Complex organic molecules play a crucial role in our modern daily life. A highly important 
methodology to generate those molecules is olefin metathesis. The success of olefin 
metathesis is based on a high level of functional group tolerance, chemoselectivity, 
reliability, user friendliness and the good commercial availability of the catalysts.[7] A lot of 
energy was invested to develop efficient and user friendly systems, allowing this 
transformation to become one of the most commonly used organic reaction.[7] The 
importance of olefin metathesis is also highlighted by the Nobel Prize in 2005, which was 
awarded to Schrock, Grubbs and Chauvin for their fundamental work in this field.[8] 
 
Alkyne metathesis is another effective way to form C-C bonds.[1, 9] It was first described by 
Pennella et al. who showed that WO3 on silica can convert a mixture of 2-pentyne and 2-
butyne to 3-hexyne (Figure 1.1).[10]
 
 
Figure 1.1: Milestones in alkyne metathesis research.[10-11] 
The first homogeneous catalyst for alkyne metathesis was developed by Mortreux and 
Blanchard.[11a] Their work could show that heating a mixture of [Mo(CO)6] and resorcinol to 
160 °C allowed the metathesis of methyltolane 5 to tolane 6 and dimethyltolane 7 to 
1 Introduction 
2 
 
proceed (Scheme 1.1). However, high reaction temperatures and limited functional group 
tolerance led to only a few applications.[1] 
 
Scheme 1.1: The first example for an alkyne metathesis with a homogeneous catalyst. 
Later, considerable efforts have been placed in the synthesis of new alkyne metathesis 
catalysts as shown in Figure 1. The mechanism for alkyne metathesis was proposed by Katz 
and is related to the catalytic cycle proposed by Chauvin for olefin metathesis (Scheme 
1.2).[1, 11b] The alkylidyne A is reacting with the alkyne X in a formal [2+2]-cycloaddition to 
form a metallacyclobutadiene B, for which a second resonance structure C can be drawn. 
After cycloreversion, an alkyne Y and a new active alkylidyne D are formed, which eventually 
closes the catalytic cycle. 
 
Scheme 1.2: Mechanism of alkyne metathesis reaction.  
A couple of years later this mechanistic proposal could be substantiated by experimental 
results.[11c] Schrock and coworkers managed to isolate metallacyclobutadiene species such as 
8 and characterized them via NMR and X-ray analysis (Figure 1.2).[11d, 12] They showed that 
metallacyclobutadienes 8 are catalytically active species, thereby proofing that they play a 
role in the catalytic cycle of alkyne metathesis. 
 
Figure 1.2: Metallacyclobutadiene complexes 8, intermediates in alkyne metathesis reactions. 
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1.2 Applications of Alkyne Metathesis 
In recent years considerable progress was made in catalyst development, leading to a variety 
of applications.[1] Alkyne metathesis reactions can be assigned to four different classes 
(Scheme 1.3).[9d] There are alkyne cross metathesis (ACM) reactions, in which two alkynes (R1 
≠ R2) react with each other to furnish the cross metathesis product and a side product e.g. 
butyne. In a ring closing alkyne metathesis (RCAM) reaction a diyne is closed to furnish cyclic 
alkynes.  
 
 Scheme 1.3: Different reaction patterns of alkyne metathesis.[13] 
Furthermore there are two types of polymerization reactions, namely acyclic diyne 
metathesis polymerization (ADIMET) in which a diyne is polymerized under liberation of 
butyne, and ring-opening alkyne metathesis polymerization (ROAMP) where a cyclic alkyne is 
opened to generate polymeric structures. 
Many interesting products arise from these reactions (Figure 1.3), for example carbazole-
based macrocycle 9, which can be generated through cyclic alkyne oligomerization with high 
selectivity.[11g, 14] Its rigid, planar and conjugated backbone is an interesting structural motif 
to generate nanomaterials with internal channels that could find application in 
optoelectronic devices.[9c]  
Prostaglandin derivative 10 is an example for the application of an ACM reaction.[15] ACM is 
especially successful when the coupling partners have different steric and/or electronic 
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properties to avoid a statistical product distribution.[1] Furthermore, an effective ACM 
reaction of terminal alkynes with propynyl(trimethyl)silane was recently reported.[16] 
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Figure 1.3: Examples for molecules generated with different alkyne metathesis approaches. The C-C 
bonds that were formed through the metathesis reaction are highlighted in red. 
Poly(arylene-ethynylene)s (PAEs) 11-13 are attractive polymers, which can be generated via 
ADIMET in high molecular weights without diyne defects in the backbone that often pose a 
problem when accessing PAEs through Pd/Cu-catalyzed couplings.[9c] PAEs are highly 
interesting for material science since they exhibit interesting electronic and optical 
properties.[17]  
RCAM has been applied in many natural product syntheses since the alkyne is a versatile 
structural motif for further functionalization as shown, for example, in the case of the total 
synthesis of Enigmazole A 14.[18] Furthermore, the first ring closing metathesis of terminal 
diynes (TRAM) was described recently.[11i]  
Disilane polymer 15, which shows interesting optical properties and becomes conducting 
upon treatment with SbF5, is generated from a cyclodiyne through ROAMP.
[9c, 19] However, 
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there are only few application for ROAMP[19-20] probably due to the lack of suitable 
substrates.[9c] 
The applications illustrated above show the variety of research fields that can benefit from 
alkyne methesis reactions, ranging from material since and supramolecular chemistry to the 
total synthesis of natural products aiming at the identification of drug candidates. A 
description of the catalysts utilized to synthesize most of the molecules displayed above is 
found in chapters 3 and 4.  
2 Alkyne Metathesis Catalysts Based on Siloxy Ligands 
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2 Alkyne Metathesis Catalysts Based on Siloxy Ligands 
2.1 Introduction 
2.1.1 Molybdenum Nitrido Complexes with Siloxy Ligands 
In recent years remarkable progress was achieved leading to highly active, user friendly 
alkyne metathesis catalysts that bear a broad tolerance towards functional groups. This 
development has produced air-stable alkyne metathesis precatalysts that can be stored on 
the bench for several years and easily be activated in situ.[11g, 21]  
At the beginning of this development stood nitrido complex 19, which was treated with 
different alcohols, phenols or silanols to generate precatalysts like 20 in situ (Scheme 2.1). 
Nitrido complex 20 is converted to the active alkylidyne 21 by reacting with alkynes.[21] In 
this way, triphenylsilanol was found to be the ligand of choice since it is commercially 
available and offered highly active catalysts.[21]  
 
Scheme 2.1: Generation of the active alkylidyne 21 from nitrido precatalysts 19. 
The nitrido precatalysts 20 could be stabilized by pyridine[21], which led to adduct 22 that can 
be handled in air (Figure 2.1). Pyridine adduct 22 is activated by heating to 80 °C in the 
reaction mixture. Basically unlimited stability was achieved by stabilizing the complex with 
1,10-phenanthroline 23.[11g] In this case, the active species can be generated by treatment 
with MnCl2. 
 
Figure 2.1: Stabilized forms of nitrido complex 20. 
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The potential of these catalysts was proven in several natural product syntheses. The 
pyridine adduct 22 was successfully applied in the synthesis of (−)-Nakadomarin A[22] and 
Cruentaren A[23]. Mixtures of nitrido complex 19 and triphenylsilanol were used in the 
syntheses of Cruentaren A[24] and (±)-Haliclonacyclamine C[25]. However, the development 
soon moved on to molybdenum alkylidyne complexes, since only a small portion of the 
nitrido complex 20 is reacting to the actual catalyst, alkylidyne 21, indicating that already 
small amounts of the alkylidyne 21 are highly active.[1] 
2.1.2 Molybdenum Alkylidyne Complexes with Siloxy Ligands 
In order to get hold of the supposedly highly active alkylidynes, tribromo alkylidyne complex 
26, which is accessible through a scaleable and efficient synthesis from molybdenum 
hexacarbonyl via the Fischer-Carbene 24 and the Schrock-Alkylidyne 25, was used as the 
starting compound (Scheme 2.2).[26] 
 
Scheme 2.2: Gram scale synthesis of catalyst precursor 26. Conditions: a) ArLi, Et2O, rt; b) Me4NBr, H2O, rt; 
c) oxalyl bromide, CH2Cl2, ─78 °C to ─20 °C; d) Br2, DME, CH2Cl2, ─78 °C to rt. 
When using KOSiPh3 as the ligand source, tribromo alkylidyne complex 26 was selectively 
transferred to the ate-complex 27 by using 4 equiv of the silanolate (Scheme 2.3).[26a] With 3 
equiv of KOSiPh3 the neutral complex 28 could be selectively generated. In solution, the ate-
complex 27 is in equilibrium with small amounts of the neutral complex 28, which is actually 
the active species. Both compounds are highly active, but not stable in air. By adding 1,10-
phenanthroline to the ate complex 27, an air stable, easy to handle precatalyst 3 could be 
isolated on gram scale. Precatalyst 3 can be activated similarly to the nitro complex 23 by 
the addition of MnCl2 or ZnCl2.  
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Scheme 2.3: Synthesis of modern alkyne metathesis catalysts based on siloxy ligands. 
Catalyst 28 and congeners tolerate a broad variety of functional groups such as esters, 
ethers, nitriles, pyridines, thiophenes and in some cases also protic groups.[1, 6, 11g, 26a] To 
demonstrate the potential of those new catalysts, the ate-complex 27 was successfully 
applied in several total syntheses in our group, such as Tulearin C[27], (R,Z)-5-Muscenone[28], 
5,6-Dihydrocineromycin B[29], Enigmazole A[18], Hybridalactone[30] and Ecklonialactones A, B, 
and C[30]. The neutral complex 28 was successfully applied in the syntheses of Brefeldin A[31], 
Mandelalide A[32] and the formal total synthesis of Kendomycin[33]. 
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2.2 Aims and Scope 
As discussed before, metathesis catalyst 28 tolerates a variety of functional groups. 
However, the functional group tolerance was not comprehensively tested, leaving out some 
synthetically interesting structural motifs such as secondary or tertiary amines, azides, 
primary alkyl halides, indoles, sulfoxides, sulfonamides among others. Therefore we sought 
to perform an extensive substrate scope screen for catalyst 28 to determine the limits of 
substrate tolerance. Furthermore, we set out to investigate the compatibility of free hydroxy 
groups, either aromatic or aliphatic, with alkyne metathesis.  
2.3 Extended Substrate Scope of [Mo(≡CC6H4OMe)(OSiPh3)3]  
2.3.1 Homo Metathesis Reactions 
The syntheses of the investigated substrates are described in the experimental section 
(Chapter 7.2.2). The reactions were first carried out with a catalyst loading of 2 mol% at 
room temperature and the progress was monitored by TLC or GCMS. Catalyst loading, 
temperature and time were individually modified to achieve best results. Only the highest 
yielding conditions are displayed in the Table 2.1. 
 
Table 2.1: Intermolecular metathesis reaction with [Mo(≡CC6H4OMe)(OSiPh3)3] (28) of alkynes of the 
general type RC≡CMe. 
OH
29a
OHHO
30a
OH
29b
HO OH
30b
HO
29c
O
31
OH
6
32
OH
6
HO
6 33
5
OH
34
5
OH
OH
5
35
80 3 3 87
80 5 7 93
80 5 48 -a
120 5 14 -b
80 7 24 66
1
2
3
4
5
entry substrate product temp. [°C] 28 [%] time [h] yield [%]
a) No dimerization product was observed, only starting material and cyclization product 31 
b) Only starting material recovered 
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a) Starting material and decomposition 
b) Only starting material recovered 
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a) Only starting material recovered 
 
The investigations showed significant reactivity differences depending on the chemical 
surrounding of the hydroxy groups. In general, elevated temperatures were necessary to 
effectively convert substrates containing free hydroxy groups. Substrates 29a and 29b with 
phenolic ─OH groups in the para- or meta-position respectively were tolerated (Table 2.1, 
Entry 1-2) while substrate 29c with a hydroxy group in the ortho-position only led to 
benzofuran 31 (Table 2.1, Entry 3). Secondary alcohol 34 is still moderately well tolerated, 
while primary alcohol 32 deactivates the catalyst (Table 2.1, Entry 4-5). Furthermore, 
substrates with free hydroxy groups in propargylic or homopropargylic position did not 
undergo homo metathesis reaction at all. 
For amines we observed similar trends. Para-substituted aniline 36a did not lead to full 
conversion, therefore only moderate yields were observed, while ortho substituted aniline 
36b did not react at all (Table 2.1, Entry 6-7). The tertiary amine 38a posed no problem, 
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while secondary amine 38b needed prolonged reaction time, and the primary amine 38c was 
not tolerated at all. When the primary amine 38c was protected as a phthalimide 38d, the 
metathesis reaction proceeded successfully (Table 2.1, Entry 8-11). This indicates that more 
sterically hindered amines are tolerated, while unhindered primary amines deactivate the 
catalyst.  
Highly coordinating Weinreb amide 40 needed a higher catalyst loading, an increased 
temperature and prolonged reaction time, and could only be metathesized in moderate 
yield due to incomplete conversion (Table 2.1, Entry 12). Furthermore, we compared a row 
of α-acidic compounds. While malonate 44 reacted smoothly, acetoacetate 42 needed a 
higher catalyst loading (Table 2.1, Entry 13-14). For substrate 46, where the malonate is in 
propargylic position, no reaction was observed (Table 2.1, Entry 15). Amino acid derivative 
48 and indole 50 could be effectively metathesized (Table 2.1, Entry 16-17). 
A ketone next to the alkyne 53b did not undergo a homo metathesis reaction, probably due 
to the electron poor character of the alkyne. Surprisingly the sterically demanding acetal 
derivative 53a was metathesized efficiently (Table 2.1, Entry 18-19). Thioether 55a was also 
accepted, while sulfoxide 55b needed a higher temperature, as well as an increased catalyst 
loading and a longer reaction time, probably due to its coordinating character (Table 2.1, 
Entry 20-21). Bromide 57, iodide 59 and azide 61 were tolerated without problems in homo 
metathesis reactions (Table 2.1, Entry 22-24).  
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2.3.2 ACM Reactions 
Substrates 53b, 66, and 68 did not undergo homo metathesis in any of the attempted 
reaction conditions. However, this lack of reactivity does not allow for the evaluation of the 
substrates´ capacity to undergo alkyne metathesis. Therefore we submitted these substrates 
to cross metathesis reactions with highly reactive alkynes such as 4-octyne (63) or bromo 
alkyne 57 in order to determine their ability to participate alkyne metathesis. 
Table 2.2: Cross metathesis reactions with [Mo(≡CC6H4OMe)(OSiPh3)3] 28.
a) MnCl2 (20 mol%) was added. 
 
Since alkyne 53b with a ketone in propargylic position did not undergo homo metathesis, we 
tried an ACM reaction with 4-octyne (63). Elevated temperatures and the addition of MnCl2, 
which probably coordinates to the ketone and therefore avoids its coordination to the 
molybdenum catalyst, were needed in order to allow the reaction to proceed (Table 2.2, 
Entry 1). Acetal derivative 53a reacted smoothly with 4-octyne (63) (Table 2.2, Entry 2), in 
analogy to the homo metathesis results (Table 2.1, Entry 18). Neoheptyne 66, which did not 
undergo homo metathesis due to sterical hindrance, could be coupled to bromo alkyne 57. 
Coupling of neoheptyne 66 to the borane 68 was possible even though the yield was low due 
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to isolation problems (Table 2.2, Entry 3-4). We further examined amino acid derivative 48 
which gave the desired cross metathesis product 70 when a high excess of 4-octyne (63) was 
used (Table 2.2, Entry 5). It is also noteworthy that a strict control of the reaction time was 
necessary in this case, since the homo coupling product of amino acid derivative 48 
accumulated during the reaction.  
2.4 Conclusion 
In conclusion, catalyst 28 tolerates substrates with challenging structural motifs such as 
secondary or tertiary amines, an azide, primary alkyl halides, an indole, a thioether, a 
sulfoxide, or a sulfonamide. However, substrates with protic groups are not generally 
tolerable under reaction condition. While certain substrates with protic functionalities like 
phenols in para- or meta-position to the alkyne or a secondary alcohol could be successfully 
homo metathesized, a compound containing a primary alcohol failed to give the desired 
homo metathesis product. We hypothesize that protic substrates outcompete the Ph3SiO-
groups for the metal center thus forming an unreactive metal species incapable of catalysis. 
Furthermore, substrates with highly coordinating groups such as Weinreb amides or free 
primary amines may deactivate the catalyst by blocking the coordination site that is needed 
for the reaction. Sterically demanding substrates like neoheptyne 66 were found to be 
incompetent for homo metathesis reaction but capable of ACM reactions with sterically less 
demanding substrates.  
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3 Alkyne Metathesis Catalysts Based on Multidentate Ligands 
3.1 Introduction 
Having demonstrated that substrates with protic groups can hinder alkyne metathesis 
(Chapter 2), we hypothesized that rendering the ligands more stable towards replacement 
by these substrates would improve the reactivity of the catalysts. In order to achieve these 
ends, multidentate ligands and their chelating effect will be discussed in this chapter. 
3.1.1 Early Molybdenum-Based Alkyne Metathesis Catalysts 
The molybdenum-based alkyne metathesis precatalyst 72 can be generated from a 
molybdenum(III) species 2, which was originally introduced for molecular nitrogen splitting 
by Cummins.[34] Upon treatment with CH2Cl2 in toluene, 2 reacts to chlorocomplex 71 and 
methylidynecomplex 72 (Scheme 3.1).[1, 11f, 35] The catalytically active species has 
demonstrated good functional group tolerance as evident from its employment in the 
syntheses of natural products Latrunculin A, B, C, S[36], Myxovirescin A1
[37], Cruentaren A[38] , 
Amphidinolide V[39], and Leiodermatolide[40]. 
 
Scheme 3.1: Activation of Cummin´s catalyst with CH2Cl2. 
Moore later showed that molybdenum(III) species 2 reacts with 1,1-dichloropropane to give 
the propylidyne complex 73 (Scheme 3.2).[41] The undesired chlorocomplex 72 can be 
selectively reduced to the starting molybdenum(III) species with magnesium while 
propylidyne complex 73 stays unaffected. The synthesis can be done on a gram scale.[42] 
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Scheme 3.2: Reductive recycle approach to molybdenum(VI) alkylidyne complex 73. 
The main drawback of this catalyst is that molybdenum(III) species such as 2 are highly 
sensitive to hydrolysis or oxidation and even react with N2, which leads to preparative 
difficulties.[1] Nevertheless, molybdenum alkylidyne 73 has found several applications in 
synthesis as a precatalyst, which can generate highly active catalysts in situ by treatment 
with three equivalents of phenols (in particular p-nitrophenol).[14a, 41, 43] Additionally, 
alkylidyne 73 can be immobilized on silica to yield highly active heterogeneous metathesis 
catalysts.[44] 
3.1.2 Alkyne Metathesis Catalysts with Multidentate Ligands 
Studies by Moore and coworkers have shown that sterically undemanding ligands such as p-
nitrophenol can lead to the polymerization of small substrates like 2-butyne.[2] This happens 
by a ring expansion mechanism through a repeated insertion of the alkyne substrates into 
the Mo-C bond (Scheme 3.3). 
Mo(OR)3
Et
(RO)3Mo (RO)3Mo
Et
(RO)3Mo
Et
n
+
n
 
Scheme 3.3: Ring expansion side reaction deactivating metathesis catalysts. 
Furthermore, alkyne metathesis catalysts based on monodentate phenol ligands show 
stability issues which are limiting their spectrum of applications. To address these problems, 
Zhang investigated the use of multidentate phenol ligands.[11h] Their chelating effect should 
increase the stability and lifetime of the catalyst and the linker could block the free 
coordinating site on the metal to prevent polymerization as well as non-productive substrate 
binding.[45] 
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Zhang´s catalysts 4a and 4b are generated in situ from molybdenum propylidyne 73 with the 
trisubstituted amine ligands 74a and 74b respectively (Scheme 3.4). 
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O O
O
NO2
NO2
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4b: R = NO2
Mo
Et
N
N
N
or
OH
NO2
OH
R
N
3
or
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Scheme 3.4: Phenol-based, in situ generated metathesis catalysts.  
4a was unable to promote the metathesis reaction of 4-propyneanisole even at elevated 
temperatures (70 °C). In sharp contrast, 4b proved reactive and showed a significant 
improvement of catalytic activity, lifetime and substrate scope compared to the 
monodentate analogue 75.[45] The Lewis acidity of the molybdenum center is highly reduced 
by the donating effect of the nitrogen linker and the nitro groups in 4b are needed to render 
the phenol more electron deficient.[46] It had already been shown before, that lower electron 
density on the molybdenum center improves the catalytic activity.[47] 
To address this problem Zhang`s group designed catalysts 76a-c based on tri(arylmethyl)-
ammonium ligands with a non-coordinating quaternary nitrogen linkers (Figure 3.1).[45] The 
introduction of a quaternary nitrogen linker increased the electrophilicity of the 
molybdenum center in catalysts 76a-c as compared to catalyst 4b. This increase in 
electrophilicity resulted in the improved catalytic activity of catalysts 76a-c when compared 
to 4b. Furthermore, no alkyne polymerization side reactions were observed when catalysts 
76a-c were used. However, the ionic character of the ligand led to solubility issues in organic 
solvents.[46] They also studied the electronic effects on metathesis activity by varying the 
substitution pattern of the phenol using 4-nitropropynylbenzene as test substrate. While 
catalyst 76a showed a low conversion of 43%, catalysts 76b and 76c enabled conversions of 
61% and 64% respectively, which demonstrates the importance of electrophilicity at the 
metal center.[45] 
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Figure 3.1: In situ generated metathesis catalysts76a-c based on quaternary-nitrogen-linked ligands. 
Zhang further continued this project and designed ligands such as triphenol 82b with a 
silicon linker in order to avoid the previously mentioned problems caused by tertiary or 
quaternary nitrogen linkers.[46] The access to ligand 82b is achieved through a five step 
synthesis from commercially available aldehyde 77 (Scheme 3.5). Aldehyde 77 is converted 
through ethoxymethyl protection and subsequent reduction to alcohol 79. Alcohol 79 is 
brominated with NBS to bromide 80 that is metallated and reacted with MeSiCl3 to give, 
after deprotection of acetal 81, the desired triphenolsilane-based ligand 82b.  
 
Scheme 3.5: Representative synthesis of multidentate triphenol silane ligand 82b. Conditions: a) EtOMCl, 
DIPEA, DMAP, CH2Cl2, rt, 97%; b) NaBH4, MeOH, 0 °C, quant.; c) NBS, PPh3, CH2Cl2, rt, 77%; d) Mg, THF, rt, 
then MeSiCl3, rt, 82%; e) PPTS, i-PrOH, 70 °C, 66%. 
With ligand 82b in hand, catalyst 83b was generated in situ upon addition of alkylidyne 
complex 73 (Figure 3.2).[46]  Catalyst 83b proved to be a highly reactive species allowing for 
the homo metathesis of challenging substrates such 3-(prop-1-yn-1-yl)phenol (29b). The 
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catalyst generated with ligand 82b remained active in solution for days at room 
temperature.  
The catalytic activities of in situ generated catalysts 83 were evaluated by using 4-
nitropropynylbenzene as a test substrate. Catalyst 83a gave an isolated yield of 54%, catalyst 
83b gave 58%, and catalyst 83c furnished 54%, indicating that the ligands´ sterics barely 
affects the catalysts´ activity. 
 
Figure 3.2: In situ generated triphenol silane catalysts 83a-c.  
Zhang could successfully apply his catalysts in a variety of applications like the synthesis of 
shape persistent porphyrin-based molecular cages[48], interlocked organic cages[49], ionic 
covalent organic frameworks with spiroborate linkage[50] and highly porous poly(arylene-
ethynylene) networks[51]. A major drawback of these catalysts is that the reactions are 
carried out in the highly cancerogenic and expensive solvent tetrachloromethane which 
makes this system unattractive especially for RCAM where high dilutions are needed.[46] 
Until now catalysts that are based on monodentate siloxy ligands are still superior 
concerning activity, synthesis and handling.[11g, 26a] It seems promising to combine the 
concept of multidentate ligands with the superior electronic properties of siloxy ligands. 
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3.2 Aims and Scope 
As described in chapter 2, the latest generation of alkyne metathesis catalysts based on 
siloxy ligands are powerful systems, being able to convert a broad variety of substrates. 
Nevertheless several applications showed that free hydroxy groups can deactivate the 
catalysts presumably through a ligand exchange which renders the catalyst inactive. In order 
to avoid this problem we decided to design more stable ligands which should improve the 
catalysts´ performance. So far siloxy-based ligands proofed to be superior to other ligand 
types due to their favorable electronic character. Therefore we decided to keep this 
structural motif but link the silanolates on a common backbone to generate multidentate 
ligands. The stability of the catalysts generated with these multidentate ligands should be 
higher due to their beneficial chelating effect.  
3.3 Catalyst and Ligand Synthesis  
3.3.1 Initial Considerations 
We designed our first target ligands based on the ligand utilized in Zhang´s catalyst 83a 
(Figure 3.3). More precisely, we adopted the ligand-geometry in catalyst 83a for the 
backbone of our ligand as represented in structure E. However, we chose to substitute the 
phenolates of catalyst 83a with silanolates to arrive at alkylidyne complexes such as 84. 
 
Figure 3.3: Design considerations for multidentate siloxy ligands. 
An important point that needs to be kept in mind is the flexibility of the ligands. Ideally they 
should be flexible enough to provide an unhampered access to the molybdenum center even 
for bulky substrates, but on the other hand they must be rigid enough to allow the 
generation and isolation of a defined catalyst species. 
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3.3.2 Multidentate Ligands with Silicon Linkers  
Our first approach towards multidentate siloxy ligands was inspired by Kung, who 
synthesized dentrimeric structures through the hydrosilylation of tetravinylsilane (85) to 
chlorosilane 86, which was converted to acyloxysilane 87 via esterification (Scheme 3.6).[52] 
By repeating this procedure he successfully generated dentrimeric structures. 
 
Scheme 3.6: Literature example for the generation of dentrimeric structures via hydrosilylation. 
Conditions: a) chlorodimethylsilane, Karstedt´s cat., THF, reflux; b) pyridine, 88, toluene, rt. 
Inspired by these results, we planned the synthesis of our target ligands starting from 
trivinylsilanes 90, which should be converted to silanols 89 through hydrosilylation with 
different commercially available chlorosilanes 91 and subsequent hydrolysis (Scheme 3.7). 
89 could be reacted with a molybdenum alkylidyne precursor in order to generate 
metathesis catalysts 84. The synthesis is designed in a way as to allow for an easy variation 
of R1 and R2 in order to investigate electronic and steric effects on catalyst formation, 
stability and reactivity.  
 
Scheme 3.7: Synthetic approach to multidentate silanol ligands via hydrosilylation strategy.  
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The synthesis of target silanols 89 from chlorosilanes 91 and trivinylsilanes 90 proceeded in 
moderate yield on gram scale using Karstedt´s catalyst 92 for the hydrosilylation reactions 
(Scheme 3.8, Entry 1, 2, 4). We further tried to synthesize a methyl derivative 89c, but our 
attempts only led to polymeric materials (Scheme 3.8, Entry 3). Mesityl derivative 89e, which 
we planned to synthesize in order to examine the effect of a sterically demanding 
substituent R2 was not accessible by this strategy due to incomplete hydrosilylation, 
probably caused by steric hindrance (Scheme 3.8, Entry 5).  
 
Scheme 3.8: Synthesis of multidentate ligands 89 with a silicon connecting unit. Conditions: a) Karstedt´s 
cat. 92, toluene, 50 °C to 70 °C; b) NEt3, H2O, rt. 
With these ligands in hand we tried to generate the proposed catalysts 84. Despite 
considerable efforts we did not manage to isolate a defined catalyst species. All attempts to 
synthesize a monomeric species led to inseparable mixtures of compounds probably due to 
the sterically flexible character of our ligands (Scheme 3.9). We think that the ligands 
generate networks between molybdenum centers, leading to oligomeric or polymeric 
materials. 
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Scheme 3.9: Summary of different approaches to generate a defined catalyst species 84. 
In order to evaluate the new ligands we generated the catalysts in situ from molybdenum 
alkylidyne 73 and the corresponding ligands 89 in analogy to Zhang´s methodology described 
in chapter 3.1.2. Phenylpropyne 93 was used as test substrate. The results showed that 
silanols with aromatic substituents R1 lead to fast homodimerization reaction (Scheme 3.10, 
Entry 1, 2). In contrast, a silanol with aliphatic substituents R1 resulted in low conversion 
(Scheme 3.10, Entry 3). The beneficial effect of ligands 89 was verified by a control 
experiment in which molybdenum precatalyst 73 was tested without the addition of silanol 
ligands, which led to a low conversion (Scheme 3.10, Entry 4). 
 
Scheme 3.10: Test reactions with in situ generated catalysts. Conditions: 5 mol% 73 and 5 mol% 89. 
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The catalytic activity of the crude materials was highly promising and surpassed in some 
cases the results obtained with the previous catalyst generation 28 (Chapter 3.4, Tables 3.1, 
3.2, 3.3). However, the ligands did not favor the formation of a defined catalyst species. 
Based on these findings we decided that the ligand design requires optimization. The new 
design should still contain the siloxy motif but a different ligand geometry needs to be found 
in order to get a defined catalyst species. 
3.3.3 Multidentate Ligands with Trisubstituted Aromatic Linkers 
To address the points mentioned above we planned to make use of π-π-interactions in order 
to generate a monomeric species. When using a trisubstituted aromatic linker unit, two of 
the ligands might undergo a stacking interaction and therefore lead to a preorientation of 
the sidechains, which should facilitate the generation of a defined species (Scheme 3.11). 
We decided to synthesize two ligands with different linker lengths: 94a (two carbon atoms) 
and 94b (three carbon atoms). 
 
Scheme 3.11: Ligand design making use of stacking effects. 
Their preparation started from commercial 1,3,5-tribromobenzene (95) which was converted 
to the corresponding trienes 96a and 96b by Stille coupling with vinyltributylstanane or 
allyltributylstannane, respectively (Scheme 3.12). Hydrosilylation of triolefins 96a and 96b 
followed by hydrolysis afforded triols 94a and 94b. The target ligands were synthesized over 
the two steps with an overall yield of 33% on a 150 mg scale for 94a and with 36% on a 
750 mg scale for 94b.  
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Scheme 3.12: Synthesis of multidentate ligand 94 with an aromatic connecting unit. Conditions: a) 
vinyltributylstannane, Pd(PPh3)4, DMF, 135 °C, 80% for 96a; allyltributylstannane, Pd(PPh3)4, DMF, 120 °C, 
76% for 96b; b) Karstedt´s cat., chlorodiphenylsilane, toluene, 70 °C; then NEt3, H2O, rt, 41% over 2 steps 
for 94a; Karstedt´s cat., chlorodiphenylsilane, toluene, 50 °C; then NEt3, H2O, rt, 47% over 2 steps for 94b.  
Disappointingly all attempts to generate a defined species with ligand 94a and 94b failed. 
The reactivity of the catalysts generated from molybdenum precatalyst 73 and the 
corresponding ligands 94a and 94b was highly promising. Both catalysts showed full 
conversions of phenylpropyne 93 to tolane 6 after 15 min reaction time at room 
temperature with a catalyst loading of 5 mol%. 
3.3.4 Multidentate Ligands with Hexasubstituted Aromatic Linkers 
Since trisubstituted aromatic linkers did not lead to a defined species, we decided to stick 
with the aromatic linker and make use of steric effects by introducing further substituents at 
the aromatic core. The envisaged target ligands should contain an aromatic linker with 
alternating ethyl groups and silanol containing sidechains (Scheme 3.13). It can be 
postulated that the substituents will arrange in an alternating orientation through steric 
effects like shown in the literature for comparable hexasubstituted arenes.[53] This would 
lead to a preorientation that could favor the formation of a monomeric species. Therefore 
we decided to synthesize three ligands 97a-c with different linker lengths. 
 
Scheme 3.13: Ligand design with a hexasubstituted aromatic linker. 
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To synthesize our target ligand 97c with a three carbon linker we started from commercial 
1,3,5-triethylbenzene (98), which was converted to hexasubstituted arene 99 through 
bromination (Scheme 3.14). Stille coupling of tribromide 99 with allyltributylstannane led to 
triolefin 100c which was converted to triol 97c by a one pot hydrosilylation/hydrolysis 
process. The target ligand 97c was synthesized over three steps with a total yield of 25% on 
a 0.5 g scale. The synthesis of the two carbon linker analog 97b failed since the 
hydrosilylation reaction did not lead to the desired product in a selective fashion; instead a 
mixture of compounds with different degrees of hydrosilylation was obtained. 
 
Scheme 3.14: Synthesis of multidentate ligands 97 with an aromatic hexasubstituted connecting unit. 
Conditions: a) Br2, Fe, 0 °C -> rt, 76%, b) tributylvinylstannane, Pd(PPh3)4, DMF, 135 °C, 37% for 100b; 
allyltributylstannane, Pd(PPh3)4, DMF, 135 °C, 60% for 100c; c) Karstedt´s cat., chlorodiphenylsilane, 
toluene, 70 °C; then NEt3, H2O, rt, complex mixture 97b; Karstedt´s cat., chlorodiphenylsilane, toluene, 
70 °C; then NEt3, H2O, rt, 54% over 2 steps for 97c. 
X-ray diffraction analysis of triolefin 100c nicely proved our expectation that the substituents 
on the aromatic core would align in an alternating orientation (Figure3.4). 
 
Figure 3.4: X-ray structure of the hexasubstituted aromatic linker 100c showing the alternating 
orientation of the side chains. 
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The tridentate silanol ligand 97c also showed an alternating orientation of the substituents 
(Figure 3.5). In the solid state, however, the hydroxy groups all point to the outside. Based 
on this data it is not possible to conclude, how the ligand will behave in solution and 
whether a monomeric species is likely to be achieved. 
 
Figure 3.5: X-ray structure of multidentate ligand 97c showing the alternating orientation of the side 
chains. 
For the synthesis of the one carbon linker analog 97a we utilized a procedure developed by 
Kabe and coworkers.[53] The synthesis commenced with tribromide 101, which was 
metallated and converted to trisilane 102 with chlorodiphenylsilane (Scheme 3.15). The 
target triol 97a was generated through a bromination/hydrolysis sequence of trisilane 102. 
 
Scheme 3.15: Synthesis of multidentate ligand 97a with a hexasubstituted aromatic linker. Conditions: a) 
Mg, chlorodiphenylsilane, THF, ─20 °C -> rt, 65%, b) NBS, CH2Cl2, rt, then NEt3, H2O, rt, 87% over 2 steps. 
Neither ligand 97a nor 97c furnished a defined catalyst species. The catalysts generated from 
molybdenum precatalyst 73 and the corresponding ligands 97a or 97c were highly active, 
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showing full conversions of phenylpropyne 93 to tolane 6 for 97c and a conversion of 95% 
for 97a after 15 min reaction time at room temperature with 5 mol% catalyst loading. At this 
point we decided to evaluate the feasibility of more constrained ligands for the formation of 
a defined catalyst species. 
3.3.5 Calyx[4]arene- and Silsesquioxane-Based Systems 
Since we were so far not able to isolate any crystalline species probably due to the high 
flexibility of the multidentate ligands shown in chapters 3.3.2 to 3.3.4, we decided to use 
sterically more constrained ligands like calyx[4]arenes 103 or silsesquioxanes 104 (Scheme 
3.16). 
 
Scheme 3.16: Structural considerations for constrained multidentate ligands. 
In order to generate a neutral catalyst from calyx[4]arenes 103a we used a protocol 
developed by Radius[54] to selectively mono-methylate tetra hydroxy calyx[4]arene 103a. The 
resulting calyx[4]arene derivative 103b reacted with molybdenum nitrido complex 19 to 
generate nitrido complex 105 (Scheme 3.17). Nitrido complex 105 was previously described 
by Radius, but it was not evaluated in alkyne metathesis reactions.[55] Even though complex 
105 was air stable and a defined species, its metathesis activity was very low. 
 
Scheme 3.17: Synthesis of calyx[4]arene based catalyst 105b with a methyl-capped hydroxy group. 
Conditions: a) K2CO3, MeI, MeCN, reflux, 58%; b) 19, toluene, rt, 45%. 
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We assume that the low metathesis activity is a result of the coordination of the ether to the 
molybdenum center blocking the free site needed for substrate binding in the metathesis 
reaction (Figure 3.7). This assumption is supported by X-ray structure analysis, which shows 
an O1-Mo1 bond length of 2.228(3) Å (Figure 3.6).[56]  
 
Figure 3.6: X-ray structure of methoxy calyx[4]arene nitrido complex 105b. 
In order to overcome this problem we decided to remove one of the oxygen atoms. A 
tridentate calyx[4]arenes 103c could lead to complex 105c which leaves a free coordination 
site at the molybdenum center. This should allow the unhindered coordination of the alkyne 
during the metathesis reaction. 
 
Figure 3.7: Catalyst design considerations for calyx[4]arene-based catalysts 105b and 105c. 
The synthesis of calyx[4]arene derivative 103c was performed according to a procedure 
developed by Taoufik and coworkers (Scheme 3.18).[57] Calyx[4]arene 103a was converted to 
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the phosphorylated derivative 106 by a silylation/phosphorylation sequence. Birch reduction 
of intermediate 106 yielded the target triol 103c.  
 
Scheme 3.18: Synthesis of calyx[4]arene-based tridentate ligand 103c. Conditions: a) MeSiCl3, TEA, 
toluene, rt; b) n-BuLi, ClP(O)(EtO)2, toluene, rt, 61% over 2 steps; c) K, NH3, toluene, −78 °C, 48%. 
Disappointingly ligand 103c did not furnish an isolatable catalyst species on treatment with 
molybdenum nitrido complex 19 since the crude material could not be precipitated even 
from pentane at ─78 °C. Furthermore, the catalytic activity of the in situ generated systems 
from molybdenum precatalyst 73 and the corresponding ligands 103b or 103c was very low 
(Scheme 3.19, Entry 1, 2). This is probably due to the fact that phenols are electronically less 
favorable for alkyne metathesis applications than siloxy ligands. 
 
Scheme 3.19: Test reactions with in situ generated catalysts. Conditions: 5 mol% 73 and 5 mol% of the 
corresponding ligands 103b-c and 104a-b. 
We also utilized silsesquioxanes for which some preliminary studies had already been 
conducted by Moore.[58] He successfully used catalysts generated from monodentate 
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silsesquioxanes with cyclopentyl residues in alkyne metathesis reactions. Moore also 
described an in situ generated system from a multidentate silsesquioxane with cyclopentyl 
residues and molybdenum alkylidyne 73 which was reported to lead to polymerization of the 
butyne side product. We examined two electronically different silsesquioxanes. While 
silsesquioxane 104a with alkyl residues led to no activity (Scheme 3.19, Entry 3), its analog 
104b bearing aromatic residues afforded a catalytic species with high activity (Scheme 3.19, 
Entry 4). A mixture of 73 and 104b was further evaluated in the homo metathesis reaction of 
primary alcohol 32, leading to low conversion according to TLC. Both silsesquioxanes 104a 
and 104b did not lead to defined species. 
3.3.6 Conclusion  
The studies described above show that multidentate siloxy ligands lead to highly active 
catalyst systems with molybdenum alkylidyne 73 as a precatalyst. The activity depends on 
the substituents on the silicon atom. While ligands with aromatic substituents such as 89a 
and 89d led to highly proficient systems, ligand 89b with aliphatic substituents were less 
appropriate. Furthermore, the geometry of the ligand plays only a minor role, with ligand 89 
(silicon linker) as well as ligands 94 and 97 (aromatic linkers) all forming highly active 
catalysts. In contrast constrained ligands like calyx[4]arenes and silsesquioxanes mainly 
furnished unreactive species probably due to electronic effects and a constrained geometry. 
The only exception was 104b, which furnished a highly reactive system. Our attempts to 
isolate a defined, highly active complex failed due to the formation of product mixtures. 
Gratifyingly, the systems generated in situ from multidentate silanol ligands and 
molybdenum alkylidyne 73 show very good results with complex molecules and in many 
cases significantly surpass the performance of the previous catalyst generation 28 as 
described in the next chapter. 
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3.4 Substrate Scope of In Situ Generated Catalysts  
3.4.1 Homometathesis Reactions 
Some of the catalysts that were generated from molybdenum alkylidyne 73 and the siloxy 
ligands described in Chapter 3.3 showed a promising reactivity. Therefore we decided to 
evaluate the performance of these catalysts with substrates that were found to be 
troublesome for catalyst 28. 
Table 3.1: Homo metathesis reactions. Comparison of [Mo(≡CC6H4OMe)(OSiPh3)3] (28) with systems 
generated in situ from molybdenum alkylidyne 73 and multidentate silanols 89a and 97c. 
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Homo dimerization experiments showed that catalyst 28 gives good yields at elevated 
temperatures when dealing with substrates containing phenolic hydroxy groups (Table 3.1, 
Entry 1-2). When working at room temperature, the performance of catalyst 28 is surpassed 
by the multidentate systems in the case of p-phenol substrate 29a. Substrate 32 containing a 
primary hydroxy group  underwent metathesis reaction when using multidentate systems, 
while 28 did not lead to any significant yields even at elevated temperatures (Table 3.1, 
Entry 3). For substrate 34 containing a secondary alcohol, the yield achieved with 
monodentate system 28 dropped considerably when running the reaction at room 
temperature, while the multidentate systems still produced good yields (Table 3.1, Entry 4). 
Improvements were also observed for the strongly coordinating Weinreb amide 40 when 
using the multidentate systems (Table 3.1, Entry 5). Surprisingly, we did not detect a 
significant difference in the performance of 89a and 97c, indicating that the type of linker is 
rather unimportant for the activity of the catalysts (Table 3.1, Entry 1-5). 
The results can be rationalized by chelating effects which render catalysts with multidentate 
siloxy ligands more stable compared to their analogs with monodentate siloxy ligands. We 
assume that the monodentate ligand in catalyst 28 is more prone to be replaced by protic 
substrates which would render the catalysts less reactive/unreactive. In order to evaluate 
this postulate and to exclude effects that may be caused by the different alkylidynes in 
complex 28 (aryl) and complex 73 (alkyl), we compared catalysts that were generated from 
complex 73 with monodentate ligand 107 or multidentate ligand 97c. 8-Decinol (32) was 
used as a test substrate and both reactions were run for 14 h at room temperature. The 
homodimerization product 33 was isolated in 5% yield when the catalyst generated with the 
monodentate ligand 107 was used (Scheme 3.20, Entry 1). The catalyst generated with the 
multidentate ligand 97c furnished 72% yield, which supports the notion that the multi-
dentate geometry improves the stability towards ligand replacement (Scheme 3.20, Entry 2). 
Scheme 3.20: Comparison of in situ generated metathesis catalysts from multidentate ligand 97c and 
monodentate ligand 107. 
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In general the position of a free hydroxy group is very important for the outcome of alkyne 
metathesis reactions. This is illustrated by the fact that alkynes 108 and 109 with free 
hydroxy groups in either propargylic or homo-propargylic position did not undergo homo 
metathesis reactions (Figure 3.8). Also the o-phenol 29c was not tolerated as well as acid 
110. 
 
Figure 3.8: Substrates that did not undergo homo metathesis reactions with either multidentate or 
monodentate systems. 
3.4.2 RCAM Reactions 
We compared the efficiency of metathesis catalyst 28 and systems generated from complex 
73 with multidentate ligands in the RCAM reactions of substrates containing protected or 
unprotected hydroxy groups in propargylic position.  
For mono-MOM/TES protected substrates 111a and 111b the RCAM reaction proceeded in 
acceptable yield when the system based on complex 73 and multidentate ligand 97c was 
used, while the use of catalyst 28 did not furnish any RCAM products (Table 3.2, Entry 1). 
Mono acetate/benzoate protected substrates 111c and 111d did not lead to cyclization 
products with any of the examined catalysts. 
The crude NMR spectra of the RCAM reactions of diynes 111c and 111d, in which one of the 
hydroxy groups is acylated, showed that an ethyl group is transferred to the side with the 
free hydroxy group (Figure 3.9). Further reaction seems to be unfavorable since no RCAM 
products were observed. 
 
Figure 3.9: Ethyl transfer product generated in the RCAM reactions of mono acetate or mono benzoate 
protected diynes 111c-d. 
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Table 3.2: RCAM reactions. Comparison of [Mo(≡CC6H4OMe)(OSiPh3)3] (28) with systems generated in situ 
from molybdenum alkylidyne 73 and multidentate silanol 97c. 
substrate product
yield [%] yield [%]
71a 0be: TES
70a 54bf: MOM
0a 0bg: Ac
0a 0bh: Bz
R
64a 0ba: TES
67a 0bb: MOM
0a 0bc: Ac
0a 0bd: Bz
53a 0bi: H
OR
OR1
RO
R1O
9
111
112
OR
OH
TBSO
OH
OH
OTBS
9
OH
OR
9
a: TBS
b: H
113 114
115
116
-
90c,d
76c,d
40a 0b
0b,d
0b,d
Mo
OMe
Ph3SiO
Ph3SiO
OSiPh3
28
Mo
N
N
N
tBu
Ar
tBu
Ar
tBu
Ar
SiSi
Ph
Ph
HO
Ph
Ph
OH
Si
Ph
Ph
HO 97c
entry
1
2
3
73
R1
H
H
H
H
H
TES
MOM
Ac
Bz
-
-
-
73/97c 28
a) (22 mol%) 97c, (20 mol%) 73, MS 5 Å, toluene, 110 °C; b) 28 (20 mol%), MS 5 Å, toluene, 110 °C; c) 
(20 mol%) 97c, (20 mol%) 73, MS 5 Å, toluene, 60 °C; c) (25 mol%) 97c, (20 mol%) 73, MS 5 Å, toluene, 
110 °C; d) Experiments conducted by M. Ilg.  
 
The RCAM reactions of bis-TES and bis-MOM protected substrates 111e-f proceeded in good 
yields when the multidentate system was used (Table 3.2, Entry 1). Acetate and benzoate 
protected substrates 111g-h did not lead to cyclization products. The bis-MOM protected 
substrate 111f was the only case in which catalyst 28 furnished any RCAM product. 
Impressingly even the completely unprotected diol 111i could be cyclized with moderate 
yield when using the multidentate system. 
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In order to find reasons for the superior performance of the multidentate system (Table 3.2, 
Entry 1), we conducted experiments in which we compared catalysts generated in situ from 
molybdenum alkylidyne 73 and either tridentate ligand 97c or monodentate ligand 107 
(Scheme 3.21). Surprisingly the system generated with the monodentate ligand also 
catalyzed the reaction, even though it stopped at 60% conversion (Scheme 3.21, Entry 2). 
This indicates that the nature of the alkylidyne is important for the initiation step. 
Furthermore it shows that the longtime stability of the multidentate system is better 
compared to that of the monodentate analog. 
 
Scheme 3.21: Comparison of catalysts generated in situ with multidentate 97c and monodentate 107 
ligands. 
Alkylidyne 73 is a catalytically active species at elevated temperature, therefore we 
performed a control experiment in which we submitted diyne 111i to molybdenum 
alkylidyne 73 at 110 °C without the addition of siloxy ligands. Only traces of the desired 
product 112i were detected in the crude product and the mass balance led to the conclusion 
that this reaction suffered from a significant material loss probably due to ring expansion 
polymerization reaction.  
Substrates with a propargylic hydroxy-group on one side and a protected alcohol next to an 
enyne motif 113 and 115a were successfully metathesized using the multidentate system 
(Table 3.2, Entry 2-3).[59] Interestingly Z-enyne 114 was formed in better yield compared to E-
enyne 116a. The RCAM reaction of completely unprotected E-enyne 115b could only be 
accomplished in low yield (Table 3.2, Entry 3). 
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3.4.3 Applications to Natural Product Synthesis 
The newly developed alkyne metathesis catalysts were applied in the total syntheses of two 
natural products; Ivorenolide A and Manshurolide.[59] Additionally these catalysts were 
successfully employed in studies towards the synthesis of Lythrancepines.[59] In the total 
synthesis of Ivorenolide A, the diyne metathesis of substrate 117 to diyne 118 was 
accomplished in good yield when applying the multidentate system, whereas 28 only 
furnished low yields (Table 3.3, Entry 1). The multidentate system could further proof its 
value in the total synthesis of Manshurolide. The key RCAM reaction failed with the standard 
system 28, but the system generated with molybdenum alkylidyne 73 and multidentate 
silanol 89d furnished the highly strained E,E-diene macrocycle 120 in good yield (Table 3.3, 
Entry 2).  
Table 3.3: RCAM reactions in natural product synthesis. Comparison of [Mo(≡CC6H4OMe)(OSiPh3)3] (28) 
with systems generated in situ from molybdenum alkylidyne 73 and multidentate silanols. 
substrate product yield [%] yield [%]
HO
120119
83d,f 0e,f
Mo
OMe
Ph3SiO
Ph3SiO
OSiPh3
28
Mo
N
N
N
tBu
Ar
tBu
Ar
tBu
Ar
Si
Si
Ph
Si
Si
OH
HO
PhPh
Ph
Ph
Ph
Ph
OH
89d
SiSi
Ph
Ph
HO
Ph
Ph
OH
Si
Ph
Ph
HO 97c
entry
1
2
73
O
O
MOMO
OMOM
O
O
OMOMMOMO
78a,c 38
b,c
117 118
HO
 
a) (20 mol%) 97c, (20 mol%) 73, MS 5 Å, toluene, 60 °C; b) 28 (35 mol%), MS 5 Å, toluene, 60 °C; c) 
Experiments conducted by F. Ungeheuer; d) (10 mol%) 89d, (10 mol%) 73, MS 5 Å, toluene, 120 °C; e) 28 
(20 mol%), MS 5 Å, toluene, 120 °C; f) Experiments conducted by Dr. L. Hoffmeister. 
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Furthermore we demonstrated the usefulness of the newly developed catalysts in a 
synthetic approach towards the Lythrancepines. The key step in this synthesis, RCAM of 
triyne 121b to diyne 122b, was used as a proficiency test for various catalysts in this highly 
challenging transformation (Scheme 3.22).[60]  
 
Scheme 3.22: Application of catalysts with multidentate ligands in the total synthesis of Lythrancepines. 
The experiments were performed by Dr. K. Gebauer. a) Yields were determined by LC-MS of the crude 
reaction mixture; b) Isolated yields. 
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The standard catalyst 28 was not able to effectively convert triyne 121a into diyne 122a with 
a TES-protected hydroxy group in one of the propargylic positions (Scheme 3.22, Entry 1). 
Removal of the sterically demanding TES group led to some conversion when using the 
neutral complex 28 or ate complex 123, but the yield of the desired product 122b was still 
very low (Scheme 3.22, Entry 2-3). A screening of different multidentate ligands led to 
significantly better results (Scheme 3.22, Entry 4-9). While the systems with silicon linkers 
89a,d did not produce satisfactory yields (Scheme 3.22, Entry 4-5), the systems with 
aromatic linkers 94b and 97c led to good conversions and acceptable yields (Scheme 3.22, 
Entry 6-8). The yield could be further improved by raising the reaction temperature to 110 °C 
to give the desired macrocycle in 66% yield when utilizing the hexasubstituted arene 97c 
(Scheme 3.22, Entry 9). 
It is especially noteworthy that the ratio of monomeric cycle to open and closed dimeric 
species significantly improved when using the multidentate systems. 
3.4.4 Conclusion 
The newly developed in situ generated alkyne metathesis catalysts based on multidentate 
siloxy ligands showed their potential in various challenging ACM and RCAM reactions where 
the previous generation of metathesis catalysts 28 faced problems or completely failed to 
work. This opens the way to address new structural motifs in total synthesis via alkyne 
metathesis. 
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4 Formal Synthesis of (+)-Aspicilin 
4.1 Introduction 
4.1.1 Isolation, Structure Validation, and Biological Activity 
(+)-Aspicilin was first isolated in 1900 from lichen Aspicilia calcarea which belongs to the 
Lecanoraceae family.[61] Its constitution was determined by Huneck nearly 75 years later via 
mass spectroscopy, IR spectroscopy and NMR spectroscopy in addition to chemical 
degradation experiments (Scheme 4.1).[62] The triol motif was confirmed by NMR 
spectroscopy as well as through chemical degradation with Jones reagent to diacid 124. The 
(E)-olefin motif was validated by NMR and reduction to macrocycle 125 which consumed 1 
equiv of hydrogen. Furthermore, the unsaturation was identified to be in α,β-position to the 
carbonyl via UV-spectroscopy (211 nm). The lactone motif was confirmed by the IR carbonyl 
band, as well as through hydrolysis of macrocycle 125 to open chain acid 126.  
 
Scheme 4.1: Structure validation of (+)-Aspicilin. Conditions: a) CrO3/H2SO4, acetone, rt; b) Pt/C, H2, EtOH, 
rt; c) KOH, MeOH, reflux.  
The absolute configuration was determined by Quinkert through a combination of NMR and 
X-ray analysis, as well as chemical degradation/fragment synthesis (Scheme 4.2).[63] The 
relative configuration was determined by single-crystal X-ray analysis and 1H-NMR (COSY and 
NOE) analysis of the acetonide (C4-C5) of (+)-Aspicilin (to reduce the conformational 
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flexibility). To determine the absolute configuration, (+)-Aspicilin was disassembled by 
periodate cleavage and reduction to give diol 127, for which the configuration could be 
determined through chemical synthesis from 1,10-decanediol (128) and (S)-propylene oxide 
(129). 
 
Scheme 4.2: Proving the absolute configuration by chemical synthesis of degradation product 127. 
Conditions: a) NaIO4, MeOH/H2O (9:1), rt; b) LiAlH4, Et2O, rt; c) HBr, petroleum ether, 80 °C; d) 
dihydropyran, PPTS, CH2Cl2, rt; e) Mg, THF; f) 1,5-cyclooctadiene, CuCl, rt. 
(+)-Aspicilin was tested against various cancer cell lines in an MTT assay.[64] It exhibits 
inhibitory activity on the proliferation of cancer cell lines A549 (IC50 = 14.7 µM over 24 h), 
HeLa (IC50 = 17.9 µM over 24 h) and MCF7 (IC50 = 12.0 µM over 24 h), whereas Neuro2a, and 
MDA-MB-231 were not affected. No potential antibacterial and antifungal activities were 
observed.  
4.1.2 Preceding Synthetic Studies 
(+)-Aspicilin has received considerable attraction by organic chemists, leading to 16 total 
syntheses (Quinkert,[65] Keinan,[66] Oppolzer,[67] Enders,[68] Kobayashi,[69] Hatakeymama,[70] 
Tanaka,[71] Ley,[72] Banwell,[73] Raghavan,[74] Markó,[75] Yadav,[76] Reddy,[64] Hou,[77] Gandi,[78] 
Shaw[79]), one formal synthesis (Hoveyda[80]) and two syntheses of the enantiomer (─)-
Aspicilin (Zwanenburg,[81] Solladié[82]) (Figure 4.1). The macrocycle was closed in most of 
those syntheses via Yamaguchi macrolactonization or ring closing olefin metathesis (RCM). In 
the following, there is a short description of Oppolzer´s approach since our formal synthesis 
intercepts his intermediate 132. Moreover, Hoveyda´s synthesis is discussed since he 
disconnects the same C-C bond to form the macrocycle of (+)-Aspicilin as we plan for our 
synthesis.  
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Figure 4.1: Overview of previous retrosynthetic disconnections. 
4.1.3 Oppolzer´s Total Synthesis of (+)-Aspicilin by Asymmetric Alkenylation 
The Oppolzer group planned to introduce the unsaturation at a late stage by selenoxide 
elimination (Scheme 4.3).[67] The triol motif was to be introduced via epoxidation/epoxide 
opening, with stereocontrol by the already existing allylic stereocenter of macrocycle 130. 
For the closure of the macrocycle 130, an intramolecular alkenylzinc/aldehyde addition from 
open chain precursor 131 was envisaged. This transformation was chosen due to its previous 
successful employment in the synthesis of (R)-(─)-muscone.[83] 
O
O
OH
OH
OH
(+)-Aspicilin
O
O
OH
O
O
O
intramolecular
alkenylzinc/aldehyde
addition
selenoxide
elimination
130 131
 
Scheme 4.3: Retrosynthetic analysis of (+)-Aspicilin by Oppolzer et al.[67] 
The synthesis (Scheme 4.4) commenced with (S)-propylene oxide (129), which was 
converted via copper-catalyzed epoxide opening, esterification, acetal cleavage and 
subsequent Swern oxidation to open chain aldehyde 131. As the key step, they closed the 
macrocycle with an asymmetric cyclization that proceeded via hydroboration, boron/zinc-
transmetalation and dimethylaminoisoborneol catalyzed intramolecular addition to afford 
macrocycle 130 with 60% yield and a diastereoselectivity of 91%. The α,β-unsaturation was 
installed after protection of alcohol 130 by a phenylselenation/selenide-
oxidation/selenoxide-elimination process to yield (E,E)-dienol 132 after deprotection. They 
continued their synthesis with a hydroxyl-directed epoxidation and acetylation to give 
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product 133. Subsequent treatment with BF3·Et2O gave cyclic oxonium ion 134 that was 
converted to a 1:1 mixture of monoacetates 135a and 135b upon treatment with water. 
Deprotection furnished (+)-Aspicilin in a total of twelve steps from literature known 
compounds (2 extra steps from commercially available 1,10-decanediol (128)) and 22% 
overall yield. 
 
Scheme 4.4: Oppolzer`s asymmetric macrocyclization approach. Conditions: a) BrMg(CH2)10OTHP, 
Cu(COD)Cl; b) 4-pentynoic acid, DCC, DMAP; c) TsOH, MeOH; d) (COCl)2, DMSO, NEt3, 76% over 4 steps; e) 
(c-hex)2BH, Et2Zn, (−)-DAIB, 60%, 91% ds.; f) TBSCl, DBU; g) LICA, THF, −78 °C, then TBSCl, HMPA, then 
PhSeBr, magnesium monoperoxyphthalate; h) HF·py, 82% over 3 steps; i) t-BuOOH, VO(acac)2, 77%; j) 
Ac2O, NEt3, DMAP, quant.; k) BF3.Et2O, rt; l) NaHCO3aq., 81%; m) 1% HCl, MeOH, rt, 97%. 
 4.1.4 Hoveyda´s Formal Synthesis of (+)-Aspicilin by Z-selective RCM 
Another interesting approach was described by Hoveyda´s group, who designed a formal 
synthesis of (+)-Aspicilin in which the macrocycle 136 was formed from triene 137 with a 
newly developed Z-selective olefin metathesis catalysts 141 (Scheme 4.5).[80]  
 
Scheme 4.5: Retrosynthetic analysis of (+)-Aspicilin by Hoveyda et al.[80]  
Their synthesis started from literature known olefin 138 that was converted to epoxide 139 
via a sequence of TBS protection, olefin cross metathesis and Sharpless epoxidation (Scheme 
4.6). Epoxide 139 was converted to alcohol 140 by a three step sequence; a radical epoxide-
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opening/hydroxy-eliminating transformation, a PMB protection, and a TBS deprotection. 
Following the three step synthesis, alcohol 140 was converted to metathesis precursor 137 
via esterification. RCM of ester 137 with catalyst 141 afforded stereoisomerically pure (E,Z)-
dienoate 136 after deprotection. Accessing Quinkert´s intermediate, dienoate 136, thus 
completed the formal synthesis of (+)-Aspicilin.[65a] Hoveyda´s approach took 9 steps from 
literature known olefin 138 with an overall yield of 9%. This was the first example of a 
catalyst-controlled stereoselective macrocyclic RCM reaction to generate (E,Z)-dienoates. 
 
Scheme 4.6: Hoveyda`s stereoselective RCM approach. Conditions: synthesis of 138 literature known[69] a) 
(t-Bu)Me2SiCl, imidazole, DMF, rt; b) (Z)-but-2-ene-1,4-diol, 2mol% 142, CH2Cl2, 71% over 2 steps; c) (−)-
diethyl tartrate, Ti(Oi-Pr)4, t-BuOOH, CH2Cl2, −20 °C, 56%; d) Cp2TiCl2, Zn, ZnCl2, THF, rt, 69%; e) 142, 
La(OTf)3, toluene, rt; f) (n-Bu)4NF, THF, rt, 65% over 2 steps; g) pentadienoic acid, pivaloyl chloride, DMAP, 
NEt3, rt, 80%; h) 10 mol% 141, benzene, rt, 133 mbar, 69%, >98:2 Z/E; i) DDQ, CH2Cl2/H2O, 0 °C, 91%; see 
ref.[65a] for the completion of the synthesis. 
4.2 Aims and Scope 
Our formal synthesis of (+)-Aspicilin targeted Oppolzer´s E,E-diene intermediate 132. The 
E,E-diene should be built by utilizing RCAM in concert with a post-metathetic modification 
based on a hydrostannylation/destannylation sequence. This synthesis was chosen as a 
challenge for the recently developed ruthenium-catalyzed trans-hydrostannylation.[5] 
Furthermore, the molecule was chosen as a trial for RCAM since the formation of 
macrocyclic E-enynes has proven difficult due to the formation of cyclic dimers.[6] 
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4.3 Preliminary Studies and Formal Synthesis 
4.3.1 Preliminary Studies on Monomer to Dimer Ratios in RCAM 
A previous study had demonstrated that a compound containing an enyne motif was 
incapable of forming the desired monomer in a RCAM.[6] When diyne 144 was submitted to 
metathesis conditions, only dimeric macrocycle 145 was observed (even at high dilutions of 
0.1 mM) instead of the desired 16-membered target product (Scheme 4.7). Normally 16-
membered rings are well within the range of this methodology, with an eleven-membered 
ring being so far the smallest ring size that could be closed by RCAM.[35]  
 
Scheme 4.7: RCAM reaction of enyne 144 leading to undesired dimeric macrocycle 145. 
In order to get a better understanding of how to influence the ratio of monomeric and 
dimeric macrocycles, we decided to evaluate the effects of temperature and time. We chose 
146 as a model substrate, since its reaction can be easily monitored by 1H NMR spectroscopy 
of the crude reaction mixtures, due to the fact that the proton signals next to the ester motif 
are quite characteristic (4.31 ppm for the monomer 147 but 4.12 ppm for the dimer 148) 
(Scheme 4.8).[35]  
 
Scheme 4.8: Test reaction to evaluate the influence of time and temperature on monomer 147 to dimer 
148 ratio. 
We first evaluated possible temperature effects (Chart 4.1) and observed that elevated 
temperatures favor the formation of the monomer 147 over the dimer 148. This can be 
explained by the fact that the dimeric macrocycle 148 is the kinetically favored product, 
whereas the monomeric macrocycle 147 is the thermodynamically favored product.[84]  
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Chart 4.1: Temperature dependency of monomer 147 to dimer 148 ratio in RCAM reaction. Conditions: 
10 mol% 28, MS 5 Å, toluene 2.5 mM, 10 min reaction time. The ratios were determined by 1H NMR of the 
crude reaction mixture. 
The reaction time is also influencing the ratio of monomer 147 to dimer 148 in the sense 
that short reaction times are leading to higher monomer to dimer ratios (Chart 4.2). 
Increased reaction times lead to reopening of the highly strained monomeric macrocycle 
147. 
  
Chart 4.2: Time dependency of monomer 147 to dimer 148 ratio in RCAM reaction. Conditions: 10 mol% 
28, MS 5 Å, toluene 2.5 mM, 20 °C. The ratios were determined by 1H NMR of the crude reaction mixture. 
In conclusion, high temperatures and short reaction times favor the formation of the 
monomeric cycle 147, providing crucial information towards our formal synthesis of (+)-
Aspicilin. 
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4.3.2 Retrosynthetic Analysis of (+)-Aspicilin 
We decided to target the known diene 132 of Oppolzer´s synthesis of (+)-Aspicilin (Scheme 
4.9).[67] The diene motif was considered a result of a hydrostannylation/destannylation 
sequence from enyne 149, utilizing the protocol recently developed in our group.[5] The 
latter was proposed to derive from diyne 150, which can be synthesized from alcohol 
fragment 151 and acid fragment 152 by esterification. 
The intended acid fragment 152 can be constructed via Stille coupling based on a procedure 
described by Dr. Josep Llaveria Cros.[85] For the alcohol fragment 151, the secondary alcohol 
could be introduced by an epoxide opening. Furthermore, we envisaged that the propargyl 
alkyne could be introduced via asymmetric alkynylation procedures.  
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Scheme 4.9: Retrosynthetic analysis of (+)-Aspicilin. 
4.3.3 Synthesis of Fragments 151 and 152 
The synthesis of acid 152 starts from commercially available ethyl propiolate (153), which 
was converted to (E)-iodoacrylate 154 by an iodination/isomerization sequence (Scheme 
4.10). The (E)-iodide 154 was submitted to a Stille cross-coupling with propynyl stannane 
155, which was synthesized according to literature[86] to furnish (E)-enyne 156 which was 
hydrolyzed to obtain the target compound 152 in four steps with an overall yield of 64%. 
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Scheme 4.10: Synthesis of the acid fragment 152. Conditions: a) NaI, MeCN, reflux; b) HIaq., toluene, 80 °C, 
77% over 2 steps; c) 155, 4 mol% bis-(acetonitrile)-palladium(II)-chloride, DMF, rt, 91%; d) LiOH, 
H2O/THF/EtOH 5/5/1, rt, 91%. 
The synthesis of alcohol fragment 151 begins with diol 157, which was converted to 
aldehyde 158 via mono bromination and subsequent oxidation, using a convenient 
procedure developed by Stahl and coworkers (Scheme 4.11).[87] In an earlier version of our 
synthesis, we tried various conditions to introduce the alkyne on THP protected aldehyde 
161. Utilizing the methodology from Pu´s group[88], we could only achieve a moderate yield 
of 42%. Trost´s Zn-prophenol-catalyzed asymmetric alkyne addition[89] furnished the target 
alkyne, with a low yield of 56% and an enantiomeric excess of only 81%. Carreira´s 
alkynylation protocol[90] led to acceptable yields of 65% and an excellent ee of 96%. 
Therefore we utilized Carreira´s alkynylation procedure[90] without further screening. The 
alkyne was introduced with a high enantiomeric excess of 94% using (+)-N-methylephedrine 
as a chiral additive.[90] The propargylic alcohol 159 was isolated with a moderate yield of 
65%, due to partial N-alkylation of (+)-N-methylephedrine by bromides 158 and 159. Alcohol 
159 was TBS protected to furnish TBS-ether 160. The hydrocarbon chain of TBS-ether 160 
was elongated by a copper-catalyzed epoxide opening reaction to yield the desired alcohol 
151 in five steps with an overall yield of 30%. 
 
Scheme 4.11: Synthesis of the alcohol fragment 151. Conditions: a) HBraq., toluene, reflux, 73%; b) 5 mol% 
Cu(MeCN)4(PF6), bpy, NMI, TEMPO, MeCN, air, rt, quant.; c) propyne, (+)-N-methylephedrine, Zn(OTf)2, 
NEt3, toluene, rt, 65%, 94% ee; d) TBSCl, imidazole, CH2Cl2, 0 °C to rt, 90%; e) Mg, I2 (cat.), THF, reflux; then 
4 mol% Li2CuCl4, (S)-propylene oxide, THF, 0 °C, 71%. 
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Esterification of alcohol 51 and acid 152 under standard conditions proceeded uneventfully 
to yield metathesis precursor 150 (Scheme 4.12). 
 
Scheme 4.12: Coupling of alcohol fragment 151 and acid fragment 152 to metathesis precursor 150. 
Conditions: a) DCC, DMAP, CH2Cl2, 0 °C, 93%. 
4.3.4 Ring Closing Alkyne Metathesis 
The RCAM key step needed some optimization. Our first attempt, in which we tried to close 
the macrocycle at room temperature, furnished the cyclic dimer 162b after deprotection as 
the main product with 58% yield over both steps (Scheme 4.13). 
 
Scheme 4.13: Initial RCAM of diyne 150 with non-optimized conditions. Conditions: a) 10 mol% 
[(Ph3SiO)3Mo≡CC6H4OMe] 28, MS 5 Å, toluene, rt, 2h; b) TBAF, THF, rt, 58% over 2 steps. 
We applied the knowledge from our model studies and screened different temperatures and 
reaction times for the RCAM reaction of diyne 150. The ratio of monomer 149a to dimer 
149b was improved to 3 to 1 when the reaction was run at 110 °C for one hour. By 
optimizing the reaction time, the monomer to dimer ratio could further be improved to 12 
to 1 (Chart 4.3).  
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Chart 4.3: Time dependency of monomer 149a to dimer 149b ratio in RCAM reaction. The reactions were 
carried out with 20 mol% [(Ph3SiO)3Mo≡CC6H4OMe] 28 at 110 °C. Ratios were determined by HPLC. 
 
With the optimized conditions in hand we could successfully close the macrocycle on a 
500 mg scale to yield the desired enyne 149a in 78% isolated yield (Scheme 4.14). 
 
Scheme 4.14: Optimized conditions for the formation of cyclic enyne 149a via RCAM. Conditions: a) 
10 mol% [(Ph3SiO)3Mo≡CC6H4OMe] 28, MS 5 Å, toluene, 110 °C, 78% (monomer to dimer = 12 : 1).  
4.3.5 Completion of the Formal Synthesis of (+)-Aspicilin 
To complete the synthesis, we deprotected the macrocycle 149a to yield enyne 162a with a 
free hydroxy group in the propargylic position which was needed as a directing group for the 
trans-hydrostannylation step (Scheme 4.15). Literature studies have indicated that alkynes 
as part of an 1,3-enyne motif are challenging substrates to address by Ru-catalyzed trans-
additions.[91] These difficulties are caused by the high affinity of the electron rich 1,3-enyne 
moiety engaging its 4π electrons in coordination to the ruthenium center. However, the 
problem can be addressed with a hydroxy group adjacent to the alkyne. This can be 
explained by hydrogen bonding between the ─OH group and the chlorine anion of the 
catalyst [RuCp*Cl]4, which favors the binding of the proximal alkyne over the competing 1,3-
enyne.[91] The hydrostannylation proceeded with excellent regioselectivity and furnished 
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only the proximally stannylated products 163a and 163b (Figure 4.2) with a good cis/trans 
selectivity of 12.5 : 1. The formal synthesis was completed by destannylation of trans-
stannane 163a with CuTC to yield Oppolzer´s (E,E)-diene intermediate 132. 
 
Scheme 4.15: Trans-hydrostannylation/destannylation sequence to reduce enyne 149a to (E,E)-diene 132. 
Conditions: a) TBAF, THF, 0 °C to rt, 85%; b) 2 mol% [RuCp*Cl]4, HSnBu3, CH2Cl2, rt, 66% (crude ratio of 
stereoisomers: 12.5 to 1); c) CuTC, DMF, rt, 83%. 
 
Figure 4.2: Trans-hydrostannylation products 163a and 163b. 
4.4 Conclusion 
We managed to complete our formal synthesis of (+)-Aspicilin in 14 steps and ten steps in 
the longest linear sequence from commercially available 1,10-decanediol (157) with an 
overall yield of 10%. The synthesis illustrates how important a strict control of temperature 
and reaction time is for the monomer-to-dimer ratio in RCAM reactions. Furthermore, it 
shows that trans-hydrostannylation can be performed on macrocyclic 1,3-enynes with 
excellent regioselectivity and good stereoselectivity.  
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5 Synthesis of Stapled Peptides via Alkyne Metathesis 
5.1 Introduction 
5.1.1 Small Molecules, Biologics, and Peptides as Drugs 
Almost all therapeutic agents currently used as pharmaceuticals can be classified as either 
small molecules or “biologics”.[3] Small molecules, compounds with a mass below ca. 500 Da, 
are typically able to penetrate through the cell membrane.[92] Their targets are often 
proteins with hydrophobic binding pockets. If the target protein has a shallow surface small 
molecules cannot interact effectively. In such cases, protein-based molecules (biologics) with 
a molecular mass above 5 kDa can be designed that bind to the target protein´s surface. 
However, biologics can only be used for extracellular applications since they are not capable 
of penetrating the cell membrane. Due to these macromolecules´ inability to pass through 
the cell membrane as well as the incapability of small molecules to address certain proteins, 
there exist numerous intracellular targets that cannot be addressed. Peptide-based drugs 
have the potential to close this gap since they have excellent surface recognition properties 
and a lower toxicity compared to small molecule therapeutics.[3, 93] However, it is necessary 
to chemically stabilize the bioactive peptide conformation since peptides otherwise adopt a 
flexible conformation in solution, which leads to low cell membrane permeability and 
proteolytic instability.  
Peptide based pharmaceuticals are important, with currently more than 60 FDA-approved 
peptide products on the market, approximately 140 in clinical trial, and more than 500 in 
preclinical study.[94] Amongst the most widely used peptide based drugs is Copaxone for the 
treatment of multiple sclerosis, Lupron and Zoladex for breast and prostate cancer therapy, 
and Sandostatin which is used for the treatment of acromegaly and cancer.[92] The 
importance of these compounds is illustrated by the sales of each compound exceeding 1 
billion dollars annually.  
5.1.2 Small GTPases Addressed by Stapled Peptides  
Small GTPases are a group of pharmaceutically relevant targets, which have proven difficult 
to address.[95] Even though the pharmaceutical industry and academia put a lot of effort in 
5 Synthesis of Stapled Peptides via Alkyne Metathesis 
53 
 
the development of efficient modulators to address small GTPases, no approved drugs are 
available so far.[95g] Rab proteins, a subfamily of the small GTPases, are important regulators 
of intracellular vesicular transport and trafficking. They are regulated through protein-
protein interactions and play an important role in neurodegenerative diseases and various 
forms of cancer.[4, 96] Waldmann and coworkers could show that Rab-GTPases can be 
effectively targeted with hydrocarbon-stapled peptides generated via RCM.[4]  
5.1.3 Overview of Methodologies to Generate Stapled Peptides 
Since α-helical moieties of proteins are involved in many protein-protein interactions, their 
stabilization in smaller bioactive peptide derivatives has been established with a variety of 
methods, for example side-chain cross-linking.[3, 97] Some of these methodologies can be 
applied to peptides with only natural amino acids in their sequence, such as the formation of 
lactam-bridges between lysine and aspartic acid[98] as schematically shown in amide 164, 
disulfide bridges between two cysteine moieties[99] like in disulfide 165, cross-linkers 
between two cysteine sidechains[100] as demonstrated by bipyridine 166, and cross-linkers 
between two lysine moieties[101] as in amide 167 (Figure 5.1). 
 
Figure 5.1: Different approaches to stapled peptides by utilizing only natural amino acids in the peptide 
chain. 
Furthermore, there are several approaches using unnatural amino acids to generate stapled 
peptide structures, amongst which are azide-alkyne cycloaddition[102] as shown in triazole 
168, C–H activation of tryptophan and coupling with iodo tyrosine or iodo phenyl-alanine[103] 
as shown in indole 169, olefin-bridges formed via RCM between two modified serine 
moieties[104] like in olefin 170, and all-hydrocarbon olefin-brides formed via RCM spanning 
one or two turns of the α-helix as in peptides 171 or 172 respectively (Figure 5.2).[105] 
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Figure 5.2: Different approaches to stapled peptides by utilizing unusual amino acids in the peptide chain. 
5.2 Aims and Scope 
Even though there already exists a variety of methods to generate stapled peptides, seen in 
the light of possible applications in pharmaceutics, it seems worthwhile to establish further 
methodologies. Stapled peptides can be generated through RCM (Chapter 5.1). However, 
unlike RCM, RCAM still has to be demonstrated as a suitable reaction for this cause. 
Additionally, once RCAM is capable of peptides stapling, the alkyne moiety would serve as a 
useful handle for further functionalization of the macrocycles. Finally, with both forms of 
metathesis successful in the formation of macrocyclic peptides, one can imagine the 
selective formation of bicyclic structures where one ring is closed via RCM and the other ring 
via RCAM. Based on these ambitions, we sought to synthesize hydrocarbon-stapled peptides 
and study their effects on Rab-GTPase. 
5.3 Stapled Peptides via Alkyne Metathesis 
5.3.1 RCAM of Immobilized Alkynes 
The peptides used in this work were synthesized on solid-support using the Fmoc-
strategy.[106] They were bound to the solid support with Rink amide linkers.[106] We first 
evaluated different solid support materials concerning their compatibility with the RCAM 
reaction (Figure 5.3). All resins needed to be dried by suspending them in toluene over MS 
5 Å for four days, while exchanging the solvent daily. The best results concerning RCAM 
conversions were observed when using a polystyrene based solid support with a 
polyethylene glycol linker as in amine 175 to which the Rink amide was attached. Solid 
supports in which the Rink amide was directly attached to either a polyethylene glycol core 
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like in amine 173 or a polystyrene core as shown in compound 174 resulted in low 
conversions. One explanation could be that through the ethylene glycol linking chain the 
peptide is further away from the polymeric support, thereby increasing the accessibility for 
the metathesis catalyst. 
 
Figure 5.3: Different solid supports with Rink amide linkers. 
In order to prove the robustness of our methodology, we performed the RCAM on peptide 
176a (Figure 5.4) that contained all functionalities present in the 20 proteinogenic amino 
acids (Table 5.1). Impressingly the metathesis reaction proceeded smoothly, but it was 
necessary to use 1.5 equivalents of catalyst 28 to reach full conversion. This is probably due 
to residual moisture in the solid support and technical problems when handling very small 
amounts of the catalyst. The neutral complex 28 led to better results than the ate-complex 
123, which might be explained by unfavorable interactions of the charged species 123 with 
the highly functionalized peptide 176a. 
Table 5.1: Comparison of different solid supports and alkyne metathesis catalysts for the RCAM of peptide 
176a. The reactions were performed in 0.15 mL of dry toluene in the presence of MS 5 Å in a flame-dried 
Schlenk tube under argon for 3 h at 40 ° C. Conversions were determined by LC-MS. 
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Figure 5.4: Test peptide 176a for the RCAM reaction on solid support. The protecting groups that were 
present during metathesis reaction are indicated. The shown structure corresponds to the peptide that is 
isolated after cleavage from the solid support prior to running the RCAM reaction. 
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5.3.2 Bicyclic Peptides via Orthogonal RCM and RCAM 
With suitable RCAM conditions in hand, we established a methodology to chemo- and 
regioselectively generate bicyclic peptides via a combination of RCM and RCAM (Scheme 
5.1).[107] Starting from solid support bound peptide 177a containing two alkyne-
functionalized building blocks Y1/Y2 and two olefin-functionalized amino acids O, the bicyclic 
peptide 177b was selectively generated through a one-pot RCM/RCAM procedure. Test 
peptide 177a was designed to contain all functionalities of proteinogenic amino acids, 
excluding sulfur containing amino acids. 
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Scheme 5.1: Synthesis of an adjacent bicyclic peptide 177b via tandem RCM and RCAM in a one-pot 
reaction. R = side chain of a proteinogenic amino acid except Cys or Met. Conditions: a) Alkyne metathesis 
catalyst 28, Grubbs 1st generation catalyst, toluene, 40 °C, 2 × 1.5 h. b) cleavage from solid support and 
deprotection. The experiments were conducted by P. Cromm. 
 
It was even possible to selectively generate the intertwined bicyclic peptide 178b starting 
from immobilized peptide 178a with alternating alkyne- and olefin-containing amino acids in 
the chain (Scheme 5.2).[107] This led to an edge-on bicyclic structure with a more constrained 
geometry.  
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Scheme 5.2: Synthesis of intertwined bicyclic peptide 178b via tandem RCM and RCAM in a one-pot 
reaction. R = side chain of a proteinogenic amino acid except Cys or Met. Conditions: a) Alkyne metathesis 
catalyst 28, Grubbs 1st generation catalyst, dry toluene, 40 °C, 2 × 1.5 h. b) cleavage from solid support 
and deprotection. The experiments were conducted by P. Cromm. 
5.3.3 Biological Evaluation of Alkyne Stapled Peptides 
In order to evaluate the biological affinity of alkyne stapled peptides, the Waldmann group 
synthesized a row of monocyclic and bicyclic peptides with different architectures and 
compared their binding affinity towards the small GTPase Rab8a (GppNHp) (see Chapter 
5.1.2).[107] The sequence and architecture of those peptides is based on the interaction motif 
of Rab6 interacting protein wt-R6IP. wtRIP, an unmodified sequence of Rab6-interacting 
protein wt-R6IP, was shown to bind the small GTPase Rab8a with moderate affinity (Table 
5.2, Entry 1). However, StRIP3, a hydrocarbon-stapled monocyclic peptide, whose sequence 
resembles that of wtRIP, shows a 5-fold improvement in binding affinity compared to wtRIP 
(Table 5.2, Entry 2).[4] Building upon this knowledge, analogue 179b, an alkyne stapled 
monocyclic peptide, showed a 10-fold improvement in binding affinity compared to wtRIP 
(Table 5.2, Entry 3). More Impressingly, bicyclic peptide derivatives 180b and 181b showed 
even further improvement relative to their monocyclic analogs 179b and StRIP3 (Table 5.2, 
Entry 4, 5). Bicyclic peptide 180b is so far the most potent binder of an activated Rab 
GTPase. 
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Table 5.2: a) Affinity of wild-type sequence of Rab6 interacting protein wtRIP (aa 900 – 916) and mono-
alkene StRIP3, mono-alkyne 179b and bicyclic peptide derivatives 180b, 181b towards Rab8a6-
176(GppNHp). The affinities towards Rab8a6-176(GppNHp) were determined by fluorescence polarization 
assays (rel. Kd = Kd/Kd [StRIP3]); b) Sequence of peptide 180b, the most potent binder to an activated Rab 
GTPase known. The experiments were conducted by P. Cromm. 
 
5.4 Functionalization of Immobilized Alkynes 
Our next goal was to establish conditions to functionalize the triple bond generated via 
RCAM. Towards this end, hydration, azide-alkyne cycloaddition, Pauson-Khand reaction, 
hydrostannylation, hydroborylation, and dibromination reactions were envisioned on alkyne 
containing peptides. With these reactions interesting approaches to further modify the 
stapled peptides could be accomplished. In order to find suitable reaction conditions and 
limit incompatibilities with the amino acid side chains, we used the simplified test peptide 
182b (Scheme 5.3).  
 
Scheme 5.3: Test peptide 182b for alkyne functionalization reactions on solid support. The shown 
structures correspond to the peptides which are isolated after cleavage from the solid support. RCAM 
conditions: catalyst 28, toluene, 40 °C, 3 h. 
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5.4.1 Gold-Catalyzed Hydration 
In order to hydrate the alkyne, we used a gold-catalyzed methodology developed by Nolan 
and coworkers.[108] The reaction is normally performed at 120 °C which would be 
troublesome for the peptide´s stability. Therefore we first screened different reaction 
conditions with 5-decyne as a test substrate (Scheme 5.4). The experiments revealed that 
the reaction is also possible at 60 °C when the reaction times are increased (Scheme 5.4, 
Entry 1-3). The solid support showed better swelling properties in MeOH compared to 1,4-
dioxane, therefore the reaction was run in MeOH/H2O (2/1), which lowered the reaction 
time significantly (Scheme 5.4, Entry 4).  
 
Scheme 5.4: Condition screening for the gold-catalyzed hydration of alkynes. Conversions were monitored 
by GC-MS. 
Gold-catalyst 186, which was generated from complex 185 by treatment with silver p-
toluenesulfonate according to the literature[109], was used for the hydration of test peptide 
182b (Scheme 5.5). The reaction was performed in pure MeOH since water prevented the 
solid support from swelling properly. In order to achieve full conversion, the catalyst loading 
had to be increased to 50%. The reaction proceeded smoothly to achieve the target peptide 
182c after cleavage from the solid support. LC-MS did not reveal any regioselectivity. 
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Scheme 5.5: Gold-catalyzed hydration of test peptide 182b. The side chains R are defined in Scheme 5.3. 
Conversions were determined by LC-MS. 
 
The same conditions were applied to the more complex peptide 176b but the desired 
product 176c was only generated in trace quantities (Scheme 5.6). The reactions mainly lead 
to extensive decomposition (Scheme 5.6, Entry 1, 2). This can perhaps be attributed to the 
high density of functional groups present in peptide 176b which can interact with the gold 
catalyst. The long reaction time could be one reason for decomposition; therefore the 
reaction was tried in a microwave reactor with superheated solvent and shorter reaction 
time (Scheme 5.6, Entry 3, 4). However, these changes did not improve the reaction 
outcome either. Additionally, a more electrophilic gold complex 187 was used, hypothesizing 
that this would increase the affinity towards the alkyne but only starting material and 
extensive decomposition was observed (Scheme 5.6, Entry 5). 
 
Scheme 5.6: Gold-catalyzed hydratisation of test peptide 176b. The side chains R are defined in Figure 5.4. 
For RCAM conditions see Table 5.1. The reactions yielded complex mixtures that were analyzed by LC-MS. 
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Even though the hydration methodology can be used on immobilized peptides, certain 
amino acids seem to deactivate the catalyst and lead to decomposition. It is likely that the S-
containing methionine binds to the gold catalyst.  
5.4.2 Azide-Alkyne Cycloaddition 
Another versatile way to functionalize alkynes is through azide-alkyne cycloaddition 
(AAC).[110] Terminal alkynes are the substrates of choice, whereas there are far less reports in 
the literature for unstrained internal alkynes. 5-Decyne (183) was employed as a test 
substrate to evaluate suitable methods, such as a ruthenium-AAC methodology developed 
by Fokin and coworkers.[110b] When phosphine-based ruthenium-catalyst 189 was used at 
60 °C, moderate conversions and significant (20%) amounts of a (E)-N-benzyl-1-
phenylmethanimine were observed (Scheme 5.7, Entry 1, 2). Ruthenium-COD catalyst 190 
allowed the reaction to proceed at room temperature and led to good conversions already 
after 1 h reaction time (Scheme 5.7, Entry 3, 4). Attempts to utilize a copper-catalyzed AAC 
methodology developed by Nolan and coworkers[111] failed with CuIPr catalyst 191 (Scheme 
5.7, Entry 5, 6).  
 
Scheme 5.7: Condition screening for the ruthenium-catalyzed azide alkyne cyclization. Conversions were 
monitored by GC-MS. 
With suitable conditions in hand, several structural motifs were successfully coupled to 
peptide 182b leading to benzyl derivative 182d, sugar derivative 182e, PEG derivative 182f 
and biotin derivative 182g (Scheme 5.8). Coupling of dye-containing azides did not give the 
desired products 182h and 182i, probably due to unfavorable interactions of the Ru-catalyst 
with the aromatic moiety of the dye molecules. 
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Scheme 5.8: Ruthenium-AAC to couple various azide-containing structural motifs to test peptide 182b. 
The side chains R are defined in Scheme 5.3. Conditions: a) 190, toluene, 60 °C; b) TFA/TIPS/H2O 
(95/2.5/2.5), rt. The reactions were monitored via LC-MS. 
 
All attempts to apply the azide-alkyne cyclization protocol to the highly functionalized test 
peptide 176b failed. In this case manly decomposition products and residual starting 
material were observed. 
5.4.3 Further Functionalization Attempts 
We further managed to successfully dibrominate[112] the alkyne in a monocyclic peptide with 
CuBr2. Our attempts to functionalize the alkyne via Pauson-Khand
[113] reaction failed under 
all tested conditions and only led to decomposition. Hydrostannylation[5, 91] led to extensive 
material loss, probably due to residual water in the solid support which caused the 
decomposition of the ruthenium-catalyst while generating HCl, which cleaved the peptide 
off the solid support during the reaction.  
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5.5 Conclusion 
In conclusion we have demonstrated that RCAM can be applied to immobilized peptides to 
generate macrocycles. Impressingly all (protected) functionalities present in the 20 
proteinogenic amino acids were tolerated. Additionally, we successfully accomplished the 
synthesis of adjacent and intertwined bicyclic peptides via tandem RCM and RCAM 
reactions. The immobilized alkynes were further functionalized via hydration, azide-alkyne 
cycloaddition or dibromination. However, it seems that certain amino acids are not 
tolerated. In order to get a clearer picture, further experiments with different amino acid 
combinations in the sequence are needed. 
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6 Summary and Conclusion 
The last couple of years have seen considerable progress in alkyne metathesis. This 
development led to catalysts with remarkable activity and functional group tolerance as 
demonstrated in highly elaborate applications.[1] However, despite these advances there are 
still unmet needs in the field. The objective of this thesis was therefore to develop new 
alkyne metathesis catalysts and extend the scope of application for this transformation. 
 
1) Extended substrate scope of catalyst 28  
The latest generation of siloxy-based alkyne metathesis catalysts developed in the Fürstner 
group has proven its quality in a wide range of applications in total synthesis.[1] However, the 
functional group tolerance was so far not comprehensively screened, leaving out some 
synthetically interesting structural motifs. Therefore, an extensive substrate scope screening 
for catalyst 28 was performed to determine the limits of substrate tolerance. 
 
Scheme 6.1: Metathesis reactions of methyl capped alkynes to homo dimers with catalyst 28. 
Catalyst 28 was found to tolerate a broad variety of substrates with challenging structural 
motifs such as secondary or tertiary amines, an azide, primary alkyl halides, an indole, a 
thioether, a sulfoxide or a sulfonamide (Scheme 6.1). However, substrates with protic groups 
were not generally tolerated. We assumed that these incompatibilities are caused by 
ligand/substrate competition and therefore decided to design catalysts with multidentate 
siloxy ligands exploiting their stabilizing chelate effect. 
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2) Alkyne metathesis catalysts based on multidentate siloxy ligands 
Zhang et al. have demonstrated that alkyne metathesis catalysts based on multidentate 
phenol ligands are more stable than their monodentate analogs.[46] Furthermore, our group 
has demonstrated that siloxy-based alkyne metathesis catalysts are amongst the most active 
and selective alkyne metathesis catalysts.[1] Both principles were combined in the design of 
tridentate silanols of type B (Scheme 6.2). An efficient and scalable method was established 
to synthesize these tridentate ligands B via hydrosilylation of triolefin precursors A with 
chlorosilanes 91 and subsequent hydrolysis. 
 
Scheme 6.2: General synthesis of tridentate silanols B. 
Different ligand geometries were investigated, aiming for the formation of a defined catalyst 
species as illustrated in structures C, D, E (Scheme 6.3).  
 
Scheme 6.3: Strategies to generate a defined species (R = CEt, CC6H4OMe or N).  
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However, all attempts to isolate a defined catalyst species failed due to the formation of 
product mixtures. Therefore, the catalysts were generated in situ from the multidentate 
siloxy ligands and molybdenum alkylidyne 73. While ligands with aromatic substituents such 
as 89a and 89d led to highly active systems, the use of ligand 89b with aliphatic substituents 
was inadequate. The geometry of the ligand plays only a minor role, which is demonstrated 
by the fact that ligands 89a, b (silicon linker) as well as ligands 94 and 97 (aromatic linkers) 
performed similarly well. In contrast, constrained ligands like calyx[4]arenes 103b, c and 
silsesquioxanes 104a, b mainly furnished unreactive systems probably due to electronic 
effects and a constrained geometry. 
The catalysts that were generated in situ from molybdenum alkylidyne 73 and silanols 89a, d 
or 97c were tested in a number of challenging alkyne metathesis reactions (Scheme 6.4).[59] 
Gratifyingly they showed excellent stability and tolerated substrates containing free alcohols 
and highly coordinating groups. Their potential was further underlined by the RCAM reaction 
of diynes with two protected or unprotected hydroxy groups in propargylic positions.  
 
Scheme 6.4: Metathesis reactions with new two-component catalyst systems. 
In parallel work in this laboratory, these catalysts enabled the RCAM in three natural product 
synthesis projects (Ivorenolide A, Manshurolide, Lythrancepines) where other commonly 
used catalysts failed (Figure 6.1).[59] 
 
Figure 6.1: Key intermediates in natural product syntheses formed by the new two-component catalyst 
systems. 
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3) Formal total synthesis of (+)-Aspicilin  
The feasibility of constructing an E,E-diene in a macrocyclic molecule by a sequence of RCAM 
and trans-hydrostannylation/destannylation was demonstrated within the formal synthesis 
of (+)-Aspicilin. The 18-membered macrocyclic core structure 149a could be generated via 
RCAM at high temperature and under strict control of the reaction time (Scheme 6.5).  
 
Scheme 6.5: RCAM of diyne 150 to generate enyne 149a. 
Furthermore, a newly developed hydrostannylation methodology was applied for the first 
time on a macrocyclic 1,3-enyne.[5] Enyne 162a was converted to stannane 163a with 
excellent regioselectivity and a favorable cis/trans selectivity of 12.5 : 1 (Scheme 6.6). 
Subsequent destannylation of trans-stannane 163a with CuTC furnished the target of our 
synthesis E,E-diene 132. The formal synthesis of (+)-Aspicilin was completed with an overall 
yield of 10% for the longest linear sequence of ten steps. 
 
Scheme 6.6: Hydrostannylation of enyne 162a to stannane 163a and subsequent destannylation to diene 
132. 
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4) Stabilization of α-helical peptides using ring closing alkyne metathesis 
Hydrocarbon-stapled peptides are a promising tool for targeting challenging protein-protein 
interactions, which are not accessible via classic small molecule approaches.[3] One way to 
enforce an α-helical conformation is the introduction of an all-carbon macrocyclic bridge 
connecting two turns of a helix (Scheme 6.7).[4] In order to accomplish this goal a 
hydrocarbon tether was introduced by RCAM using immobilized precursors F. Impressingly 
all (protected) functionalities present in the 20 proteinogenic amino acids were 
tolerated.[107] 
 
Scheme 6.7: RCAM to stabilize α-helical peptides. 
Additionally, the synthesis of adjacent bicyclic peptides I and intertwined bicyclic peptides K 
was successfully accomplished via tandem RCM and RCAM reactions (Scheme 6.8).[107] The 
biological affinity of these alkyne stapled peptides was evaluated in binding affinity studies 
towards the small GTPase Rab8a. Bicyclic peptide 180b was identified to be the most potent 
binder of an activated Rab GTPase. 
 
Scheme 6.8: Formation of bicyclic peptides I and K. 
In order to further functionalize the macrocyclic scaffold L, the immobilized alkyne was 
submitted to dibromination reaction to furnish dibromo olefins such as M, hydration to 
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ketones like N, and azide-alkyne cycloadditions to form triazoles such as O (Scheme 6.9). The 
latter allowed the introduction of sidechains containing biomolecules like sugars or biotin.  
 
Scheme 6.9: Functionalization of immobilized peptides.  
In conclusion, a new two-component system for alkyne metathesis was introduced which 
surpasses the known systems in reactions of alkynes bearing primary, secondary or phenolic 
–OH groups, as well as in reactions of (bis)propargylic alcohol derivatives. The potential of 
this system was proven by the total syntheses of Manshurolide and Ivorenolide A as well as 
by a study towards Lythrancepine I. Moreover, a formal synthesis (+)-Aspicilin was reached 
where the macrocyclic E,E-diene motive was constructed by a sequence of RCAM and trans-
hydrostannylation/destannylation. Finally, the functionalization of immobilized peptides 
through RCAM and follow-up reactions of the thus formed alkynes were established. The 
work presented herein led to considerable progress in the field of alkyne metathesis 
allowing access to highly challenging macrocycles as well as cyclic peptides. This opened a 
variety of new possibilities in the synthesis of important bioactive compounds. 
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7 Experimental Procedures 
7.1 General Experimental Details 
All reactions with air- or moisture sensitive compounds were conducted in flame-dried 
glassware under argon using Schlenk technique, unless otherwise stated. The solvents were 
purified by distillation over the drying agents indicated and were transferred under Ar: THF, 
Et2O (Mg/anthracene), CH2Cl2, toluene (Na/K), MeOH (Mg, stored over MS 3 Å); DMF, 
acetonitrile and NEt3 were dried by an adsorption solvent purification system based on 
molecular sieves. Commercially available chemicals were used without further purifi-cation, 
unless otherwise stated. The molecular sieves were activated at 200 °C and 10-3 mbar for 
24 h and stored under argon. 
 
Chromatography 
Thin layer chromatography was performed with precoated plates (POLYGRAM®SIL/UV254) 
from Machery-Nagel. Detection was done under UV-light at 254 nm and by dipping the plate 
in either cerium ammonium nitrate (CAN), basic KMnO4 or acidic vanilin solution and 
development by heating. Flash chromatography was performed using Merck silica gel 60 
(40–63 μm) under a slight over pressure. The utilized solvent mixtures are indicated in the 
corresponding experiments. Analytical gas chromatography measurements were performed 
on a Hewlett Packard HP 6890 device with a HP 5973 (GC/MS) detector. 
Analytical high pressure liquid chromatography (HPLC) was performed with a Shimadzu 
LCMS2020 instrument (pumps LC-20AD, autosampler SIL-20AC, column oven CTO-20AC, 
diode array detector SPD-M20A, controller CBM-20A, ESI detector with Labsolutions as 
software) using a ZORBAX Eclipse Plus C18 column (1.8 μm, 3.0 or 4.6 mm ID × 50 mm) 
(Agilent). The oven temperature was set to 35 °C and 254 nm were used as detection 
wavelength. Preparative liquid chromatography was performed on a Shimadzu LC-20A 
prominence system (pumps LC-20AP, column oven CTO-20AC, diode array detector SPD-
M20A, fraction collector FRC-10A, controller CBM-20A with LC-solution as software). The 
analyses were partially performed in cooperation with Roswitha Leichtweiß. 
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NMR-Spectroscopy 
NMR spectra were recorded on Bruker DPX 300, AV 400, AV 500 spectrometers in the 
indicated solvents. The chemical shifts (δ) are given in ppm relative to TMS, coupling 
constants (J) are given in Hz. The solvent signals were used as a reference and the chemical 
shifts were converted to the TMS scale ([D3]-acetonitrile: δC = 118.3 ppm, δH = 1.94 ppm; 
CDCl3: δC = 77.0 ppm, δH = 7.26 ppm; CD2Cl2: δC = 53.8 ppm, δH = 5.32 ppm; [D8]-toluene: δC = 
20.7 ppm, δH = 2.09 ppm) The following abbreviations are used for multiplets: s: singlet, d: 
doublet, t: triplet, q: quartet, m: multiplet. Broad signals are indicated by b in front of the 
multiplicity. The values for 1H are rounded to two digits, those for 13C to one digit after the 
decimal point. 13C-NMR spectra are recorded in 1H decoupled mode. CD2Cl2 and [D8]-toluene 
were stored over MS 3 Å. 
 
IR-Spectroscopy 
IR spectra were measured at room temperature via ATR (attenuated total reflection) on a 
Spectrum One (Perkin-Elmer) spectrometer. The characteristic absorptions are given in 
wavenumbers (ṽ) [cm-1]. 
 
Mass-Spectrometry 
Measurements of mass spectra were undertaken by the mass spectrometry department of 
the Max-Planck-Institut für Kohlenforschung. EI-spectra were measured on a Finnigan MAT 
8200 (70 eV) or on a Finnigan MAT 8400 (70 eV) spectrometer. ESI-spectra were measured 
on a Bruker ESQ 3000 spectrometer. All values are given in mass units per elementary charge 
(m/z). Intensities are given in percent relative to the basis peak. High resolution mass spectra 
(HRMS) were recorded on a Finnigan MAT 95 spectrometer (EI) or a Bruker APEX III FT-ICR-
MS (7 Tesla magnet, ESI). 
 
X-ray Analysis 
X-ray diffraction measurements were performed by the department “Chemische 
Kristallographie” of the Max-Planck-Institut für Kohlenforschung. The measurements were 
done on a Bruker-AXS X8 Proteum diffractometer. 
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Melting Points 
Melting points were measured in open capillary on a Büchi (B-540) melting point device. 
 
Optical Rotations 
Optical rotations ([]
) were measured with a Perkin-Elmer Model 343 polarimeter. The 
values are reported as specific optical rotations with the corresponding temperature, 
concentration (c (10 mg/mL)) and solvent at a wavelength of 589 nm. 
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The following compounds were synthesized in our group by the people indicated. 
M. Ilg: 
 
G. Seidel:                                                                                 
 
K. Radkowski:                                R. Stade: 
 
 
 
O. Guth:                                                                                 A. Ahlers: 
 
 
 
Y. Suzuki:                         J. Heppekausen: 
  
O
O
N
OH
34 40
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7.2 Extended Substrate Scope of Catalyst 28 
7.2.1 Synthesis of Metathesis Catalysts 28 
((Methylsilanetriyl)tris(ethane-2,1-diyl))tris(diphenylsilanol) (28) 
According to a modified literature procedure[26a], tribromo alkylidyne 
26 (2.40 g, 4.40 mmol) was suspended in toluene (80 mL) and stirred 
for 10 min at 0 °C. The reaction mixture was cooled to ─20 °C before 
a solution of Ph3SiOK (4.14 g, 13.2 mmol) in toluene (40 mL) was 
added over 90 min at ─20 °C. Stirring was continued for 10 min at 
─20 °C, for 30 min at 0 °C, and for 30 min at room temperature before the mixture was 
concentrated to 40 mL under reduced pressure. The suspension was filtered through a plug 
of Celite® that was washed with toluene (20 mL). The solvent was removed in vacuum to 
give a brown slurry which was dried for 15 min in high vacuum. The residue was dissolved in 
Et2O (10 mL). After stirring at 0 °C for 30 min a yellow solid precipitated. The solid was 
filtered off and washed with cold Et2O (8 mL) to give the title compound 28 (1.00 g, 22%) as a 
yellow powder which contained ca. 5% of the ate complex 27. 
1H NMR (400 MHz, CD2Cl2) δ = 7.54 (d, J = 6.9 Hz, 18H), 7.37 (t, J = 7.7 Hz, 9H), 7.19 (t, J = 7.5 
Hz, 18H), 6.06 (d, J = 8.8 Hz, 2H), 5.19 (d, J = 8.8 Hz, 2H), 3.63 ppm (s, 3H); 13C NMR (100 
MHz, CD2Cl2) δ = 300.7, 158.8, 140.2, 136.4, 135.8, 131.1, 130.4, 128.4, 112.2, 55.6 ppm. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[26a] 
7.2.2 Synthesis of Metathesis Substrates  
General procedure 1: Suzuki cross-coupling of aryl iodides with sodium 1-propynyl 
Trimethylborate (1.2 equiv) was added to a suspension of sodium 1-propynyl (1.2 equiv) in 
THF. The mixture was stirred for 30 min at ambient temperature, until a clear solution was 
observed. Pd(PPh3)4 (1 mol%) and the individual aryl iodide (1.0 equiv) were added and 
stirring continued for 14 h at reflux temperature. The mixture was then allowed to reach 
ambient temperature before H2O was added. The phases were separated and the aqueous 
layer was extracted with ethyl acetate. The combined extracts were dried over MgSO4, the 
solvent was evaporated, and the crude product was purified by flash chromatography. 
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tert-Butyl(4-iodophenoxy)dimethylsilane (EP1) 
4-Iodophenol (7.36 g, 33.4 mmol) was added to a solution of TBSCl 
(6.30 g, 41.8 mmol) in CH2Cl2 (60 mL) at room temperature. NEt3 
(5.81 mL, 41.8 mmol) was added at 0 °C and the reaction mixture was stirred for 3 h at room 
temperature. The reaction was quenched by addition of water (100 mL) and the aqueous 
phase was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were 
dried over MgSO4, the solvent was evaporated, and the crude product was purified by flash 
chromatography (SiO2, hexanes) to give the title compound as a colorless oil (9.80 g, 88%). 
1H NMR (400 MHz, CDCl3): δ = 7.51 (d, J = 8.8 Hz, 2H), 6.61 (d, J = 8.8 Hz, 2H), 0.98 (s, 9H), 
0.19 ppm (s, 6H); 13C NMR (100 MHz, CDCl3): δ = 155.9, 138.5, 122.8, 83.9, 25.9, 18.3, 
−4.3 ppm.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[114] 
 
tert-Butyldimethyl(4-(prop-1-yn-1-yl)phenoxy)silane (EP2) 
tert-Butyl(4-iodophenoxy)dimethylsilane (EP1) (8.30 g, 24.8 mmol) 
in THF (60 mL) was reacted with sodium 1-propynyl (1.97 g, 
31.7 mmol), trimethylborate (3.29 mL, 31.7 mmol) and Pd(PPh3)4 (283 mg, 0.25 mmol, 
1 mol%) according to general procedure 1. Flash chromatography (SiO2, hexanes/ethyl 
acetate, 50/1) afforded the title compound as a yellow oil (4.50 g, 79%). 
1H NMR (400 MHz, CDCl3): δ = 7.26 (d, J = 8.4 Hz, 2H), 6.74 (d, J = 8.4 Hz, 2H), 2.03 (s, 3H), 
0.97 (s, 9H), 0.19 ppm (s, 6H); 13C NMR (100 MHz, CDCl3): δ = 155.5, 133.1, 120.3, 116.9, 
84.5, 79.8, 25.8, 18.4, 4.5, −4.2 ppm; IR (film): ṽ = 3040, 2956, 2930, 2886, 2857, 1602, 1505, 
1471, 1391, 1362, 1273, 1251, 1165, 1098, 1007, 973, 906, 835, 805, 779, 739, 722, 674, 595, 
532, 453, 421 cm-1; MS (EI): m/z (%) = 246 (31), 191 (14), 190 (29), 189 (100), 115 (35), 75 
(11); HRMS (EI (DE)): m/z: calcd. for [C15H22OSi1]
+: 246.1438, found: 246.1440. 
The compound is literature known, but the SI containing the spectroscopic data is not 
available.[115] 
 
4-(Prop-1-yn-1-yl)phenol (29a) 
TBAF (1 M in THF, 20.0 mL, 20.0 mmol) was added to a solution of 
tert-butyldimethyl(4-(prop-1-yn-1-yl)phenoxy)silane (EP2) (4.50 g, 
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19.6 mol) in THF (40 mL) at room temperature. The mixture was stirred for 1.5 h at room 
temperature before the reaction was quenched with aq. sat. NH4Cl (20 mL). The aqueous 
layer was extracted with ethyl acetate (3 × 50 mL). The combined extracts were washed with 
aq. sat. NaCl (30 mL) and dried over MgSO4. The solvent was evaporated and the residue was 
purified by flash chromatography (SiO2, hexanes/ethyl acetate, 15/1 to 4/1) to give the title 
compound as a colorless solid (2.51 g, 97%).  
1H NMR (400 MHz, CD3CN): δ = 7.21 (d, J = 8.6 Hz, 2H), 7.10 (s, 1H), 6.74 (d, J = 8.6 Hz, 2H), 
1.99 ppm (s, 3H); 13C NMR (100 MHz, CD3CN): δ = 157.6, 133.8, 116.3, 116.2, 84.6, 80.1, 
4.1 ppm.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[116] 
 
tert-Butyldimethyl(3-(prop-1-yn-1-yl)phenoxy)silane (EP3)  
tert-Butyl(3-iodophenoxy)dimethylsilane (1.67 g, 5.00 mmol) in THF 
(10 mL) was reacted with sodium 1-propynyl (341 mg, 5.50 mmol), 
trimethylborate (626 µL, 5.50 mmol) and Pd(PPh3)4 (272 mg, 79 µmol, 
2 mol%) according to general procedure 1. Flash chromatography (SiO2, hexanes/ethyl 
acetate, 50/1) afforded the title compound as a colorless oil (1.13 g, 92%).  
1H NMR (400 MHz, CDCl3): δ = 7.13 (t, J = 7.8 Hz, 1H), 6.98 (d, J = 7.8 Hz, 1H), 6.87 (s, 1H), 
6.76 (d, J = 7.8 Hz, 1H), 2.04 (s, 3H), 0.98 (s, 9H), 0.19 ppm (s, 6H); 13C NMR (100 MHz, CDCl3): 
δ = 155.5, 129.4, 125.2, 124.8, 123.2, 120.0, 85.7, 79.7, 25.8, 18.3, 4.5, −4.3 ppm; MS (EI): 
m/z (%) = 246 (17), 189 (100), 173 (2), 161 (8), 128 (3), 115 (20), 75 (3); HRMS (ESI(pos)): 
m/z: calcd. for [C15H22OSi+Na]
+: 269.1327, found: 269.1332.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[117] 
 
3-(Prop-1-yn-1-yl)phenol (29b) 
TBAF (1 M in THF, 2.00 mL, 2.00 mmol) was added to a solution of tert-
butyldimethyl(3-(prop-1-yn-1-yl)phenoxy)silane (EP3) (460 mg, 
2.00 mmol) in THF (5 mL) at room temperature. The mixture was stirred 
for 1 h at room temperature before the reaction was quenched with aq. sat. NH4Cl (5 mL). 
The aqueous layer was extracted with ethyl acetate (3 × 30 mL). The combined extracts were 
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washed with aq. sat. NaCl (10 mL) and dried over MgSO4. The solvent was evaporated and 
the residue was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 15/1 to 
10/1) to give the title compound as a colorless solid (254 mg, 96%).  
1H NMR (400 MHz, CDCl3): δ = 7.15 (t, J = 7.9 Hz, 1H), 6.97 (dt, J = 7.6, 1.4 Hz, 1H), 6.86 (dd, J 
= 2.7, 1.4 Hz, 1H), 6.75 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 4.75 (s, 1H), 2.04 ppm (s, 3H). 
The compound is literature known. However, spectroscopic data are not available.[118] 
 
2-(Prop-1-yn-1-yl)phenol (29c) 
2-Iodophenol (1.37 g, 6.23 mmol) in THF (30 mL) was reacted with sodium 
1-propynyl (1.97 g, 13.1 mmol), trimethylborate (1.37 mL, 13.2 mmol) and 
Pd(PPh3)4 (250 mg, 0.22 mmol, 3 mol%) according to general procedure 1. 
Flash chromatography (SiO2, hexanes/ethyl acetate, 6/1 to 4/1) afforded the title compound 
as a slightly yellow solid (648 mg, 79%).  
1H NMR (400 MHz, (CD3)2CO): δ = 8.04 (s, 1H), 7.26 (d, J = 7.6 Hz, 1H), 7.16 (t, J = 7.6 Hz, 1H), 
6.87 (d, J = 8.3 Hz, 1H), 7.00 (t, J = 7.5 Hz, 1H), 2.04 ppm (s, 3H); 13C NMR (100 MHz, 
(CD3)2CO): δ = 158.8, 133.1, 129.8, 119.9, 116.2, 112.0, 91.7, 75.7, 3.9 ppm.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[119] 
 
4-(Prop-1-yn-1-yl)aniline (36a) 
4-Iodoaniline (3.03 g, 13.8 mmol) in THF (80 mL) was reacted with 
sodium 1-propynyl (2.33 g, 37.6 mmol), trimethylborate (4.32 mL, 
38.0 mmol) and Pd(PPh3)4 (238 mg, 0.21 mmol, 2 mol%) according to general procedure 1. 
Flash chromatography (SiO2, hexanes/ethyl acetate, 4/1 + 2% NEt3) afforded the title 
compound as a brown oil (1.53 g, 85%).  
1H NMR (400 MHz, CD3CN): δ = 7.06 (d, J = 8.6 Hz, 2H), 6.53 (d, J = 8.6 Hz, 2H), 4.35 − 4.15 
(bs, 2H), 1.94 ppm (s, 3H); 13C NMR (100 MHz, CD3CN): δ = 149.1, 133.8, 115.5, 113.3, 83.9, 
81.3, 4.5 ppm. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[116] 
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1-(Oct-6-yn-1-yl)piperidine (38a) 
K2CO3 (1.93 g, 14.0 mmol), 1,4,7,10,13,16-hexa-oxacyclo-
octadecane (150 mg, 567 µmol) and 1-bromo-6-octyne (2.00 g, 
10.6 mmol) were successively added to a solution of piperidine (880 µl, 9.00 mmol) in 
acetonitrile (12 mL) at ambient temperature. The reaction mixture was stirred at reflux 
temperature for 22 h. The mixture was filtered through a plug of silica, which was rinsed 
with ethyl acetate (80 mL). The solvent was evaporated and the crude material was purified 
by distillation (65 °C, 10-3 mbar) to give the title compound as a colorless oil (1.34 g, 77%).  
1H NMR (400 MHz, CDCl3): δ = 2.35 (bs, 4H), 2.29 − 2.24 (m, 2H), 2.14 − 2.08 (m, 2H), 1.77 (t, 
J = 2.6 Hz, 3H), 1.61 − 1.54 (m, 4H), 1.53 − 1.31 ppm (m, 8H); 13C NMR (100 MHz, CDCl3): δ = 
79.4, 75.6, 59.6, 54.8, 29.2, 27.2, 26.7, 26.1, 24.7, 18.8, 3.6 ppm; IR (film): ṽ = 2931, 2855, 
2799, 2762, 1442, 1376, 1351, 1328, 1307, 1269, 1154, 1122, 1094, 1040, 990, 862, 779, 732 
cm-1; MS (EI): m/z (%) = 193 (1), 151 (2), 125 (3), 124 (3), 99 (7), 98 (100), 96 (2), 84 (4), 70 
(5), 69 (2), 67 (2), 56 (2), 55 (5), 53 (2), 44 (2), 42 (4), 41 (5); HRMS (EI): m/z: calcd. for 
[C13H23N]
+: 193.1831, found: 193.1830. 
 
N-Butyloct-6-yn-1-amine (38b) 
A solution of 8-bromo-2-octyne (300 mg, 1.59 mmol) in n-butylamine 
(370 mg, 500 µL, 5.06 mmol) was stirred at 50 °C for 16 h. The solvent 
was evaporated and the crude product was dried at 50 °C for 3 h under high vacuum to 
afford the title compound as a colorless solid (279 mg, 97%). 
M.p. = 180 − 190 °C; 1H NMR (400 MHz, CDCl3): δ = 6.65 (bs, 1H), 2.99 − 2.93 (m, 4H), 2.17 − 
2.10 (m, 2H), 1.98 − 1.86 (m, 4H), 1.76 (t, J = 2.5 Hz, 3H), 1.54 − 1.37 (m, 6H), 0.95 ppm (t, J = 
7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 78.6, 76.1, 47.8, 47.7, 28.4, 27.9, 26.1, 25.5, 20.3, 
18.7, 13.6, 3.57 ppm; IR (film): ṽ = 2937, 1867, 1807, 1752, 1536, 2438, 1476, 1440, 1405, 
1378, 1346, 1290, 1266, 1134, 1044, 989, 977, 879, 823, 799, 727, 495 cm-1; MS (EI): m/z (%) 
= 181 (0.4), 166 (8), 138 (47), 125 (25), 112 (14), 110 (8), 96 (8), 95 (14), 93 (17), 86 (100), 84 
(15), 81 (11), 79 (16), 72 (8), 70 (12), 67 (22), 57 (12), 56 (13), 55 (16), 53 (9), 44 (24); HRMS 
(EI): m/z: calcd. for [C12H23N]
+: 181.1829, found: 181.1830. 
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Methyl oct-6-yn-1-yl malonate (42) 
NEt3 (3 mL) was added to a solution of oct-6-yne-1-ol 
(630 mg, 5.00 mmol) in CH2Cl2 (10 mL) at room temperature. 
A solution of methyl malonyl chloride (751 mg, 5.50 mmol) in 
CH2Cl2 (5 mL) was added to the stirred solution at 0 °C. The mixture was stirred at room 
temperature for 2 h before the reaction was quenched with HCl (2 M, 5 mL). The water layer 
was extracted with CH2Cl2 (3 × 25 mL) and the combined organic layers were washed with 
aq. NaHCO3 (10 mL) and water (20 mL). The combined extracts were dried over MgSO4, the 
solvent was evaporated, and the crude material was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, 10/1 to 6/1) to give the title compound as a colorless oil (830 mg, 
74%).  
1H NMR (400 MHz, CDCl3): δ = 4.15 (t, J = 6.9 Hz, 2H), 3.75 (s, 3H), 3.38 (s, 2H), 2.16 − 2.10 
(m, 2H), 1.77 (t, J = 2.5 Hz, 3H), 1.70 − 1.61 (m, 2H), 1.54 − 1.39 ppm (m, 4H); 13C NMR (100 
MHz, CDCl3): δ = 167.2, 166.7, 79.0, 75.9, 65.7, 52.6, 41.6, 28.7, 28.2, 25.2, 18.8, 3.6 ppm; IR 
(film): ṽ = 2951, 2862, 2219, 1731, 1673, 1437, 1411, 1333, 1272, 1199, 1148, 1019, 849, 
685, 582 cm-1; MS (EI): m/z (%) = 153 (9), 119 (21), 108 (21), 101 (42), 93 (100), 91 (27), 81 
(17), 80 (17), 79 (51), 77 (20), 69 (14), 68 (27), 67 (40), 66 (38),59 (25), 57 (11), 55 (28), 54 
(13), 53 (15), 43 (10), 41 (22), 39 (12); HRMS (ESI(pos)): m/z: calcd. for [C12H18O4+Na]
+: 
249.1099, found: 249.1097. 
 
Diethyl 2-acetamido-2-(but-2-yn-1-yl)malonate (EP4) 
In analogy to the literature[120], a solution of diethyl acetamidomalonate 
(1.04 g, 5.00 mmol) in DMF (5 mL) was added to a suspension of NaH 
(142 mg, 5.92 mmol) in DMF (5 mL) at 0 °C. The mixture was allowed to 
reach room temperature before 1-bromo-butyne (825 mg, 6.20 mmol) 
was added. After stirring for 3 h at 90 °C the solvent was evaporated. 
The residue was dissolved in water (20 mL) and the mixture was extracted with ethyl acetate 
(4 × 25 mL). The combined organic layers were dried over MgSO4, the solvent was 
evaporated, and the residue was purified by flash chromatography (SiO2, hexanes/ethyl 
acetate, 4/1 to 2/1) to give the title compound as a colorless oil (752 mg, 59%).  
1H NMR (400 MHz, CDCl3): δ = 6.89 (bs, 1H), 4.31 − 4.19 (m, 4H), 3.21 − 3.17 (m, 2H), 2.05 (s, 
3H), 1.73 (t, J = 2.6 Hz, 3H), 1.26 ppm (t, J = 7.1 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ = 169.2, 
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167.1, 78.9, 72.9, 65.8, 62.9, 24.3, 23.2, 14.1, 3.6 ppm; IR (film): ṽ = 3227, 3033, 2927, 2937, 
1738, 1638, 1529, 1430, 1369, 1313, 1285, 1229, 1190, 1095, 1055, 1012, 952, 869, 810, 665, 
619, 530, 455 cm-1; MS (EI): m/z (%) = 210 (16), 197 (12), 196 (97), 174 (45), 165 (10), 155 
(11), 154 (100), 153 (27), 150 (43), 146 (13), 136 812), 126 (56), 125 (14), 110 (16), 108 (37), 
82 (17), 81 (12), 80 (45), 79 (14), 53 (23), 45 (12), 43 (55); HRMS (ESI(pos)): m/z: calcd. for 
[C13H19NO5+Na]
+: 292.1155, found: 292.1157. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[120] 
 
2-Acetamidohex-4-ynoic acid (EP5) 
In analogy to the literature[120], NaOH (120 mg, 3.00 mmol) was added to 
as solution of diethyl 2-acetamido-2-(but-2-yn-1-yl)malonate (EP4) 
(650 mg, 2.40 mmol) in a mixture of EtOH (15 mL) and water (10 mL) at 
room temperature. The mixture was stirred at reflux temperature for 26 h 
before the solvent was reduced to 5 mL under vacuum. Aq. HCl (2 M, 4 mL) was added and 
the water layer was extracted with ethyl acetate (3 × 25 mL). Aq. NaHCO3 (25 mL) was added 
to the aqueous layer before extraction with ethyl acetate (3 × 25 mL). The combined organic 
layers were dried over MgSO4 and the solvent was evaporated to give the title compound as 
a colorless solid (317 mg, 78%). 
1H NMR (400 MHz, CDCl3): δ = 6.38 (bd, J = 7.8 Hz, 1H), 6.20 − 5.50 (bs, 1H), 4.70 (dt, J = 7.8, 
4.8 Hz, 1H), 2.83 − 2.67 (m, 2H), 2.10 (s, 3H), 1.78 ppm (t, J = 2.5 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ = 173.6, 171.1, 79.8, 72.9, 51.2, 23.2, 22.5, 3.7 ppm; MS (EI): m/z (%) = 169 (12), 
124 (35), 116 (7), 110 (24), 88 (6), 82 (58), 80 (11), 74 860), 67 (12), 60 (51), 53 (14), 43 (100), 
39 (12), 28 (19); HRMS (EI): m/z: calcd. for [C8H11NO3]: 169.0739, found: 169.0739.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[120] 
 
Methyl 2-acetamidohex-4-ynoate (48) 
In analogy to the literature[120], thionyl chloride (238 mg, 145 µl, 
2.00 mmol) was added to a solution of 2-acetamidohex-4-ynoic acid (EP5) 
(307 mg, 1.82 mmol) in MeOH (10 mL) at 0 °C. The reaction mixture was 
allowed to warm to room temperature and stirred for 5 h before the 
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solvent was evaporated. The crude material was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, 1/2 to 0/1) to give the title compound as a colorless solid (298 mg, 
90%).  
1H NMR (400 MHz, CDCl3): δ = 6.34 − 6.26 (bs, 1H), 4.74 − 4.66 (m, 1H), 3.76 (s, 3H), 2.74 − 
2.62 (m, 2H), 2.05 (s, 3H), 1.76 ppm (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 171.6, 170.5, 
79.4, 73.0, 52.8, 51.1, 23.4, 22.9, 3.6 ppm; IR (film): ṽ = 3305, 2951, 1751, 1645, 1552, 1429, 
1372, 1350, 1283, 1229, 1201, 1131, 1054, 1022, 936, 907, 804, 710, 677 cm-1; MS (EI): m/z 
(%) = 193 (4),130 (11), 124 (100), 109 (6), 93 (6), 88 (81), 82 (63), 67 (10), 60 (21), 55 (6), 43 
(42); HRMS (EI): m/z: calcd. for [C9H13NO3]: 183.0896, found: 183.0895.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[120] 
 
2-Iodo-3-methyl-1H-indole (EP6) 
In analogy to the literature[121], n-BuLi (27.8 mL, 44.5 mmol, 1.6 M in hexane) 
was added over 90 min to a solution of 3-methylindole (5.60 g, 42.7 mmol) in 
THF (100 mL) at ─78 °C. The mixture was stirred for 30 min at ─78°C before 
CO2 was introduced to the solution for 20 min at this temperature. The solvent was 
evaporated at 0 °C. THF (80 mL) and t-BuLi (1.7 M pentane, 26.5 mL, 45.1 mmol) were 
successively added at ─78 °C. The mixture was stirred for 1 h at ─78°C. 1,2-Diiodoethane 
(14.4 g, 51.1 mmol, dissolved in 15 mL THF) was added at ─78 °C and the mixture was stirred 
for 14 h at ─78 °C. Water (5 mL) was added before the mixture was slowly warmed to room 
temperature. Aq. sat. NH4Cl (50 ml) was added and the aqueous layer was extracted with 
ethyl acetate (2 × 100 mL). The combined extracts were washed with aq. sat. Na2S2O3 
(80 mL) and brine (50 mL) before they were dried over MgSO4. The solvent was evaporated 
and the crude material was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 
15/1 to 10/1) to give the title compound as a yellow brown solid (4.61 g, 42%).  
1H NMR (400 MHz, CDCl3): δ = 7.84 (bs, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.25 (d, J = 7.7 Hz, 1H), 
7.13 − 7.05 (m, 2H), 2.27 ppm (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 138.9, 128.2, 122.4, 
119.8, 118.3, 78.1, 12.0 ppm.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[122] 
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3-Methyl-2-(prop-1-yn-1-yl)-1H-indole (50) 
2-Iodo-3-methyl-1H-indole (EP6) (850 mg, 3.31 mmol) in THF (50 mL) 
was reacted with sodium 1-propynyl (1.05 g, 17.0 mmol), 
trimethylborate (1.95 mL, 17.3 mmol) and Pd(PPh3)4 (203 mg, 
176 µmol, 5 mol%) according to general procedure 1. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 30/1 to 15/1) afforded the title compound as an orange solid 
(243 mg, 44%).  
M.p. = 71.0 − 71.5 °C; 1H NMR (400 MHz, CDCl3): δ = 7.83 (bs, 1H), 7.50 (d, J = 7.7 Hz, 1H), 
7.23 (d, J = 7.7 Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 7.09 (t, J = 7.7 Hz, 1H), 2.36 (s, 3H), 2.14 ppm 
(s, 3H); 13C NMR (100 MHz, CDCl3): δ = 135.6, 128.2, 123.2, 119.8, 119.2, 117.4, 116.8, 110.7, 
91.8, 71.9, 9.7, 4.9 ppm; IR (film): ṽ = 3416, 3387, 3053, 2912, 1612, 1524, 1457, 1434, 1337, 
1306, 1240, 1157, 1005, 957, 928, 738, 665, 576, 530, 463, 432 cm-1; MS (EI): m/z (%) = 169 
(100), 154 (5), 139 (9), 128 (5), 115 (6), 101 (3), 84 (20), 77 (8), 70 (6), 63 (5); HRMS (EI): m/z: 
calcd. for [C12H11N]
+: 169.0890, found: 169.0891. 
 
2-Butyl-2-(prop-1-yn-1-yl)-1,3-dioxolane (53a) 
In analogy to the literature[123], 1,2-bis(trimethylsiloxy)ethane (350 mg, 
1.60 mmol) and oct-2-yne-4-one (53b) (100 mg, 0.81 mmol) were added 
to a solution of TMSOTf (5 mg, 22 µmol) in CH2Cl2 (3 mL) at ─78 °C. The 
reaction mixture was stirred for 14 h at ─30 °C and for 5 h at ─20 °C. Aq. sat. NaHCO3 (5 mL) 
was added and the water layer was extracted with CH2Cl2 (3 × 20 mL). The combined organic 
layers were washed with brine (10 mL) and dried over MgSO4. The solvent was evaporated 
and the crude material was purified by flash chromatography (SiO2, pentane/Et2O, 30/1) to 
give the title compound as a colorless oil (101 mg, 75%). 
1H NMR (400 MHz, CDCl3): δ = 4.08 − 4.04 (m, 2H), 3.96 − 3.92 (m, 2H), 1.86 − 1.82 (m, 2H), 
1.84 (s, 3H), 1.54 − 1.47 (m, 2H), 1.40 − 1.30 (m, 2H), 0.91 ppm (t, J = 7.4 Hz, 3H); 13C NMR 
(100 MHz, CDCl3): δ = 103.7, 80.6, 77.6, 64.7, 39.6, 26.4, 22.9, 14.3, 3.5 ppm; IR (film): ṽ = 
2956, 2932, 2874, 2236, 1736, 1468, 1380, 1343, 1296, 1240, 1196, 1164, 1116, 1084, 1032, 
963, 946, 881, 750, 672 cm-1; MS (EI): m/z (%) = 168 (0.1), 153 (10), 126 (7), 111 (100), 95 (3), 
83 (4), 77 (4), 67 (35), 55 (5), 39 (5); HRMS (CI(DE) i-Butane): m/z: calcd. for [C10H17O2]
+: 
169.1227, found: 169.1229. 
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Oct-2-yn-4-one (53b) 
In analogy to the literature[123], 1-propynylmagnesium bromide (0.5 M in 
THF, 15.0 mL, 7.50 mmol) was added to a mixture of ZnCl2 (1 M in Et2O, 
7.50 mL, 7.50 mmol) and THF (10 mL) at 0 °C. After stirring for 15 min, 
valeroyl chloride (600 mg, 4.98 mmol) was added and stirring continued for 1 h at 0 °C. Aq. 
sat. NH4Cl (5 mL) was added at ─10 °C. The aqueous layer was extracted with ethyl acetate (3 
× 30 mL). The combined organic layers were dried over MgSO4, the solvent was evaporated, 
and the crude material was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 
50/1 to 30/1) to give the title compound as a colorless oil (235 mg, 38%). 
1H NMR (400 MHz, CDCl3): δ = 2.52 (t, J = 7.5 Hz, 2H), 2.01 (s, 3H), 1.68 − 1.60 (m, 2H), 1.39 − 
1.29 (m, 2H), 0.91 ppm (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 188.6, 89.9, 80.4, 
45.3, 26.3, 22.3, 13.9, 4.2 ppm; IR (film): ṽ = 2959, 2933, 2873, 2219, 1735, 1670, 1465, 1407, 
1379, 1315, 1248, 1171, 1104, 1001, 964, 951, 882, 766, 732, 652, 566 cm-1; MS (EI): m/z (%) 
= 124 (0.4), 109 (9), 95 (5), 82 (53), 67 (100), 41 (6), 39 (9); HRMS (EI): m/z: calcd. for 
[C8H12O]
+: 124.0887, found: 124.0888.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[124] 
 
8-Azidooct-2-yne (61) 
A mixture of NaN3 (222 mg, 3.40 mmol), 8-bromo-2-octyne (189 mg, 
1.00 mmol) and water (2 mL) was stirred in a microwave reactor for 2 h at 
120 °C. The aqueous layer was extracted with methyl t-butyl ether (3 × 10 mL). The 
combined extracts were dried over MgSO4, the solvent was evaporated, and the crude 
material was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 50/1) to give 
the title compound  as a colorless oil (121 mg, 80%). 
1H NMR (400 MHz, CDCl3): δ = 3.27 (t, J = 6.9 Hz, 2H), 2.18 − 2.11 (m, 2H), 1.78 (t, J = 2.6 Hz, 
3H), 1.66 − 1.57 (m, 2H), 1.53 − 1.43 ppm (m, 4H); 13C NMR (100 MHz, CDCl3): δ = 78.9, 76.0, 
51.6, 28.7, 28.6, 26.1, 18.7, 3.6 ppm; IR (film): ṽ = 2930, 2859, 2093, 1727, 1679, 1578, 1456, 
1349, 1245, 1123, 1072, 970, 897, 825, 744 cm-1; MS (EI): m/z (%) = 151 (0.02), 122 (17), 108 
(19), 105 (6), 94 (76), 91 (23), 80 (40), 77 (20), 70 (27), 67 (72), 56 (58), 53 (84), 41 (100), 39 
(56), 30 (44), 29 (95); HRMS (CI(FE) i-Butane): m/z: calcd. for [C8H14N3]
+: 152.1189, found: 
152.1188. 
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Undec-9-yn-2-one (EP7) 
Oxalyl chloride (707 mg, 5.57 mmol) was added to a solution of 
DMSO (660 µl, 9.30 mmol) in CH2Cl2 (10 mL) at ─78 °C. The 
mixture was stirred for 5 min before undec-9-yn-2-ol (34) 
(780 mg, 4.64 mmol) in CH2Cl2 (5 mL) was added over 5 min. After 90 min at ─78 °C, NEt3 
(2.58 mL, 18.6 mmol) was added and the reaction mixture was allowed to warm to room 
temperature before water (20 mL) was added. The aqueous layer was extracted with CH2Cl2 
(30 mL). The combined organic layers were washed with aq. sat. NH4Cl (5 mL), aq. sat. 
Na2CO3 (5 mL), and water (5 mL). The combined extracts were dried over MgSO4, the solvent 
was evaporated, and the crude material was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, 10/1) to give the title compound as a colorless oil (450 mg, 58%). 
1H NMR (400 MHz, CDCl3): δ = 2.41 (t, J = 7.2 Hz, 2H), 2.12 (s, 3H), 2.12 − 2.06 (m, 2H), 1.76 
(t, J = 2.6 Hz, 3H), 1.61 − 1.52 (m, 2H), 1.50 − 1.23 ppm (m, 6H); 13C NMR (100 MHz, CDCl3): δ 
= 209.3, 79.3, 75.6, 43.8, 30.0, 29.0, 28.8, 28.7, 23.9, 18.8, 3.6 ppm; IR (film): ṽ = 2932, 2857, 
2219, 1712, 1434, 1357, 1164, 944, 720, 597, 521 cm-1; MS (EI): m/z (%) = 123 (7), 108 (16), 
93 (21), 81 (18), 79 (22), 71 (14), 68 (34), 67 (24), 58 (27), 55 (18), 53 (12), 43 (100), 41 (18), 
39 (11); HRMS (ESI(pos)): m/z: calcd. for [C11H18O+Na]
+: 189.1249, found: 189.1250. 
 
Undec-9-yn-2-one oxime (EP8) 
Undec-9-yn-2-one (EP7) (410 mg 2.47 mmol) was added to a 
solution of sodium acetate (243 mg, 2.96 mmol) and 
hydroxylammonium chloride (206 mg, 2.96 mmol) in a mixture 
of MeOH (5 mL) and water (100 µL) at ambient temperature. The mixture was stirred for 2 h 
at reflux temperature. The mixture was allowed to reach room temperature before water 
(20 mL) was added. The aqueous layer was extracted with ethyl acetate (3 × 30 mL). The 
combined extracts were dried over MgSO4, the solvent was evaporated, and the residue was 
purified by flash chromatography (SiO2, hexanes/ethyl acetate, 6/1 to 2/1) to give the title 
compound  as a colorless oil (392 mg, 88%, mixture of diastereomers).  
1H NMR (400 MHz, CDCl3): δ = 8.40 − 7.30 (bs, 1H), 2.18 (t, J =7.6 Hz, 2H), 2.14 − 2.08 (m, 2H), 
1.87 (s, 3H), 1.77 (t, J = 2.5 Hz, 3H), 1.56 − 1.26 ppm (m, 8H); 13C NMR (100 MHz, CDCl3): δ = 
159.0, 79.4, 75.6, 36.0, 29.1, 28.9, 28.7, 26.3, 18.8, 13.4, 3.6 ppm; IR (film): ṽ = 3226, 2928, 
2857, 1663, 1424, 1367, 1258, 1012, 925, 648 cm-1. MS (EI): m/z (%) = 150 (7), 122 (6), 109 
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(5), 108 (8), 96 (7), 93 (6), 91 (6), 86 (11), 84 (5), 82 (6), 81 (9), 79 (12), 73 (48), 71 (5), 70 
(45), 68 (6), 67 (13), 65 (5), 58 (7), 57 (100), 55 (19), 54 (7), 53 (13), 44 (5), 43 (7), 42 (43), 41 
(29), 39 (14), 29 (15), 27 (10); HRMS (ESI(pos)): m/z: calcd. for [C11H19NO+Na]
+: 182.1540, 
found: 182.1539.  
7.2.3 Homo Metathesis Reactions 
General procedure 2: Alkyne homo metathesis reactions with catalyst 28 
The alkyne and MS 5 Å (1 g per mmol alkyne) were stirred in toluene (0.2 M based on the 
alkyne) for 30 min before metathesis catalyst 28 was added in one portion. The reaction 
mixture was stirred under the individual conditions. The suspension was filtered through a 
plug of Celite®, which was carefully rinsed with ethyl acetate. The solvent was evaporated 
and the residue was purified by flash chromatography. 
 
4,4'-(Ethyne-1,2-diyl)dianiline (37a) 
4-(Prop-1-yne-1-yl)aniline (36a) (65 mg, 0.50 mmol) was 
stirred with MS 5 Å (600 mg) and catalyst 28 (20.0 mg, 
19.2 µmol, 4 mol%) in toluene (5 mL) for 13 h at 80 °C according to general procedure 2. 
Flash chromatography (SiO2, hexanes/ethyl acetate, 2/1 to 0/1 + 1% NEt3) afforded the title 
compound as a colorless solid (27 mg, 52%).  
1H NMR (400 MHz, CD3OD): δ = 7.17 (d, J = 8.3 Hz, 4H), 6.65 (d, J = 8.3 Hz, 4H), 4.83 ppm (s, 
6H); 13C NMR (100 MHz, CD3OD): δ = 149.1, 133.3, 115.9, 114.0, 88.4 ppm; IR (film): ṽ = 3418, 
3371, 2594, 2525, 2490, 2446, 1604, 1516, 1325, 1274, 1172, 1148, 1107, 822, 521 cm-1; MS 
DE(EI): m/z (%) = 209 (17), 208 (100), 180 (7), 152 (5), 104 (9), 90 (5); HRMS (ESI(pos)): m/z: 
calcd. for [C14H12N2+H]
+: 209.1072, found: 209.1073. 
The compound is literature known. 1H- and 13C-spectra were recorded in different 
solvents.[115, 125] 
 
1,12-Di(piperidin-1-yl)dodec-6-yne (39a) 
1-(Oct-6-yn-1-yl)piperidine (38a) (88 mg, 0.46 mmol) was 
stirred with MS 5 Å (840 mg) and catalyst 28 (18.2 mg, 
17.5 µmol, 4 mol%) in toluene (5 mL) for 1 h at room 
temperature according to general procedure 2. Flash 
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chromatography (SiO2, hexanes/ethyl acetate, 4/1 to 1/1 + 5% NEt3) afforded the title 
compound as a colorless oil (63 mg, 81%).  
1H NMR (400 MHz, CDCl3): δ = 2.42 − 2.30 (b, 8H), 2.30 − 2.24 (m, 4H), 2.13 (t, J = 7.0 Hz, 4H), 
1.61 − 1.54 (m, 8H), 1.53 − 1.31 ppm (m, 16H); 13C NMR (100 MHz, CDCl3): δ = 80.3, 59.7, 
54.8, 29.3, 27.2, 26.7, 26.2, 24.7, 18.9 ppm; IR (film): ṽ = 3392, 2931, 2856, 2799, 2762, 2517, 
1655, 1442, 1376, 1350, 1307, 1269, 1153, 1121, 1039, 962, 907, 860, 779, 731, 640, 514 cm-
1; MS (EI): m/z (%) = 332 (0.17), 248 (2), 234 (2), 206 (2), 204 (2), 178 (2), 151 (2), 124 (8), 111 
(2), 98 (100), 96 (4), 84 (8), 70 (5), 67 (2), 55 (6); HRMS (ESI(pos)): m/z: calcd. for 
[C22H40N2+H]
+: 333.3264, found: 333.3264. 
 
N
1
,N
12
-Dibutyldodec-6-yne-1,12-diamine (39b) 
N-Butyloct-6-yn-1-amine (28b) (90.0 mg, 0.496 mmol) was 
stirred with MS 5 Å (500 mg) and catalyst 28 (14.3 mg, 
13.7 µmol, 3 mol%) in toluene (2.5 mL) for 16 h at room 
temperature according to general procedure 2. Flash chromatography (SiO2, ethyl 
acetate/MeOH 10/1 to ethyl acetate/MeOH 5/1 + 5% NEt3) afforded the title compound as a 
colorless solid (59.1 mg, 77%).  
M.p. = 230 °C (decomp.); 1H NMR (400 MHz, CDCl3): δ = 3.68 (s, 2H), 2.71 – 2.61 (m, 8H), 2.20 
– 2.10 (m, 4H), 1.64 – 1.30 (m, 20H), 0.91 ppm (t, J = 7.3 Hz, 6H); 13C NMR (100 MHz, CDCl3): 
δ = 80.3, 49.7, 49.5, 31.5, 28.9, 26.6, 20.6, 18.8, 14.1 ppm; IR (film): ṽ = 2953, 2867, 2798, 
2450, 1442, 1344, 1042, 888, 790, 758 cm-1; MS (EI): m/z (%) = 308 (6), 266 (13), 265 (59), 
252 (8), 251 (40), 236 (15), 194 (24), 192 (19), 167 (11), 166 (27), 154 (26), 112 (50), 111 (14), 
93 (11), 86 (100), 84 (14), 81 (22), 67 (16), 44 (58); HRMS (ESI(pos)): m/z: calcd. for 
[C20H40N2+H]
+: 309.3264, found: 309.3264. 
 
2,2'-(Octadec-9-yne-1,18-diyl)bis(isoindoline-1,3-dione) (39d) 
2-(Undec-9-yn-1-yl)isoindoline-1,3-dione (38d) 
(145 mg, 0.488 mmol) was stirred with MS 5 Å 
(540 mg) and catalyst 28 (21.3 mg, 20.5 µmol, 
4 mol%) in toluene (4 mL) for 1 h at room 
temperature according to general procedure 2. Flash 
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chromatography (SiO2, hexanes/ethyl acetate, 6/1 to 4/1) afforded the title compound as a 
colorless solid (121 mg, 92%).  
M.p. = 75 − 76 °C, 1H NMR (400 MHz, CDCl3): δ = 7.85 − 7.80 (m, 4H), 7.72 − 7.67 (m, 4H), 
3.66 (t, J = 7.3 Hz, 4H), 2.11 (t, J = 7.0 Hz, 4H), 1.71 − 1.60 (m, 4H), 1.49 − 1.40 (m, 4H), 1.39 − 
1.24 ppm (m, 16H); 13C NMR (100 MHz, CDCl3): δ = 168.6, 133.9, 132.3, 123.3, 80.3, 38.2, 
29.2, 29.1, 28.9, 28.7, 27.0, 18.9 ppm; IR (film): ṽ = 2927, 2851, 1772, 1723, 1464, 1343, 
1393, 1359, 1331, 1187, 1119, 1054, 997, 924, 873, 801, 711, 624, 554, 531, 512, 475 cm-1; 
MS (EI): m/z (%) = 540 (7), 393 (18), 230 (8), 202 (7), 164 (40), 161 (20), 160 (100), 150 (53), 
148 (20), 135 (9), 133 (7), 130 (13), 121 (9), 95 (11), 81 (13), 67 (12), 55 (7); HRMS (ESI(pos)): 
m/z: calcd. for [C34H40N2O4+Na]
+: 563.2880, found: 563.2880. 
 
Dimethyl 3,24-dioxohexacos-13-ynedioate (43) 
Methyl 3-oxopentadec-13-ynoate (42) (23.1 mg, 
87 µmol) was stirred with MS 5 Å (270 mg) and 
catalyst 28 (12.5 mg, 12.0 µmol, 14 mol%) in 
toluene (2 mL) for 20 h at 80 °C according to general 
procedure 2. Flash chromatography (SiO2, hexanes/ethyl acetate, 10/1 to 4/1) afforded the 
title compound as a colorless solid (14.9 mg, 72%).  
M.p. = 78.5 − 79 °C. 1H NMR (400 MHz, CDCl3): δ = 3.74 (s, 6H), 3.44 (s, 4H), 2.52 (t, J = 7.3 
Hz, 4H), 2.13 (t, J = 7.0 Hz, 4H), 1.62 − 1.53 (m, 4H), 1.50 − 1.42 (m, 4H), 1.39 − 1.24 ppm (m, 
20H); 13C NMR (100 MHz, CDCl3): δ = 202.9, 168.0, 80.4, 52.4, 49.2, 43.2, 29.5, 29.4, 29.3, 
29.2, 29.1, 29.0, 23.6, 18.9 ppm; IR (film): ṽ = 2923, 2867, 2807, 2438, 1441, 1266, 1044, 879, 
823, 799, 728, 495 cm-1; MS (ESI(pos)) m/z (%) = 501.3 (100 [M+Na]+); HRMS (ESI(pos)): m/z: 
calcd. for [C28H46O6+Na]
+: 501.3191, found: 501.3187. 
 
O,O'-(Dodec-6-yne-1,12-diyl) dimethyl dimalonate (45) 
Methyl oct-6-yn-1-yl malonate (44) 
(205 mg, 0.91 mmol) was stirred with MS 
5 Å (1.1 g) and catalyst 28 (15.0 mg, 
14.4 µmol, 2 mol%) in toluene (5 mL) for 4 h at 80 °C according to general procedure 2. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 6/1 to 2/1) afforded the title compound as a 
colorless oil (169 mg, 94%).  
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1H NMR (400 MHz, CDCl3): δ = 4.14 (t, J = 6.6 Hz, 4H), 3.74 (s, 6H), 3.37 (s, 4H), 2.15 (t, J = 6.8 
Hz, 4H), 1.70 − 1.62 (m, 4H), 1.54 − 1.39 ppm (m, 8H); 13C NMR (100 MHz, CDCl3): δ = 167.2, 
166.7, 80.1, 65.7, 52.6, 41.5, 28.8, 28.2, 25.1, 18.8 ppm; IR (film): ṽ = 2953, 2864, 2212, 1728, 
1673, 1437, 1411, 1334, 1272, 1198, 1147, 1018, 908, 850, 787, 685, 579 cm-1; MS (ESI(pos)) 
m/z (%) = 421 (100 [M+Na]+); HRMS (ESI(pos)): m/z: calcd. for [C20H30O8+Na]
+: 421.1837, 
found: 421.1833. 
 
Dimethyl 2,7-diacetamidooct-4-ynedioate (49) 
Methyl 2-acetamidohex-4-ynoate (48) (50 mg, 273 µmol) was 
stirred with MS 5 Å (720 mg) and catalyst 28 (16.0 mg, 15.4 µmol, 
6 mol%) in toluene (5 mL) for 1 h at room temperature according 
to general procedure 2. Flash chromatography (SiO2, ethyl 
acetate/MeOH, 1/0 to 10/1) afforded the title compound as a 
colorless solid (38 mg, 89%, mixture of diastereomers).  
1H NMR (400 MHz, CDCl3): δ = 7.19 (bd, J = 9.1 Hz, 2H), 6.54 (bd, J = 8.5 Hz, 2H), 4.90 (dt, J = 
9.3, 3.8 Hz, 2H), 4.81 (dt, J = 8.4, 4.1 Hz, 2H), 3.80 (s, 6H), 3.80 (s, 6H), 2.74 – 2.54 (m, 8H), 
2.14 (s, 6H), 2.13 ppm (s, 6H); 13C NMR (100 MHz, CDCl3): δ = 172.7, 171.54, 170.50, 170.4, 
78.6, 78.0, 52.9, 50.7, 50.4, 23.6, 23.3, 23.2, 22.9 ppm; IR (film): ṽ = 3302, 2955, 2453, 1722, 
1638, 1552, 1474, 1417, 1345, 1282, 1264, 1239, 1202, 1034, 1007, 788, 684, 595, 512, 458 
cm-1; MS (EI): m/z (%) = 312 (27), 253 (26), 238 (15), 211 (90 ), 182 (100), 169 (88), 151 (11), 
140 (14), 131 (11), 124 (30), 109 (32), 99 (11), 88 (86), 82 (42), 80 (36), 60 (13), 43 (89); 
HRMS (ESI(pos)): m/z: calcd. for [C14H20N2O6+Na]
+: 335.1211, found: 335.121.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[120] 
 
1,2-Bis(3-methyl-1H-indol-2-yl)ethyne (51) 
3-Methyl-2-(prop-1-yn-1-yl)-1H-indole (50) (33.0 mg, 
195 µmol) was stirred with MS 5 Å (240 mg) and catalyst 28 
(9.3 mg, 8.9 µmol, 5 mol%) in toluene (5 mL) for 1 h at room 
temperature according to general procedure 2. The crude material was washed with CH2Cl2 
(1 mL) to afford the title compound as a colorless solid (24.3 mg, 88%).  
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M.p. = decomp. 260 °C; 1H NMR (400 MHz, CO(CH3)2): δ = 10.42 (bs, 2H), 7.55 (d, J = 8.1 Hz, 
2H), 7.37 (d, J = 8.1 Hz, 2H), 7.20 (t, J = 7.6 Hz, 2H), 7.08 (t, J = 7.6 Hz, 2H), 2.45 ppm (s, 6H); 
13C NMR (100 MHz, CO(CH3)2): δ = 137.7, 128.8, 124.3, 120.4, 119.9, 118.2, 117.6, 112.0, 
87.8, 10.0 ppm; IR (film): ṽ = 3393, 3049, 2914, 2528, 1466, 1440, 1373, 1338, 1318, 1242, 
1161, 1116, 1063, 1028, 1003, 959, 925, 871, 834, 742, 680, 663, 573, 537, 503, 474, 444, 
422 cm-1; MS (EI): m/z (%) = 284 (100), 283 (29), 282 (7), 281 (8), 269 (17), 268 (7), 241 (2), 
167 (2), 154 (5), 142 (10), 141 (15), 128 (3), 127 (3), 77 (2); HRMS (EI): m/z: calcd. for 
[C20H16N2]
+: 284.1313, found: 284.1313. 
 
1,2-Bis(2-butyl-1,3-dioxolan-2-yl)ethyne (54a) 
2-Butyl-2-(prop-1-yn-1-yl)-1,3-dioxolane (53a) (21.1 mg, 
0.125 mmol) was stirred with MS 5 Å (260 mg) and catalyst 28 
(7.0 mg, 6.7 µmol, 5 mol%) in toluene (2 mL) for 5 h at room 
temperature according to general procedure 2. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 30/1 to 10/1) afforded the title compound as 
a colorless oil (14.8 mg, 73%).  
1H NMR (400 MHz, CDCl3): δ = 4.08 − 4.01 (m, 4H), 4.00 − 3.94 (m, 4H), 1.89 − 1.85 (m, 4H), 
1.54 − 1.48 (m, 4H), 1.40 − 1.33 (m, 4H), 0.91 ppm (t, J = 7.3 Hz, 6H); 13C NMR (100 MHz, 
CDCl3): δ = 103.4, 81.6, 64.7, 38.9, 26.2, 22.7, 14.1 ppm; IR (film): ṽ = 2956, 2931, 2892, 2874, 
1468, 1380, 1342, 1296, 1259, 1236, 1198, 1160, 1118, 1048, 1029, 968, 945, 886, 587 cm-1; 
MS (EI): m/z (%) = 282 (0.21), 225 (100), 183 (29), 169 (3), 153 (15), 129 (24), 123 (26), 97 
(48), 79 (6), 57 (10); HRMS (ESI(pos)): m/z: calcd. for [C16H26O4+Na]
+: 305.1724, found: 
305.1723. 
 
1,12-Bis(tridecylthio)dodec-6-yne (56a) 
Oct-6-yn-1-yl(tridecyl)sulfane (55a) (144 mg, 0.46 mmol) 
was stirred with MS 5 Å (840 mg) and catalyst 28 (11.5 mg, 
11.0 µmol, 2 mol%) in toluene (5 mL) for 2 h at room 
temperature according to general procedure 2. Flash chromatography (SiO2, pentane/CH2Cl2, 
6/1 to 2/1) afforded the title compound as a colorless solid (112 mg, 85%). 
M.p. = 55 − 56 °C, 1H NMR (400 MHz, CDCl3): δ = 2.53 − 2.47 (m, 8H), 2.17 − 2.12 (m, 4H), 
1.64 − 1.53 (m, 8H), 1.51 − 1.45 (m, 8H), 1.42 − 1.21 (m, 36H), 0.88 ppm (t, J = 6.9 Hz, 6H); 13C 
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NMR (100 MHz, CDCl3): δ = 80.3, 32.4, 32.3, 32.1, 29.9, 29.81, 29.78, 29.76, 29.7, 29.5, 29.44, 
29.41, 29.1, 28.9, 28.3, 22.8, 18.8, 14.3 ppm; IR (film): ṽ = 2953, 2917, 2847, 1459, 1426, 
1370, 1297, 1250, 1199, 1186, 1026, 813, 762, 725, 512 cm-1; MS (EI): m/z (%) = 566 (4), 397 
(88), 365 (100), 311 (5), 229 (13), 197 (36), 195 (27), 141 (11), 107 (5), 101 (10), 95 (10), 87 
(14), 81 (13), 69 (11), 67 (10), 57 (19), 55 (17), 43 (22); HRMS (EI): m/z: calcd. for [C36H70S2]
+: 
566.4917, found: 566.4919. 
 
1,12-Bis(tridecylsulfinyl)dodec-6-yne (56b) 
1-(Oct-6-yn-1-ylsulfinyl)tridecane (55b) (86.0 mg, 263 µmol) 
was stirred with MS 5 Å (850 mg) and catalyst 28 (15.2 mg, 
14.6 µmol, 5 mol%) in toluene (5 mL) for 16 h at 80 °C 
according to general procedure 2. Flash chromatography 
(SiO2, CH2Cl2/ethyl acetate 1/1 to CH2Cl2/MeOH 10/1) afforded the title compound as a 
colorless solid (59 mg, 75%). 
M.p. = 108 − 110 °C, 1H NMR (400 MHz, CDCl3): δ = 2.73 − 2.56 (m, 8H), 2.20 − 2.13 (m, 4H), 
1.83 − 1.68 (m, 8H), 1.61 − 1.38 (m, 12H), 1.36 − 1.20 (m, 32H), 0.87 ppm (t, J = 6.9 Hz, 6H); 
13C NMR (100 MHz, CDCl3): δ = 80.2, 52.7, 52.5, 32.0, 29.74, 29.73, 29.67, 29.51, 29.46, 29.4, 
29.0, 28.8, 28.2, 22.81, 22.76, 22.4, 18.7, 14.2 ppm; IR (film): ṽ = 2912, 2848, 1466, 1081, 
1015, 723, 463 cm-1. MS (EI): m/z (%) = 598 (22), 581 (20), 430 (39), 429 (54), 381 (26), 365 
(43), 363 (67), 201 (87), 97 (28), 95 (38), 93 (27), 91 (22), 87 (23), 85 (22), 83 (41), 81 (61), 71 
(34), 70 (20), 69 (59), 67 (47), 57 (78), 56 (25), 55 (88), 43 (100), 41 (73), 29 (28); HRMS 
(ESI(pos)): m/z: calcd. for [C36H70O2S2+Na]
+: 621.4711, found: 621.4709. 
 
1,12-Dibromododec-6-yne (58) 
8-Bromooct-2-yne (57) (250 mg, 1.32 mmol) was stirred with MS 5 Å 
(1.25 g) and catalyst 28 (15.0 mg, 16 µmol, 1 mol%) in toluene 
(6 mL) for 2 h at room temperature according to general procedure 
2. Flash chromatography (SiO2, pentane) afforded the title compound as a colorless oil 
(212 mg, 91%). 
1H NMR (400 MHz, CDCl3): δ = 3.41 (t, J = 6.9 Hz, 4H), 2.16 (t, J = 6.5 Hz, 4H), 1.87 (dt, J = 6.9, 
6.9 Hz, 4H), 1.58 − 1.45 ppm (m, 8H); 13C NMR (100 MHz, CDCl3): δ = 80.3, 33.9, 32.6, 28.4, 
27.6, 18.8 ppm; IR (film): ṽ = 3302, 2936, 2860, 2213, 1904, 1732, 1671, 1431, 1349, 1230, 
S
S
11
11 4
4
O
O
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1199, 1023, 732, 642 cm-1; MS (EI): m/z (%) = 324 (1), 245 (9), 243 (9), 203 (9), 201 (9), 189 
(10), 187 (10), 163 (11), 135 (20), 121 (14), 109 (39), 95 (90), 81 (100), 67 (94), 55 (68), 41 
(47), 29 (20); HRMS (EI): m/z: calcd. for [C12H20Br2]
+: 321.9928, found: 321.9932. 
 
1,24-Diiodotetracos-11-yne (60) 
14-Iodotetradec-2-yne (59) (71 mg, 0.22 mmol) was stirred with 
MS 5 Å (345 mg) and catalyst 28 (11.0 mg, 10.6 µmol, 5 mol%) in 
toluene (4 mL) for 90 min at room temperature according to general procedure 2. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 1/0 to 50/1) afforded the title compound as a 
colorless solid (52 mg, 78%).  
M.p. = 54 − 54.5 °C, 1H NMR (400 MHz, CDCl3): δ = 3.18 (t, J = 7.1 Hz, 4H), 2.12 (t, J = 7.1 Hz, 
4H), 1.85 − 1.77 (m, 4H), 1.49 − 1.42 (m, 4H), 1.40 − 1.24 ppm (m, 28H); 13C NMR (100 MHz, 
CDCl3): δ = 80.5, 33.7, 30.6, 29.6, 29.5, 29.31, 29.27, 29.0, 28.7, 18.9, 7.4 ppm; IR (film): ṽ = 
2953, 2917, 2846, 1457, 1422, 1336, 1314, 1289, 1259, 1229, 1197, 1163, 1097, 1050, 1035, 
982, 802, 724, 602, 527, 456 cm-1; MS (EI): m/z (%) = 586 (15), 459 (8), 361 (7), 305 (9), 210 
(5), 155 (13), 151 (10), 137 (20), 123 (33), 111 (18), 109 (59), 95 (100), 81 (91), 67 (68), 57 
(16), 55 (69), 43 (28), 41 (43); HRMS (EI): m/z: calcd. for [C24H44I2]
+: 586.1528, found: 
586.1532. 
 
1,12-Diazidododec-6-yne (62) 
8-Azidooct-2-yne (61) (151 mg, 1.00 mmol) was stirred with MS 5 Å 
(1 g) and catalyst 28 (13.8 mg, 13.3 µmol, 2 mol%) in toluene (5 mL) 
for 16 h at room temperature according to general procedure 2. 
Flash chromatography (SiO2, hexanes/ethyl acetate, 100/1 to 50/1) afforded the title 
compound as a colorless oil (119 mg, 85%).  
1H NMR (400 MHz, CDCl3): δ = 3.27 (t, J = 6.9 Hz, 4H), 2.19 − 2.14 (m, 4H), 1.66 − 1.57 (m, 
4H), 1.55 − 1.42 ppm (m, 8H); 13C NMR (100 MHz, CDCl3): δ = 80.2, 51.5, 28.7, 28.6, 26.1, 
18.7 ppm; IR (film): ṽ = 2936, 2861, 2087, 1456, 1349, 1333, 1257, 1097, 1026, 896, 839, 733, 
668, 637, 557 cm-1; MS (EI): m/z (%) = 206 (2), 178 (17), 164 (23), 163 (24), 150 (15), 136 (30), 
122 (66), 108 (42), 94 (45), 91 (48), 84 (10), 79 (62), 77 (59), 67 (63), 55 (75), 41 (100), 28 
(62); HRMS (CI(DE), i-Butane): m/z: calcd. for [C12H21N6]
+: 249.1826, found: 249.1828. 
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7.2.4 Cross Metathesis Reactions 
General procedure 3: Alkyne cross metathesis with catalyst [Mo(≡CC6H4OMe)(OSiPh3)3] 28 
The alkynes were stirred with MS 5 Å (1 g per mmol alkyne) in toluene (0.2 M based on the 
alkyne) for 30 min before metathesis catalyst 28 was added in one portion. The reaction 
mixture was stirred under the individual conditions. The crude material was filtered through 
a plug of Celite®, which was carefully rinsed with ethyl acetate. The solvent was evaporated 
and the residue was purified by flash chromatography. 
 
Dec-6-yn-5-one (64) 
Oct-2-yn-4-one (53b) (21.8 mg, 0.176 mmol) and 4-octyne (63) 
(82.5 mg, 0.749 mmol) were stirred with MS 5 Å (370 mg), MnCl2 
(5.1 mg, 0.041 mmol), and catalyst 28 (9.8 mg, 9.4 µmol, 6 mol%) 
in toluene (2.5 mL) for 16 h at 120 °C according to general procedure 3. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 50/1) afforded the title compound as a 
colorless oil (20.2 mg, 75%). 
1H NMR (400 MHz, CDCl3): δ = 2.52 (t, J = 7.5 Hz, 2H), 2.34 (t, J = 7.1 Hz, 2H), 1.69 − 1.56 (m, 
4H), 1.40 − 1.29 (m, 2H), 1.02 (t, J = 7.3 Hz, 3H), 0.92 ppm (t, J = 7.3 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ = 188.7, 94.2, 81.2, 45.4, 26.4, 22.3, 21.4, 21.0, 13.9, 13.6 ppm; IR (film): ṽ = 
3070, 2966, 2935, 2874, 2230, 2708, 1462, 1429, 1366, 1339, 1246, 1157, 1115, 1069, 1028, 
997, 834, 752, 711, 700, 516 cm-1; MS (EI): m/z (%) = 137 (7), 110 (35), 96 (7), 95 (100), 82 
(12), 67 (16), 53 (15), 41 (11), 39 (7); HRMS (CI, (FE) i-Butane): m/z: calcd. for [C10H17O]
+: 
153.1281, found: 153.1279. 
 
 2-Butyl-2-(pent-1-yn-1-yl)-1,3-dioxolane (65)  
2-Butyl-2-(prop-1-yn-1-yl)-1,3-dioxolane (53a) (59.0 mg, 
0.351 mmol) and 4-octyne (63) (150 mg, 1.36 mmol) were stirred 
with MS 5 Å (1 g) and catalyst 28 (23.1 mg, 22.2 µmol, 6 mol%) in 
toluene (5 mL) for 30 min at room temperature according to general procedure 3. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 50/1) afforded the title compound as a 
colorless oil (51.2 mg, 74%).  
1H NMR (400 MHz, CDCl3): δ = 4.10 − 4.02 (m, 2H), 4.01 − 3.91 (m, 2H), 2.19 (t, J = 7.2 Hz, 
2H), 1.89 − 1.82 (m, 2H), 1.58 − 1.48 (m, 4H), 1.42 − 1.31 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H), 
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0.91 ppm (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 103.7, 84.9, 78.5, 64.6, 39.5, 26.4, 
22.8, 22.1, 20.7, 14.1, 13.6 ppm; IR (film): ṽ = 2958, 2932, 2873, 2233, 1463, 1379, 1339, 
1294, 1238, 1196, 1161, 1116, 1089, 1070, 1038, 965, 884, 787, 740, 671 cm-1; MS (EI): m/z 
(%) = 196 (0.1), 154 (5), 153 (20), 139 (100), 125 (5), 95 (32), 83 (5), 79 (9), 77 (5), 67 (9), 66 
(5), 65 (6), 55 (7), 53 (7), 41 (9), 39 (5); HRMS (ESI(pos)): m/z: calcd. for [C12H20O3+Na]
+: 
219.1356, found: 219.1356. 
 
9-Bromo-2,2-dimethylnon-3-yne (67) 
8-Bromooct-2-yne (57) (95 mg, 0.5 mmol) and 4,4-dimethylpent-
2-yne (66) (48 mg, 0.5 mmol) were stirred with MS 5 Å (1 g) and 
catalyst 28 (50 mg, 48.0 µmol, 10 mol%) in toluene (5 mL) for 
2.5 h at room temperature according to  general procedure 3. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 1/0 to 100/1) afforded the title compound as a colorless oil (61 mg, 
53%). 
1H NMR (400 MHz, CDCl3): δ = 3.42 (t, J = 6.8 Hz, 2H), 2.16 (t, J = 6.5 Hz, 2H), 1.92 − 1.84 (m, 
2H), 1.58 − 1.46 (m, 4H), 1.20 ppm (s, 9H); 13C NMR (100 MHz, CDCl3): δ = 89.6, 78.1, 33.9, 
32.5, 31.6, 28.4, 27.4, 19.7 ppm; IR (film): ṽ = 2966, 2937, 2862, 1475, 1456, 1437, 1390, 
1361, 1332, 1265, 1241, 1205, 1068, 1031, 928, 895, 819, 731, 643, 563, 538, 513, 412 cm-1; 
MS (EI): m/z (%) = 230 (0.3), 217 (11), 215 (11), 175 (5), 173 (5), 161 (7), 159 (6), 137 (5), 135 
(14), 123 (9), 121 (6), 109 (45), 107 (38), 95 (96), 91 (25), 83 (31), 81 (100), 69 (49), 67 (65), 
65 (16), 57 (27), 55 (46), 53 (18), 43 (14), 41 (20); HRMS (EI): m/z: calcd. for [C11H19Br]
+: 
230.0673, found: 230.0670. 
 
2-(3,3-Dimethylbut-1-yn-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (69) 
4,4,5,5-Tetramethyl-2-(prop-1-yn-1-yl)-1,3,2-dioxaborolane (68) 
(249 mg, 1.50 mmol) and 4,4-dimethylpent-2-yne (66) (240 mg, 
2.50 mmol) were stirred with MS 5 Å (2.5 g) and catalyst 28 (30.3 mg, 
29.1 µmol, 2 mol%) in toluene (12.5 mL) for 84 h at 60 °C according to 
general procedure 3. Sublimation (10-3 mbar, 60 °C) afforded the title compound as a 
colorless solid (116mg, 37%).  
1H NMR (400 MHz, CDCl3): δ = 1.27 (s, 12H), 1.24 (s, 9H); 
13C NMR (100 MHz, CDCl3): δ = 84.2, 
30.7, 28.6, 24.9, 24.8 ppm. 
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The analytical and spectroscopic data are in agreement with those reported in the 
literature.[126] 
 
Methyl 2-acetamidooct-4-ynoate (70) 
Methyl 2-acetamidohex-4-ynoate (48) (24.3 mg, 0.133 mmol) and 4-
octyne (63) (225 mg, 2.04 mmol) were stirred with MS 5 Å (300 mg) 
and catalyst 28 (30.3 mg, 29.1 µmol, 22 mol%) in toluene (2 mL) for 
1 h at room temperature according to general procedure 3. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 2/1) afforded the title compound as a 
colorless oil (22.4 mg, 80%).  
1H NMR (400 MHz, CDCl3): δ = 6.25 (d, J = 6.9 Hz, 1H), 4.70 (dt, J = 8.1, 4.2 Hz, 1H), 3.76 (s, 
3H), 2.77 − 2.63 (m, 2H), 2.10 (tt, J = 7.0, 2.4 Hz, 2H), 2.04 (s, 3H), 1.52 − 1.42 (m, 2H), 
0.94 ppm (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 171.4, 169.8, 84.0, 74.1, 52.7, 
51.2, 23.3, 23.0, 22.4, 20.7, 13.5 ppm; IR (film): ṽ = 3298, 3086, 2926, 2929, 2863, 1738, 
1650, 1553, 1430, 1373, 1352, 1302, 1284, 1227, 1201, 1181, 1131, 1055, 1022, 935, 910, 
808, 791, 718, 677, 600, 518, 456 cm-1; MS (EI): m/z (%) = 211 (2), 183 (7), 153 (5), 152 (44), 
137 (19), 124 (41), 110 (38), 109 (8), 93 (5), 88 (100), 80 (11), 79 (6), 68 (18), 60 (12), 53 (6), 
43 (33); HRMS (ESI(pos)): m/z: calcd. for [C11H17N1O3+Na]
+: 234.1101, found: 234.1101. 
 
7.3 Synthesis of Multidentate Ligands 
7.3.1 Synthesis of Ligands with Silicon Linkers 
Phenyltrivinylsilane (90d) 
Trichloromethylsilane (2.12 g, 10.0 mmol) was added dropwise at room 
temperature over 60 min to a solution of vinylmagnesium bromide (1 M in 
THF, 31.0 mL, 31.0 mmol) in THF (20 mL). After stirring for 16 h the reaction 
mixture was cooled to 0 °C and aq. sat. NH4Cl (30 mL) was added. Stirring was 
continued for 10 min at room temperature before the aqueous layer was extracted with 
ethyl acetate (2 × 50 mL) and the combined extracts were dried over MgSO4. Evaporation of 
the solvent and purification of the residue by flash chromatography (SiO2, hexanes) afforded 
the title compound as a colorless oil (1.23 g, 66%).  
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1H NMR (400 MHz, CDCl3): δ = 7.54 – 7.59 (m, 2H), 7.35 – 7.42 (m, 3H), 6.35 (dd, J = 19.9, 
14.6 Hz, 3H), 6.21 (dd, J = 14.6, 4.0 Hz, 3H), 5.84 ppm (dd, J = 19.9, 4.0 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ = 136.1, 135.2, 134.6, 133.9, 129.6, 128.0 ppm; IR (film): ṽ = 3051, 3007, 
2969, 2944, 1590, 1428, 1400, 1266, 1110, 1006, 956, 809, 699, 619, 549, 471 cm-1; MS (EI): 
m/z (%) = 186 (12), 159 (38), 158 (100), 157 (13), 133 (50), 132 (23), 131 (47), 130 (22), 128 
(13), 108 (11), 107 (47), 106 (10), 105 (34), 82 (23), 81 (10), 53 (12); HRMS (EI (FE)): m/z: 
calcd. for [C12H14Si]
+: 186.0864, found: 186.0865.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[127] 
 
((Methylsilanetriyl)tris(ethane-2,1-diyl))tris(diphenylsilanol) (89a) 
Trivinylmethylsilane (746 mg, 6.00 mmol) was dissolved in 
toluene (50 mL) in a flame-dried Schlenk flask. After addition 
of Karstedt`s catalyst (0.1 M in poly(dimethylsiloxane), 
0.3 mL, 0.03 mmol) the mixture was heated to 60 °C and 
diphenylchlorosilane (4.05 g, 18.5 mmol) was added 
dropwise and stirring was continued for 20 h at 60 °C. The 
mixture was then allowed to reach ambient temperature 
before H2O (10 mL) and NEt3 (0.5 mL) were added. After stirring for 20 min aq. sat. NH4Cl 
(5 mL) was added and stirring continued for another 10 min. The aqueous layer was 
extracted with ethyl acetate (3 × 100 mL) and the combined organic layers were dried over 
MgSO4. The solvent was evaporated and the crude product was purified by column 
chromatography (SiO2, hexanes/ethyl acetate, 4/1 to 3/1). The material was dissolved in 
CH2Cl2 (20 mL) and MS 3 Å (2 g) was added. After gentle stirring of the suspension for 2 h at 
room temperature, the MS was filtered off and the filtrate was evaporated. The product was 
dried for 4 h under high vacuum to afford the title compound as a colorless hygroscopic solid 
(2.43 g, 56%).  
M.p.: 55 – 65 °C; 1H NMR (400 MHz, CD3OD): δ = 7.54 – 7.48 (m, 12H), 7.35 – 7.26 (m, 18H), 
0.90 – 0.79 (m, 6H), 0.56 – 0.47 (m, 6H), –0.11 ppm (s, 3H); 13C NMR (100 MHz, CD3OD): δ = 
138.2, 135.3, 130.6, 128.8, 8.2, 4.7, –6.4 ppm; IR (film): ṽ = 3258, 3068, 3047, 3012, 2908, 
2879, 1589, 1427, 1249, 1111, 1053, 1027, 997, 818, 695, 664, 636, 499, 479, 445 cm-1; MS 
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(ESI(pos)): m/z (%) = 747.3 [M+Na]+ (100); HRMS (ESI(pos)): m/z: calcd. for [C43H48O3Si4+Na]
+: 
747.2569, found: 747.2573. 
 
((Phenylsilanetriyl)tris(ethane-2,1-diyl))tris(diphenylsilanol) (89d) 
Phenyltrivinylmethylsilane 90d (950 mg, 5.10 mmol) was 
dissolved in toluene (20 mL) in a flame-dried Schlenk flask. 
After addition of Karstedt`s catalyst (0.1 M in 
poly(dimethylsiloxane), 0.4 mL, 0.04 mmol) the mixture 
was heated to 50 °C and diphenylchlorosilane (3.91 g, 
17.9 mmol) was added dropwise and stirring was 
continued for 16 h at this temperature before a second portion of Karstedt`s catalyst (0.1 M 
in poly(dimethylsiloxane), 0.1 mL, 0.01 mmol) was added and stirring was continued for 
another 2 h at 65 °C. The mixture was then allowed to reach ambient temperature before 
H2O (20 mL) and NEt3 (0.5 mL) were added. After stirring for 20 min, aq. sat. NH4Cl (5 mL) 
was introduced and stirring was continued for 10 min. The aqueous layer was extracted with 
ethyl acetate (3 × 100 mL) and the combined organic layers were dried over MgSO4. The 
solvent was evaporated and the crude product was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, 4/1 to 2/1). The material was dissolved in CH2Cl2 (20 mL) and MS 3 Å 
(2 g) was added. After gentle stirring of the suspension for 2 h at room temperature, the MS 
was filtered off and the filtrate was evaporated. The product was dried for 4 h under high 
vacuum to afford the title compound as a colorless hygroscopic solid (2.31 g, 58%). 
M.p.: 56 – 60 °C; 1H NMR (400 MHz, CDCl3): δ = 7.51 – 7.55 (m, 12H), 7.30 – 7.42 (m, 23H), 
2.38 – 2.41 (m, 3H), 0.84 – 1.00 ppm (m, 12H); 13C NMR (100 MHz, CDCl3): δ = 136.3, 136.0, 
134.5, 134.3, 130.0, 129.2, 128.0, 127.9, 7.0, 2.3 ppm; IR (film): ṽ = 3298, 3067, 3046, 2910, 
1705, 1589, 1486, 1427, 1304, 1262, 1110, 1049, 997, 828, 694, 665, 643, 501, 471, 445 cm-1; 
MS (ESI(pos)): m/z (%) = 809.4 [M+Na]+ (100); HRMS (ESI(pos)): m/z: calcd. for 
[C48H50O3Si4+Na]
+: 809.2729, found: 809.2729. 
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Si
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((Methylsilanetriyl)tris(ethane-2,1-diyl))tris(diisopropylsilanol) (89b) 
Trivinylmethylsilane (373 mg, 3.00 mmol) was dissolved in 
toluene (10 mL) in a flame-dried Schlenk flask. After addition of 
Karstedt`s catalyst (0.1 M in poly(dimethyl-siloxane), 0.30 mL, 
0.03 mmol) the mixture was heated to 70 °C and diphenyl-
chlorosilane (1.87 mL, 1.63 g, 10.8 mmol) was added dropwise 
and stirring continued for 16 h at this temperature. The mixture 
was then allowed to reach ambient temperature before water (10 mL) and NEt3 (1 mL) were 
added. After stirring for 20 min aq. sat. NH4Cl (5 mL) was added and stirring was continued 
for another 10 min. The aqueous layer was extracted with ethyl acetate (3 × 50 mL) and the 
combined organic layers were dried over MgSO4. The solvent was evaporated and the crude 
product was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 4/1 to 2/1). The 
material was dissolved in CH2Cl2 (20 mL) and MS 3 Å (2 g) was added. After gentle stirring of 
the suspension for 2 h at room temperature, the MS was filtered off and the filtrate was 
evaporated. The product was dried for 4 h under high vacuum to afford the title compound 
as a colorless hygroscopic solid (675 mg, 43%). 
M.p.: 73 – 75 °C; 1H NMR (400 MHz, CDCl3): δ = 1.53 (bs, 3H), 0.98 – 1.04 (m, 42H), 0.51 (s, 
12H), –0.04 ppm (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 17.6, 12.8, 4.1, 3.4, –6.6 ppm; IR 
(film): ṽ = 3297, 2941, 2891, 2864, 1461, 1406, 1383, 1365, 1248, 1133, 1065, 992, 919, 882, 
807, 722, 702, 650, 466 cm-1; MS (EI): m/z (%) = 361 (33), 343 (100), 301 (4), 273 (3), 247 (2), 
201 (4), 159 (5), 131 (5), 103 (4), 75 (5); HRMS (ESI(pos)): m/z: calcd. for [C25H60O3Si4+Na]
+: 
543.3512, found: 543.3508. 
 
7.3.2 Synthesis of Ligands with Trisubstituted Aromatic Linkers 
1,3,5-Trivinylbenzene (96a) 
A solution of 1,3,5-tribromobenzene (378 mg, 1.20 mmol), 
vinyltributylstannane (1.46 g, 4.60 mmol), CsF (577 mg, 3.80 mmol) and 
(Ph3P)4Pd (231 mg, 0.20 mmol, 17 mol%) in DMF (10 mL) was stirred for 
3.5 h at 135 °C in a closed JYoung tube. After cooling to room temperature, the reaction was 
quenched with aq. sat. KF (100 mL). The mixture was diluted with methyl t-butyl ether 
(200 mL) and stirred for 10 min before water (100 mL) and aq. sat. Na/K-tartrate (100 mL) 
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were added.  The aqueous layer was extracted with methyl t-butyl ether (3 × 150 mL), the 
combined extracts were dried over MgSO4 and the solvent was evaporated. The crude 
product was purified by flash chromatography (SiO2, hexanes) to give the title compound as 
a colorless solid (150 mg, 80%). 
1H NMR (400 MHz, CDCl3): δ = 7.36 (s, 3H), 6.73 (dd, J = 17.6, 10.9 Hz, 3H), 5.80 (dd, J = 17.6, 
0.9 Hz, 3H), 5.29 ppm (dd, J = 10.9, 0.9 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 138.1, 136.7, 
123.7, 114.5 ppm; IR (film): ṽ = 3087, 3042, 3007, 2981, 2958, 2926, 2854, 1822, 1770, 1702, 
1633, 1585, 1444, 1413, 1396, 1299, 1274, 1257, 1166, 1080, 1052, 1029, 986, 903, 877, 715, 
595, 544, 483 cm-1; MS (EI): m/z (%) = 157 (12), 156 (100), 155 (23), 153 (16), 141 (26), 129 
(16), 128 (25), 127 (12), 115 (33), 77 (10); HRMS (EI(DE)): m/z: calcd. for [C12H12]: 156.0940, 
found: 156.0939.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[128] 
 
1,3,5-Triallylbenzene (96b) 
A solution of 1,3,5-tribromobenzene (1.67 g, 5.32 mmol), 
allyltributylstannane (5.50 mL, 5.87 g, 17.7 mmol) and (Ph3P)4Pd 
(1.54 g, 1.33 mmol, 25 mol%) in toluene (8 mL) was stirred for 18 h 
at 120 °C in a closed JYoung tube. After cooling to room 
temperature, the reaction was quenched with aq. sat. KF (20 mL). The mixture was diluted 
with methyl t-butyl ether (20 mL) and stirred for 15 min before water (30 mL) and aq. sat. 
Na/K-tartrate (10 mL) were added. The aqueous layer was extracted with ethyl acetate 
(3 × 50 mL), the combined organic layers were dried over MgSO4 and the solvent was 
evaporated. The crude product was purified by distillation (10-3 mbar, 65 °C) to give the title 
compound as a colorless oil (801 mg, 76%).  
1H NMR (400 MHz, CDCl3): δ = 6.87 (s, 3H), 5.96 (ddt, J = 17.0, 10.1, 6.8 Hz, 3H), 5.04 – 5.12 
(m, 6H), 3.35 ppm (d, J = 6.8 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ = 140.5, 137.7, 126.8, 
115.8, 40.3 ppm; IR (film): ṽ = 3078, 3005, 2978, 2957, 2904, 2872, 2850, 1833, 1639, 1601, 
1456, 1431, 1412, 1377, 1340, 1281, 1189, 1157, 1098, 1072, 992, 962, 909, 845, 740, 715, 
685, 654, 594, 557, 512, 451 cm-1; MS (EI): m/z (%) = 198 (28), 157 (75), 155 (14), 153 (11), 142 
(26), 141 (28), 130 (12), 129 (100), 128 (43), 127 (13), 116 (26), 115 (72), 91 (17), 77 (12), 41 (16); 
HRMS (EI(FE)): m/z: calcd. for [C15H18]: 198.1410, found: 198.1409.  
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The analytical and spectroscopic data are in agreement with those reported in the 
literature.[129] 
 
(Benzene-1,3,5-triyltris(ethane-2,1-diyl))tris(diphenylsilanol) (94a) 
1,3,5-Triallylbenzene (96a) (75 mg, 0.48 mmol) was 
dissolved in toluene (5 mL) in a flame-dried Schlenk 
flask. After addition of Karstedt`s catalyst (0.1 M in 
poly(dimethylsiloxane), 0.20 mL, 0.02 mmol) the 
mixture was heated to 70 °C and diphenylchlorosilane 
(0.39 mL, 437 mg, 2.00 mmol) was added dropwise 
and stirring continued for 16 h at 70 °C. The mixture 
was allowed to reach ambient temperature before H2O (10 mL) and NEt3 (1 mL) were added 
and the mixture stirred for 20 min. Aq. sat. NH4Cl (5 mL) was added and stirring was 
continued for another 10 min. The aqueous layer was extracted with ethyl acetate 
(3 × 50 mL) and the combined organic layers were dried over MgSO4. Evaporation of the 
solvent and flash chromatography (SiO2, hexanes/ethyl acetate, 6/1 to 2/1) of the residue 
gave the crude product which was dried with MS 3 Å (2 g) by stirring in CH2Cl2 (10 mL) for 2 h 
at room temperature. The MS was filtered off and the solvent was evaporated. The material 
was dried for 4 h under high vacuum to give the title compound as a colorless hygroscopic 
solid (150 mg, 41%).  
M.p.: 55 – 57 °C; 1H NMR (400 MHz, CDCl3): δ = 7.59 (d, J = 6.6 Hz, 12H), 7.43 – 7.32 (m, 18H), 
6.72 (s, 3H), 2.66 – 2.75 (m, 9H), 1.48 ppm (t, J = 8.0 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ = 
144.4, 136.3, 134.2, 130.0, 128.1, 125.5, 29.3, 17.0 ppm; IR (film): ṽ = 3321, 3069, 3049, 
3012, 2975, 2920, 1708, 1591, 1454, 1427, 1376, 1319, 1262, 1175, 1113, 998, 908, 830, 757, 
732, 696, 647, 603, 567, 481, 448 cm-1; MS (EI): m/z (%) = 444 (7), 366 (6), 363 (5), 199 (19), 
79 (7), 78 (100), 77 (23), 76 (5), 52 (14), 51 816), 50 (10), 39 (7); HRMS (ESI(pos)): m/z: calcd. 
for [C48H48O3Si3+Na]
+: 779.2802, found: 779.2804. 
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Si
HO OH
OH
7 Experimental Procedures 
101 
 
(Benzene-1,3,5-triyltris(propane-3,1-diyl))tris(diphenylsilanol) (94b) 
Trialkene 96b (397 mg, 2.00 mmol) was 
dissolved in toluene (10 mL) in a flame-dried 
Schlenk flask. After addition of Karstedt`s 
catalyst (2% Pt. in xylene, 0.20 mL) the mixture 
was heated to 50 °C and diphenylchlorosilane 
(1.37 mL, 1.52 g, 7.0 mmol) was added 
dropwise. The mixture was stirred for 16 h at 
this temperature before a second portion of Karstedt`s catalyst (2% Pt. in xylene, 0.30 mL) 
and diphenylchlorosilane (0.30 mL, 0.33 g, 1.1 mmol) were added and stirring continued for 
another 2 h at 60 °C. The mixture was allowed to reach ambient temperature before H2O 
(20 mL) and NEt3 (1 mL) were added. After stirring for 20 min, aq. sat. NH4Cl (5 mL) was 
added and stirring was continued for 10 min. The aqueous layer was extracted with ethyl 
acetate (3 × 50 mL) and the combined organic layers were dried over MgSO4. The solvent 
was evaporated and the crude product was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, 4/1 to 2/1). The material was dissolved in CH2Cl2 (20 mL) and MS 3 Å 
(2 g) was added. After gentle stirring for 2 h at room temperature, the MS was filtered off 
and the solvent was evaporated. The product was dried for 4 h under high vacuum to afford 
the title compound as a colorless hygroscopic solid (756 mg, 47%).  
M.p.: 57 – 65 °C; 1H NMR (400 MHz, CDCl3): δ = 7.52 – 7.56 (m, 12H), 7.30 – 7.41 (m, 18H), 
6.71 (s, 3H), 2.56 (t, J = 7.4 Hz, 6H), 2.32 – 2.38 (m, 3H), 1.70 – 1.80 (m, 6H), 1.12 – 1.17 ppm 
(m, 6H); 13C NMR (100 MHz, CDCl3): δ = 142.1, 136.3, 134.3, 130.0, 128.0, 126.5, 39.3, 24.9, 
14.8 ppm; IR (film): ṽ = 3241, 3067, 3046, 2999, 2923, 2857, 1590, 1427, 1112, 1067, 1045, 
1027, 997, 823, 734, 695, 504, 480, 448 cm-1; MS (ESI(pos)): m/z (%) = 821 [M+Na]+ (100); 
HRMS (ESI(pos)): m/z: calcd. for [C51H54O3Si3+Na]
+: 821.3274, found: 821.3273. 
7.3.3 Synthesis of Ligands with Hexasubstituted Aromatic Linkers 
1,3,5-Tribromo-2,4,6-triethylbenzene (99) 
1,3,5-Triethylbenzene (4.48 mL, 3.86 g, 23.8 mmol) was added over 
15 min to a mixture or bromine (20 mL) and iron powder (400 mg, 
7.16 mmol) at 0 °C. The mixture was warmed to room temperature and 
stirred for 16 h before it was poured into aq. sat. Na2S2O3 containing KOH 
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(30 g). After extraction of the aqueous layer with CH2Cl2 (3 × 200 mL), the combined extracts 
were dried over MgSO4. The solvent was removed and the residue recrystallized from 
ethanol to give the title compound as a colorless crystalline solid (7.20 g, 76%).  
M.p.: 103 – 105 °C; 1H NMR (400 MHz, CDCl3): δ = 3.14 (q, J = 7.7 Hz, 6H), 1.17 ppm (t, J = 7.7 
Hz, 9H); 13C NMR (100 MHz, CDCl3): δ = 142.6, 124.4, 32.8, 12.4 ppm; IR (film): ṽ = 2971, 
2935, 2870, 1534, 1461, 1360, 1313, 1240, 1075, 1054, 1003, 893, 784, 663, 620 cm-1; MS 
(EI): m/z (%) = 402 (21), 400 (61), 398 (62), 396 (22), 387 (26), 385 (81), 381 (29), 319 (12), 
223 (13), 144 (16), 143 (60), 142 (21), 141 (42), 130 (15), 129 (60), 128 (100), 127 (23), 116 
(12), 115 (62), 103 (10), 102 (12), 91 (15), 77 (26), 75 (12), 71 (12), 70 (13), 64 (16), 63 (29), 
51 (22), 39 (15); HRMS (EI(DE)): m/z: calcd. for [C12H15Br3]
+: 395.8723, found: 395.8724.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[130]  
 
1,3,5-Trivinyl-2,4,6-triethylbenzene (100b) 
Vinyltributylstannane (2.17g, 6.84 mmol) was added to a solution of 1,3,5-
tribromo-2,4,6-triethylbenzene (99) (678 mg, 1.70 mmol), (Ph3P)4Pd 
(395 mg, 342 µmol, 20 mol%) and CsF (858 mg, 5.65 mmol) in DMF 
(10 mL). The mixture was stirred for 3.5 h at 135 °C in a closed JYoung 
tube. After cooling to room temperature, methyl t-butyl ether (200 mL) and aq. sat. KF 
(100 mL) were added and stirring was continued for 10 min. Water (100 mL) and aq. sat. 
Na/K-tartrate (100 mL) were added and the aqueous layer was extracted with methyl t-butyl 
ether (3 × 150 mL). The combined extracts were dried over MgSO4, the solvent was 
evaporated and the crude product was purified by flash chromatography (SiO2, hexanes) to 
give the title compound as a colorless solid (150 mg, 37%).  
1H NMR (400 MHz, CDCl3): δ = 6.80 (dd, J = 17.9, 11.4 Hz, 3H), 5.49 (dd, J = 11.4, 2.2 Hz, 3H), 
5.24 (dd, J = 17.9, 2.2 Hz, 3H), 2.68 (q, J = 7.4 Hz, 6H), 1.02 ppm (t, J = 7.4 Hz, 9H); 13C NMR 
(100 MHz, CDCl3): δ = 138.9, 135.9, 135.8, 119.2, 24.1, 14.6 ppm; IR (film): ṽ = 3078, 2964, 
2930, 2871, 1847, 1627, 1451, 1426, 1368, 1288, 1316, 1053, 1074, 991, 918, 836, 758, 626, 
443 cm-1; MS (EI): m/z (%) = 241 (11), 240 (61), 226 (18), 225 (100), 212 (12), 211 (73), 197 
(51), 196 (52), 195 (12), 183 (42), 182 (34), 181 (39), 179 (12), 178 (13), 169 (34), 168 (23), 
167 (44), 166 (23), 165 (44), 155 (29), 154 (15), 153 (27), 152 (22), 141 (20), 128 (13), 115 
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(13), 91 (11), 89 (13), 77 (11); HRMS (EI(DE)): m/z: calcd. for [C18H24]: 240.1878, found: 
240.1880. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[131] 
 
1,3,5-Triallyl-2,4,6-triethylbenzene (100c) 
Allyltributylstannane (8.54 g, 25.8 mmol) was added to a solution of 
1,3,5-tribromo-2,4,6-triethylbenzene (99) (2,57 g, 6.45 mmol), (Ph3P)4Pd 
(1,16 g, 1.00 mmol, 16 mol%) and CsF (3.04 g, 20.0 mmol) in DMF 
(15 mL). The mixture was stirred for 3.5 h at 135 °C in a closed JYoung 
tube. After cooling to room temperature, methyl t-butyl ether (200 mL) 
and aq. sat. KF (100 mL) were added and stirring was continued for 10 min. Water (100 mL) 
and aq. sat. Na/K-tartrate (100 mL) were added and the aqueous layer was extracted with 
methyl t-butyl ether (3 × 150 mL). The combined extracts were dried over MgSO4 and the 
solvent was evaporated. Purification of the residue by flash chromatography (SiO2, hexanes) 
afforded the title compound as a colorless solid (1.10 g, 60%). 
M.p.: 57 – 58 °C; 1H NMR (400 MHz, CDCl3): δ = 6.03 (ddt, J = 17.1, 10.1, 5.0 Hz, 3H), 4.86 – 
4.83 (m, 3H), 4.72 (dq, J = 17.1, 1.9 Hz, 3H), 3.42 (dt, J = 5.0, 1.9 Hz, 6H), 2.54 (q, J = 7.5 Hz, 
6H), 1.17 ppm (t, J = 7.5 Hz, 9H); 13C NMR (100 MHz, CDCl3): δ = 140.3, 137.9, 133.0, 114.8, 
33.0, 22.9, 15.5 ppm; IR (film): ṽ = 3080, 3001, 2962, 2927, 2897, 2869, 1817, 1636, 1485, 
1448, 1422, 1403, 1376, 1291, 1227, 1198, 1117, 1059, 995, 927, 905, 823, 769, 629, 555  
cm-1; MS (EI): m/z (%) = 283 (23), 232 (100), 267 (31), 253 (32), 241 (27), 226 (19), 225 (17), 
213 (12), 212 (16), 211 (23), 200 (11), 199 (17), 197 (28), 185 (20), 183 (19), 181 (11), 171 
(14), 169 (15), 167 (14), 155 (14); HRMS (EI(DE)): m/z: calcd. for [C21H30]: 282.2345, found: 
282.2348. 
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((2,4,6-Triethylbenzene-1,3,5-triyl)tris(propane-3,1-diyl))tris(diphenylsilanol) (97c) 
Trialkene 100c (334 mg, 1.18 mmol) was 
dissolved in toluene (10 mL) in a flame-dried 
Schlenk flask. After addition of Karstedt`s 
catalyst (0.1 M in poly(dimethylsiloxane), 
0.50 mL, 0,05 mmol) the mixture was heated to 
70 °C and diphenylchlorosilane (0.88 mL, 984 mg, 
4.5 mmol) was added dropwise. The reaction 
was stirred for 16 h at this temperature before a second portion of Karstedt`s catalyst (0.1 M 
in poly(dimethylsiloxane), 0.1 mL, 0.01 mmol) and diphenylchlorosilane (0.15 mL, 168 mg, 
0.78 mmol) were added and stirring continued for another 2 h at 70 °C. The mixture was 
allowed to reach ambient temperature before water (10 mL) and NEt3 (1 mL) were added. 
After stirring for 20 min aq. sat. NH4Cl (5 mL) was added and stirring was continued for 10 
min. The aqueous layer was extracted with ethyl acetate (3 × 50 mL) and the combined 
organic layers were dried over MgSO4. The solvent was evaporated and the crude product 
was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 6/1 to 2/1). The material 
was dissolved in CH2Cl2 (20 mL) and MS 3 Å (2 g) was added. After gentle stirring for 2 h at 
room temperature the MS was filtered off and the solvent was evaporated. The product was 
dried for 4 h under high vacuum to afford the title compound as a colorless hygroscopic solid 
(560 mg, 54%).  
M.p.: 66 – 75 °C; 1H NMR (400 MHz, CDCl3): δ = 7.59 (d, J = 7.0 Hz, 12H), 7.32 – 7.44 (m, 18H), 
2.50 – 2.59 (m, 6H), 2.38 (q, J = 7.2 Hz, 6H), 2.06 – 2.13 (m, 3H), 1.55 – 1.66 (m, 6H), 1.29 (t, 
J = 7.9 Hz, 6H), 1.06 ppm (t, J = 7.2 Hz, 9H); 13C NMR (100 MHz, CDCl3): δ = 138.4, 136.4, 
136.3, 134.3, 130.0, 128.1, 33.6, 25.0, 22.6, 16.5, 15.8 ppm; IR (film): ṽ = 3299, 3068, 3047, 
2958, 2927, 2869, 1589, 1486, 1462, 1427, 1373, 1305, 1262, 1169, 1112, 1066, 1026, 997, 
965, 944, 824, 762, 736, 696, 640, 504, 479, 449 cm-1; MS (ESI(pos)): m/z (%) = 905 [M+Na]+ 
(100); HRMS (ESI(pos)): m/z: calcd. for [C57H66O3Si3+Na]
+: 905.4212, found: 905.4212. 
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((2,4,6-Triethylbenzene-1,3,5-triyl)tris(methylene))tris(diphenylsilane) (102) 
In analogy to the literature[53], a suspension of 
diphenylchlorosilane (1.52 mL, 1.71 g, 7.81 mmol) and 
magnesium (190 mg, 7.81 mmol) in THF (5 mL) was 
added to a solution of 1,3,5-tris(bromomethyl)-2,4,6-
triethyl-benzene (1.00 g, 2.27 mmol) in THF (5 mL) at 
0 °C. The mixture was stirred for 3 h at ambient 
temperature before aq. sat. NH4Cl (5 mL) was added. 
The aqueous layer was extracted with ethyl acetate (3 × 20 mL) and the combined organic 
layers were dried over MgSO4. The solvent was evaporated and the crude product was 
purified by flash chromatography (SiO2, hexanes) to give the title compound was as a 
colorless solid (1.10 g, 65%). 
1H NMR (400 MHz, CDCl3): δ = 7.48 (d, J = 6.6 Hz, 12H), 7.42 – 7.31 (m, 18H), 4.74 (t, J = 
3.5 Hz, 3H), 2.58 (d, J = 3.6 Hz, 6H), 2.21 (q, J = 7.4 Hz, 6H), 1.02 ppm (t, J = 7.4 Hz, 9H); 13C 
NMR (100 MHz, CDCl3): δ = 136.2, 135.2, 134.5, 132.6, 129.8, 128.0, 24.2, 16.2, 13.5 ppm.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[53] 
 
((2,4,6-Triethylbenzene-1,3,5-triyl)tris(methylene))tris(diphenylsilanol) (97a) 
In analogy to the literature[53], a solution of compound 
102 (751 mg, 1.00 mmol) and N-bromosuccinimide 
(587 mg, 3.30 mmol) in CH2Cl2 (8 mL) was stirred for 2 h 
at room temperature. Water (2 mL) and NEt3 (0.5 mL) 
were added and stirring was continued for 2 h before 
the solvent was removed under reduced pressure. The 
residue was extracted with ethyl acetate (3 × 20 mL). 
The combined extracts were washed with water (10 mL) and dried over MgSO4. The solvent 
was evaporated and the crude product was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, 6/1 to 2/1). The material was dissolved in CH2Cl2 (10 mL) and MS 3 Å 
(2 g) was added. After gentle stirring for 2 h at room temperature, the MS was filtered off 
and the solvent was evaporated. The product was dried for 4 h under high vacuum to afford 
the title compound as a colorless hygroscopic solid (700 mg, 87%).  
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1H NMR (400 MHz, CDCl3): δ = 7.52 (d, J = 6.5 Hz, 12H), 7.45 – 7.26 (m, 18H), 2.68 (s, 6H), 
2.30 – 2.44 (bs, 3H), 2.24 (q, J = 7.4 Hz, 6H), 0.97 ppm (t, J = 7.4 Hz, 9H); 13C NMR (100 MHz, 
CDCl3): δ = 136.9, 136.6, 134.2, 132.1, 130.0, 128.0, 24.4, 19.1, 13.5 ppm.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[53] 
7.3.4 Synthesis of Calyx[4]arene Based Systems 
Methoxy calyx[4]arene 103b 
A suspension of 4-tert-butylcalix[4]arene 103a (649 mg, 
1.00 mmol) and K2CO3 (78.8 mg, 0.570 mmol) in 
acetonitrile (30 mL) was stirred at reflux temperature for 
30 min before methyl iodide (1.42 g, 0.623 mL, 
10.0 mmol) was added. The mixture was stirred for 4 d at 
this temperature. The solvent was evaporated and the 
residue was dissolved in CH2Cl2 (100 mL) and washed with 
aq. HCl (1 M, 2 × 100 mL) and water (100 mL). The organic 
layer was dried over MgSO4, the solvent was evaporated, and the crude product was purified 
by flash chromatography (SiO2, CH2Cl2/pentane, 2/1 to 1/1) to give the title compound as a 
colorless solid (381 mg, 58%).  
1H NMR (400 MHz, CDCl3): δ = 10.1 (s, 1H), 9.60 (s, 2H), 7.13 – 7.00 (m, 8H), 4.38 (d, J = 
13.0 Hz, 2H), 4.29 (d, J = 13.5 Hz, 2H), 4.15 (s, 3H), 3.48 – 3.42 (m, 4H), 1.24 (s, 9H), 1.23 (s, 
18H), 1.22 ppm (s, 9H); 13C NMR (100 MHz, CDCl3): δ = 150.6, 148.5, 148.4, 147.9, 143.8, 
143.3, 133.5, 128.34, 128.31, 128.0, 126.6, 126.1, 125.9, 125.8, 125.7, 63.4, 34.4, 34.1, 34.0, 
33.1, 32.3, 31.6, 31.5, 31.4 ppm. IR (film): ṽ = 3249, 3150, 3047, 3023, 2955, 2905, 2867, 
1599, 1481, 1455, 1393, 1361, 1297, 1241, 1202, 1123, 1103, 1092, 1004, 945, 915, 871, 816, 
782, 745, 720, 700, 674, 627, 603, 589, 573, 555, 526, 498, 483, 461, 444, 429 cm-1; MS (EI): 
m/z (%) = 664 (27), 663 (87), 662 (100), 649 (9), 648 (23), 647 (15), 607 (6), 606 (16), 592 
(10), 591 (12), 550 (6), 549 (6), 535 (6), 493 (5), 175 (6), 57 (19); HRMS (ESI(pos)): m/z: calcd. 
for [C45H58O4+Na]
+: 685.4222, found: 685.4227. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[54] 
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Nitrido calyx[4]arene 105b 
A solution of triol 103b (144 mg, 0.217 mmol) in toluene 
(5 mL) was added over 5 min to a solution of complex 19 
(97.5 mg, 0.217 mmol) in toluene (5 ml) at room 
temperature. The resulting mixture was stirred for 1 h at 
room temperature. The solvent was evaporated and the 
residue was recrystallized from Et2O (3 mL) by cooling the 
mixture to ─78 °C over the course of 1 h. The solid was collected under argon and dried 
under high vacuum to give the title compound as an orange crystalline solid (75.0 mg, 49%).  
1H NMR (400 MHz, C6D6): δ = 7.20 – 7.17 (m, 4H), 6.91 – 6.89 (m, 2H), 6.84 – 6.81 (m, 2H), 
4.73 (d, J = 12.7 Hz, 2H), 4.35 (d, J = 12.3 Hz, 2H), 4.27 – 4.23 (m, 3H), 3.15 (d, J = 12.8 Hz, 
2H), 3.09 (d, J = 12.8 Hz, 2H), 1.36 (s, 18H), 0.85 – 0.80 (m, 9H), 0.77 – 0.71 ppm (m, 9H); 13C 
NMR (100 MHz, C6D6): δ = 156.1, 150.5, 146.0, 144.5, 134.5, 130.9, 129.32, 129.26, 126.7, 
125.71, 125.68, 124.2, 76.0, 34.0, 33.7, 33.5, 33.2, 32.5, 31.7, 30.7, 30.4 ppm; IR (film): ṽ = 
3634, 2951, 2902, 2864, 1579, 1460, 1433, 1393, 1361, 1302, 1263, 1247, 1196, 1124, 1108, 
1088, 1041, 984, 946, 916, 888, 871, 834, 798, 759, 733, 712, 678, 646, 598, 556, 511, 480, 
466, 430 cm-1; MS (EI(DE)): m/z (%) = 771 (88), 756 (100), 743 (51), 616 (38); HRMS 
(ESI(pos)): m/z: calcd. for [C45H55MoNO4+Na]
+: 794.3076, found: 794.3078. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[55] 
 
Calyx[4]arene silane EP9 
In analogy to the literature[57], NEt3 (7.51 mL, 53.9 mmol) 
was added to a suspension of calyx[4]arene 103a (10.0 g, 
15.4 mmol) in toluene (800 mL) at room temperature. The 
reaction mixture was stirred for 20 min before 
methyltrichlorosilane (3.53 mL, 4.48 g, 30.0 mmol) was 
added dropwise and the reaction mixture was stirred at 
room temperature for 16 h. The solid precipitate was filtered off and washed with hexanes 
(2 × 50 mL). The residue was dissolved in CH2Cl2 (50 mL) before methyl t-butyl ether 
(150 mL) was added, which caused a fine colorless solid to precipitate. The solid material 
was filtered over Celite® and the filtrate was evaporated to give the title compound as a 
O
tBu
O
O HO
tBu
tButBu
Si
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colorless solid (11.2 g, quant.). The material was used in the next step without further 
purification. 
 
Calyx[4]arene phosphonate 106 
In analogy to the literature[57], n-BuLi (1.6 M in hexane, 
11.2 mL, 17.9 mmol) was added to a solution of 
calyx[4]arene silane EP9 (11.2 g, 16.3 mmol) in toluene 
(500 mL) at room temperature. The mixture was stirred for 
20 min at room temperature before diethyl 
chlorophosphate (3.53 mL, 4.22 g, 24.5 mmol) was added. 
The mixture was stirred for 4 h at room temperature before it was filtered through Celite®. 
The solvent was evaporated, the residue was suspended in CH2Cl2 (100 mL) and the mixture 
was filtered over Celite®. The solvent was evaporated and the residue was suspended in 
hexanes (70 mL) at 0 °C. The solid was filtered off and dried under vacuum to give the title 
compound as a colorless solid (9.10 g, 68%).  
1H NMR (400 MHz, CDCl3): δ = 7.15 − 7.08 (m, 8H), 4.44 (d, J = 14.7 Hz, 4H), 3.69 (d, J = 
16.2 Hz, 2H), 3.55 − 3.40 (m, 6H), 1.35 (s, 18H), 1.30 (s, 9H), 1.23 (s, 9H), 0.73 (t, J = 7.1 Hz, 
6H), −0.39 ppm (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 148.7, 147.7, 147.0, 146.0, 145.3, 
144.5, 132.4, 130.8, 130.6, 130.1, 127.5, 126.6, 125.5, 124.8, 64.2, 37.3, 35.3, 34.41, 34.36, 
34.1, 31.72, 31.67, 31.61, 15.8, −8.3 ppm. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[57] 
 
15,35,55,75-Tetra-tert-butyl-1,3,5,7(1,3)-tetrabenzenacyclooctaphane-12,32,52-triol (103c) 
In analogy to the literature[57], a suspension of 
phosphate 106 (5.00 g, 6.06 mmol) in Et2O (60 mL) was 
added over 5 min to a mixture of potassium (12.0 g, 
307 mmol) and ammonia (100 mL) at ─78 °C. The 
reaction mixture was stirred for 1 h at ─78 °C. NH4Cl was 
added until the blue color disappeared. The mixture was 
allowed to warm to room temperature. The solid residue 
was extracted with CH2Cl2 (3 × 200 mL), the solvent was 
O
tBu
O
O O
tBu
tButBu
Si P
O OEt
OEt
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evaporated, and the crude material was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, 10/1 to 2/1) to give the title compound as a colorless solid (2.48 g, 
65%).  
1H NMR (400 MHz, CDCl3): δ = 7.17 − 7.01 (m, 8H), 3.91 (s, 4H), 3.86 (s, 4H), 1.29 (s, 9H), 1.25 
(s, 9H), 1.23 ppm (s, 18H); 13C NMR (100 MHz, CDCl3): δ = 151.7, 148.7, 147.4, 144.5, 143.9, 
141.2, 127.6, 127.4, 126.2, 125.7, 124.8, 124.2, 38.2, 34.7, 34.2, 34.1, 32.8, 31.59, 31.57, 
31.5 ppm; IR (film): ṽ = 3223, 2961, 2903, 2869, 1596, 1483, 1455, 1430, 1393, 1362, 1300, 
1247, 1198, 1154, 1135, 1112, 1066, 962, 949, 915, 887, 871, 817, 799, 782, 752, 735, 715, 
699, 566, 548, 518 cm-1; MS (EI): m/z (%) = 634 (12), 633 (48), 632 (100), 618 (10), 617 (22), 
577 (16), 576 (40), 575 (13), 562 (10), 561 (23), 520 (25), 519 (11), 505 (19), 57 (27); HRMS 
(ESI(neg)): m/z: calcd. for [C44H56O3]
─: 631.4163, found: 631.4157. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[57] 
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7.4 Reactions with the Two-Component Catalyst System 
7.4.1 Homocoupling Reactions 
General procedure 4: Alkyne homo metathesis using in situ generated systems containing 
the multidentate ligand 89a and precatalyst 73
[42]
 
The alkyne was stirred with MS 5 Å (1 g per mmol alkyne) in toluene (0.2 M based on the 
alkyne) for 30 min before a freshly prepared solution of trisilanol 89a and complex 73 in 
toluene, which had been stirred for 5 min, was added. The reaction mixture was stirred 
under the individual conditions. The crude material was filtered through a plug of Celite® 
which was carefully rinsed with ethyl acetate. The solvent was evaporated and the residue 
was purified by column chromatography. 
 
General procedure 5: Alkyne homo metathesis using in situ generated systems containing 
the multidentate ligand 97c and precatalyst 73
[42]
 
The alkyne was stirred with MS 5 Å (1 g per mmol alkyne) in toluene (0.2 M based on the 
alkyne) for 30 min before a freshly prepared solution of trisilanol 97c and complex 73 in 
toluene, which had been stirred for 5 min, was added. The reaction mixture was stirred 
under the individual conditions. The crude material was filtered through a plug of Celite® 
which was carefully rinsed with ethyl acetate. The solvent was evaporated and the residue 
was purified by column chromatography. 
 
3,3'-(Ethin-1,2-diyl)diphenole (30b) 
3-(Prop-1-yn-1-yl)phenol (29b) (33.0 mg, 0.25 mmol) was stirred 
with MS 5 Å (200 mg), trisilanol 97c (22.1 mg, 25.0 µmol, 
10 mol%), and complex 73 (16.6 mg, 25.0 µmol, 10 mol%) in 
toluene (2 mL) for 14 h at room temperature according to general procedure 5. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 4/1 to 2/1) afforded the title compound as a 
colorless solid (21.0 mg, 80%).  
1H NMR (400 MHz, CDCl3): δ = 7.17 (t, J = 8.0 Hz, 2H), 6.96 (ddd, J = 7.6, 1.5, 1.0 Hz, 2H), 6.90 
(dd, J = 2.6, 1.5 Hz, 2H), 6.78 ppm (ddd, J = 8.0, 2.5, 1.0 Hz, 2H); 13C NMR (100 MHz, CDCl3): 
δ = 158.5, 130.6, 125.5, 123.9, 119.0, 116.9, 89.6 ppm; IR (film): ṽ = 3236, 3059, 2992, 2613, 
1574, 1497, 1451, 1322, 1309, 1252, 1182, 1159, 1085, 970, 873, 752, 682 cm-1; MS (EI): m/z 
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(%) = 210 (100), 181 (18), 165 (5), 152 (28), 127 (5), 105 (8), 98 (2), 76 (9), 63 (7), 51 (4); 
HRMS (EI): m/z: calcd. for [C14H10O2]
+: 210.0679, found: 210.0681.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[132] 
 
4,4'-(Ethin-1,2-diyl)diphenole (30a)  
4-(Prop-1-yn-1-yl)phenol 29a (33.0 mg, 0.25 mmol) was 
stirred with MS 5 Å (200 mg), trisilanol 97c (22.1 mg, 
25.0 µmol, 10 mol%), and complex 73 (16.6 mg, 25.0 µmol, 10 mol%) in toluene (2 mL) for 
4 h at room temperature according to general procedure 5. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 4/1 to 1/1) afforded the title compound as a colorless solid (22.0 mg, 
84%).  
1H NMR (400 MHz, CD3CN): δ = 7.35 (d, J = 8.6 Hz, 4H), 7.22 (s, 2H), 6.81 ppm (d, J = 8.6 Hz, 
4H); 13C NMR (100 MHz, CD3CN): δ = 158.0, 133.8, 116.5, 115.6, 88.4 ppm; IR (film): ṽ = 3304, 
1607, 1591, 1510, 1438, 1371, 1350, 1231, 1171, 1100, 766 cm-1; MS (EI): m/z (%) = 210 
(100), 181 (7), 152 (13), 105 (11), 76 (5); HRMS (EI): m/z: calcd. for [C14H10O2]
+: 210.0680, 
found: 210.0681.  
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[116] 
 
Hexadec-8-yne-1,16-diol (33)  
Dec-8-yn-1-ol 32 (38.6 mg, 0.25 mmol) was stirred with MS 5 Å 
(200 mg), trisilanol 97c (22.1 mg, 25.0 µmol, 10 mol%), and 
complex 73 (16.6 mg, 25.0 µmol, 10 mol%) in toluene (2 mL) for 
4 h at room temperature according to general procedure 5. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 4/1 to 0/1) afforded the title compound as a colorless solid (23.0 mg, 
72%).  
M.p.: 39 – 40 °C; 1H NMR (400 MHz, CDCl3): δ = 3.63 (t, J = 6.6 Hz, 4H), 2.19 – 2.09 (m, 4H), 
1.62 – 1.29 ppm (m, 22H); 13C NMR (100 MHz, CDCl3): δ = 80.4, 63.1, 32.9, 29.1, 29.1, 28.9, 
25.8, 18.8 ppm; IR (film): ṽ = 3348, 3265, 2931, 2851, 1457, 1423, 1381, 1361, 1297, 1249, 
1211, 1133, 1109, 1094, 1055, 1040, 1014, 1005, 970, 896, 815, 756, 725, 650, 548, 478, 452, 
432, 416 cm-1; MS (EI): m/z (%) = 150 (10), 136 (23), 135 (18), 125 (10), 122 (16), 121 (75), 
7 Experimental Procedures 
112 
 
112 (13), 111 (23), 110 (16), 109 (20), 108 (28), 107 (54), 98 (47), 97 (32), 96 (23), 95 (58), 94 
(56), 93 (71), 91 (26), 85 (14), 84 (21), 83 (18), 82 (58), 81 (93), 80 (68), 79 (97), 77 (18), 72 
(11), 71 (16), 69 (26), 68 (64), 67 (100), 66 (10), 55 (59), 54 (31), 53 (11), 43 (14), 41 (36), 39 
(16); HRMS (ESI(pos)): m/z: calcd. for [C16H30O2+Na]
+: 277.2140, found: 277.2138. 
 
(2R,17R)-Octadec-9-yn-2,17-diole (35) 
(R)-Undec-9-yn-2-ole 34 (42.1 mg, 0.25 mmol) was stirred with MS 
5 Å (200 mg), trisilanol 97c (22.1 mg, 25.0 µmol, 10 mol%), and 
complex 73 (16.6 mg, 25.0 µmol, 10 mol%) in toluene (2 mL) for 
4 h at room temperature according to general procedure 5. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 4/1 to 1/1) afforded the title compound as a colorless solid (27.0 mg, 
76%).  
M.p.: 56 – 57 °C; 1H NMR (400 MHz, CDCl3): δ = 3.74 – 3.82 (m, 2H), 2.14 (t, J = 6.9 Hz, 4H), 
1.27 – 1.51 (m, 22H), 1.18 ppm (d, J = 6.3 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ = 80.4, 68.3, 
39.4, 29.3, 29.2, 28.9, 25.9, 23.7, 18.8 ppm; IR (film): ṽ = 3325, 3243, 2960, 2940, 2849, 1496, 
1466, 1373, 1354, 1294, 1127, 1107, 1046, 1010, 926, 836, 720, 673 cm-1; MS (EI): m/z (%) 
= 282 (1), 249 (4), 189 (5), 175 (7), 164 (8), 161 (10), 149 (22), 135 (58), 121 (56), 107 (48), 95 
(77), 81 (100), 67 (97), 55 (75), 45 (99), 41 (50); HRMS (ESI(pos)): m/z: calcd. for 
[C18H34O2+Na]
+: 305.2448, found: 305.2451. 
 
N1,N8-dimethoxy-N1,N8-dimethyloct-4-ynediamide (41) 
N-methoxy-N-methylhex-4-ynamide 40 (38.8 mg, 
0.25 mmol) was stirred with MS 5 Å (200 mg), trisilanol 
97c (22.1 mg, 25.0 µmol, 10 mol%), and complex 73 
(16.6 mg, 25.0 µmol, 10 mol%) in toluene (2 mL) for 4 h 
at room temperature according to general procedure 5. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 4/1 to 0/1) afforded the title compound as a colorless oil (24.0 mg, 
75%).  
1H NMR (400 MHz, CDCl3): δ = 3.69 (s, 6H), 3.18 (s, 6H), 2.59 – 2.66 (m, 4H), 2.41 ppm (t, J = 
8.4 Hz, 4H); 13C NMR (100 MHz, CDCl3): δ = 173.0, 79.6, 61.4, 32.3, 31.7, 14.4 ppm; IR (film): ṽ 
= 2937, 2247, 1736, 1656, 1420, 1386, 1336, 1242, 1177, 1107, 1044, 988, 917, 776, 728, 
646, 606, 565, 509, 487, 437 cm-1; MS (EI): m/z (%) = 256 (1), 225 (60), 196 (100), 168 (10), 
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124 (9), 107 (17), 94 (8), 79 (23), 60 (15), 39 (10); HRMS (ESI(pos)): m/z: calcd. for 
[C12H20N2O4+Na]
+: 279.1310, found: 279.1315. 
7.4.2 RCAM Reactions 
General procedure 6: Ring closing alkyne metathesis using in situ generated systems 
containing the multidentate ligand 97c and precatalyst 73
[42]
 
The diyne was stirred with MS 5 Å in toluene for 60 min at room temperature. The mixture 
was heated to 110 °C before a freshly prepared solution of trisilanol 97c and complex 73 in 
toluene, which had been stirred for 5 min, was added. The reaction mixture was stirred for 
the indicated time at 110 °C before it was filtered through a pad of Celite®, which was 
carefully rinsed with ethyl acetate. The solvent was evaporated and the residue was purified 
by flash chromatography. 
 
General procedure 7: Ring closing alkyne metathesis with catalyst 28 
The diyne was stirred with MS 5 Å in toluene for 60 min at room temperature. The mixture 
was heated to 110 °C before a freshly prepared solution of metathesis catalyst 28 in toluene 
was added in one portion. The reaction mixture was stirred for the indicated time at 110 °C 
before it was filtered through a pad of Celite®, which was carefully rinsed with ethyl acetate. 
The solvent was evaporated and the residue was purified by flash chromatography. 
 
4-((Triethylsilyl)oxy)cyclotetradec-2-yn-1-ol (112a) 
Diyne 111a (39.3 mg, 100 μmol) was stirred with MS 5 Å (200 mg), 
trisilanol 97c (19.4 mg, 22.0 μmol, 22 mol%), and complex 73 (13.3 mg, 
21.2 µmol, 20 mol%) in toluene (50 mL) for 1 h according to general 
procedure 6. Flash chromatography (SiO2, hexanes/ethyl acetate, 20/1 to 
4/1) afforded the title compound as a colorless oil (21.8 mg, 64%, mixture of diastereomers).  
1H NMR (400 MHz, CDCl3) δ = 4.53 – 4.41 (m, 2H), 1.74 – 1.60 (m, 5H), 1.49 – 1.25 (m, 16H), 
0.98 (t, J = 7.9 Hz, 9H), 0.70 – 0.59 ppm (m, 6H); 13C NMR (100 MHz, CDCl3): δ = 87.1, 86.9, 
85.4, 85.1, 63.3, 63.2, 63.1, 63.0, 38.4, 38.3, 37.2, 26.60, 26.56, 26.53, 26.47, 25.84, 25.82, 
25.78, 25.7, 23.89, 23.85, 23.8, 22.4, 22.3, 7.0, 4.92, 4.90 ppm; IR (fim): ṽ = 3359, 2931, 2874, 
2859, 1458, 1413, 1378, 1334, 1259, 1239, 1151, 1072, 1006, 802, 726, 549, 427 cm-1; MS 
(EI): m/z (%) = 309 (5), 121 (11), 107 (16), 105 (12), 104 (10), 103 (100), 95 (16), 93 (18), 91 
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(16), 87 (14), 81 (18), 79 (20), 75 (89), 67 (20), 55 (12), 47 (13); HRMS (ESI(pos)): m/z: calcd. 
for [C20H38O2Si+Na]
+: 361.2521, found: 361.2533. 
 
4-(Methoxymethoxy)cyclotetradec-2-yn-1-ol (112b) 
Diyne 111b (32.2 mg, 100 μmol) was stirred with MS 5 Å (200 mg), 
trisilanol 97c (19.4 mg, 22.0 μmol, 22 mol%), and complex 73 (13.3 mg, 
21.2 µmol, 20 mol%) in toluene (50 mL) for 1 h according to general 
procedure 6. Flash chromatography (SiO2, hexanes/ethyl acetate, 10/1 to 
4/1) afforded the title compound as a colorless oil (18 mg, 67%, mixture of diastereomers).  
1H NMR (400 MHz, CDCl3) δ = 4.92 (dd, J = 6.8, 5.5 Hz, 1H), 4.60 (dd, J = 6.8, 1.8 Hz, 1H), 4.56 
– 4.40 (m, 2H), 3.38 (s, 3H), 1.89 – 1.82 (m, 1H), 1.78 – 1.63 (m, 4H), 1.56 – 1.22 ppm (m, 
16H); 13C NMR (100 MHz, CDCl3): δ = 94.3, 87.11, 87.06, 84.1, 83.9, 66.3, 66.1, 63.0, 55.8, 
37.2, 37.1, 35.0, 34.9, 26.6, 26.50, 25.9, 25.81, 25.77, 25.7, 23.9, 23.8, 22.5, 22.4, 22.32, 
22.30 ppm; IR (film): ṽ = 3400, 2928, 2859, 1459, 1429, 1338, 1260, 1213, 1150, 1097, 1026, 
918, 865, 801, 731, 700, 509 cm-1; MS (GC-MS): m/z (%) = 206 (5), 163 (6), 149 (11), 147 (12), 
135 (19), 133 (18), 131 (13), 123 (13), 122 (11), 121 (30), 119 (21), 117 (14), 111 (17), 110 
(16), 109 (33), 108 (23), 107 (42), 106 (12), 105 (28), 98 (20), 97 (29), 96 (32), 95 (66), 94 (43), 
93 (56), 91 (68), 84 (17), 83 (32), 82 (37), 81 (88), 80 (61), 79 (100), 78 (19), 77 (35), 71 (13), 
70 (14), 69 (35), 68 (37), 67 (93), 66 (17), 65 (19), 57 (14), 56 (11), 55 (74), 54 (25), 53 (21), 45 
(79), 43 (21), 41 (59), 39 (23), 31 (26), 30 (18); HRMS (ESI(pos)): m/z: calcd. for 
[C16H28O2+Na]
+: 291.1928, found: 291.1931. 
 
3,14-bis((Triethylsilyl)oxy)cyclotetradec-1-yne (112e) 
Diyne 113a (50.7 mg, 100 μmol) was stirred with MS 5 Å (200 mg), 
trisilanol 97c (19.4 mg, 22.0 μmol, 22 mol%), and complex 73 (13.3 mg, 
21.2 µmol, 20 mol%) in toluene (50 mL) for 3 h according to general 
procedure 6. Flash chromatography (SiO2, hexanes/ethyl acetate, 1/0 to 
100/1) afforded the title compound as a colorless oil (32 mg, 71%, mixture of 
diastereomers).  
1H NMR (400 MHz, CDCl3) δ = 4.51 – 4.39 (m, 2H), 1.73 – 1.21 (m, 20H), 0.97 (t, J = 7.9 Hz, 
18H), 0.71 – 0.56 ppm (m, 12H); 13C NMR (100 MHz, CDCl3): δ = 85.9, 85.6, 63.4, 63.2, 38.7, 
38.4, 26.7, 26.4, 26.1, 25.8, 24.0, 23.8, 22.4, 22.3, 7.0, 4.94, 4.88 ppm; IR (film): ṽ = 2949, 
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2935, 2875, 1732, 1459, 1414, 1378, 1348, 1334, 1260, 1239, 1074, 1006, 975, 843, 803, 726, 
675, 533, 458 cm-1; MS (EI): m/z (%) = 425 (11), 424 (29), 423 (81), 291 (28), 217 (45), 205 
(10), 190 (18), 189 (100), 161 (17), 133 (11), 121 (14), 115 (23), 107 (17), 103 (31), 95 (12), 93 
(13), 87 (41), 81 (10), 75 (18), 59 (11); HRMS (ESI(pos)): m/z: calcd. for [C26H52O2Si2+Na]
+: 
475.3404, found: 475.3398. 
 
3,14-Bis(methoxymethoxy)cyclotetradec-1-yne (112f) 
Diyne 113b (36.7 mg, 100 μmol) was stirred with MS 5 Å (200 mg), 
trisilanol 97c (19.4 mg, 22.0 μmol, 22 mol%), and complex 73 (13.3 mg, 
21.2 µmol, 20 mol%) in toluene (50 mL) for 0.5 h according to general 
procedure 6. Flash chromatography (SiO2, hexanes/ethyl acetate, 20/1 to 
4/1) afforded the title compound as a colorless oil (22 mg, 70%, mixture of diastereomers).  
1H NMR (400 MHz, CDCl3): δ = 4.91 (dd, J = 6.8, 3.4 Hz, 2H), 4.59 (dd, J = 6.8, 3.0 Hz, 2H), 4.49 
– 4.39 (m, 2H), 3.37 (s, 6H), 1.81 – 1.62 (m, 4H), 1.55 – 1.21 ppm (m, 16H); 13C NMR (100 
MHz, CDCl3): δ = 94.3, 84.8, 84.6, 66.3, 66.2, 55.7, 35.1, 34.9, 26.6, 26.5, 25.9, 25.8, 23.82, 
23.79, 22.44, 22.38 ppm; IR (film): ṽ = 2929, 2860, 2822, 2776, 1459, 1400, 1338, 1213, 1148, 
1097, 1026, 919, 848, 792, 724, 704, 554, 441, 415 cm-1; MS (EI): m/z (%) = 161 (4), 147 (8), 
133 (11), 121 (18), 119 (11), 109 (17), 108 (12), 107 (20), 105 (13), 97 (15), 96 (10), 95 830), 
94 (17), 93 (25), 92 (11), 91 (28), 82 (12), 81 (34), 80 (25), 79 (38), 77 (13), 69 (11), 87 (32), 55 
(20), 45 (100), 41 (16); HRMS (ESI(pos)): m/z: calcd. for [C18H32O4+Na]
+: 355.2189, found: 
335.2193. 
 
Cyclotetradec-2-yne-1,4-diol (112i) 
Diyne 113e (27.8 mg, 100 μmol) was stirred with MS 5 Å (200 mg), trisilanol 
97c (19.4 mg, 22.0 μmol, 22 mol%), and complex 73 (13.3 mg, 21.2 µmol, 
20 mol%) in toluene (50 mL) for 3 h according to general procedure 6. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 4/1 to 1/1) afforded the title 
compound as a colorless solid (11.8 mg, 53%, mixture of diastereomers).  
M.p.: 110 – 111 °C; 1H NMR (400 MHz, CDCl3): δ = 4.58 – 4.44 (m, 2H), 1.98 – 1.89 (m, 2H), 
1.79 – 1.62 (m, 4H), 1.52 – 1.26 ppm (m, 16H); 13C NMR (100 MHz, CDCl3): δ = 86.5, 86.2, 
63.04, 62.96, 37.2, 37.1, 26.53, 26.50, 25.74, 25.71, 23.8, 22.4, 22.3 ppm; IR (film): ṽ = 3273, 
2923, 2856, 1729, 1457, 1443, 1341, 1297, 1146, 1107, 1020, 945, 723, 702, 590, 533, 512, 
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440 cm-1; MS (EI): m/z (%) = 208 (4), 206 (7), 165 (4), 163 (7), 149 (12), 135 (19), 133 (14), 
131 (13), 123 (10), 122 (10), 121 (29), 119 (18), 117 (14), 111 (19), 110 (15), 109 (28), 108 
(24), 107 (48), 106 (12), 105 (24), 98 (21), 97 (30), 96 (35), 95 (67), 94 (49), 93 (57), 92 (25), 
91 (62), 84 (26), 83 (44), 82 (39), 81 (91), 80 (60), 79 (100), 78 (18), 77 (34), 71 (21), 70 (30), 
69 (40), 68 (37), 67 (93), 66 (17), 65 (19), 57 (26), 56 (14), 55 (92), 54 (25), 53 (23), 43 (33), 42 
(12), 41 (68), 39 (27); HRMS (ESI(pos)): m/z: calcd. for [C14H24O2+Na]
+: 247.1667, found: 
247.1668. 
 
(E)-Cyclohexadec-2-en-4-yne-1,6-diol (120b) 
Diyne 119b (10.0 mg, 33 μmol) was stirred with MS 5 Å (200 mg), 
trisilanol 97c (6.4 mg, 7.2 μmol, 22 mol%), and complex 73 (4.4 mg, 
6.6 μmol, 20 mol%) in toluene (50 mL) for 3 h according to general 
procedure 6. Flash chromatography (SiO2, hexanes/ethyl acetate, 4/1 to 
0/1) afforded the title compound as a colorless solid (3.3 mg, 40%, 
mixture of diastereomers).  
M.p. 92 – 93 °C; 1H NMR (300 MHz, CDCl3): δ = 6.16 (ddd, J = 15.9, 6.5, 3.4 Hz, 1H), 5.71 (dt, J 
= 15.9, 1.6 Hz, 1H), 4.59 – 4.46 (m, 1H), 4.30 – 4.18 (m, 1H), 1.85 – 1.65 (m, 4H), 1.61 – 
1.19 ppm (m, 18H); 13C NMR (100 MHz, CDCl3): δ = 146.9, 146.8, 109.70, 109.68, 91.3, 91.2, 
83.99, 83.96, 72.63, 72.58, 63.37, 63.36, 37.14, 37.12, 35.54, 35.51, 28.4, 28.3, 27.9, 27.8, 
27.74, 27.72, 27.69, 27.64, 27.62, 27.61, 23.57, 23.5, 22.5 ppm; IR (film): ṽ = 3670, 3309, 
2923, 2852, 2219, 1633, 1459, 1407, 1342, 1292, 1168, 1115, 1015, 955, 871, 798, 710, 553, 
507, 469 cm-1; MS (ESI(pos)) m/z (%) = 273.2 (100 [M+Na]+); HRMS (ESI(pos)): m/z: calcd. for 
[C16H26O2+Na]
+: 273.1824, found: 273.1825. 
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7.5 Formal Synthesis of Aspicilin 
7.5.1 Synthesis of Alcohol Fragment 151 
10-Bromodecane-1-ol (EP10) 
According to literature procedure[133], HBr (48% in water, 
16.3 mL, 138 mmol) was added to a suspension of 1,10-
decanediol (20.0 g, 115 mmol) in toluene (250 mL). The resulting mixture was stirred at 
reflux temperature for 16 h. Aq. sat. Na2S2O3 (50 mL) was added and the aqueous layer was 
extracted with ethyl acetate (3 × 200 mL). The combined extracts were dried over MgSO4, 
the solvent was evaporated, and the crude product was purified by flash chromatography 
(silica, hexanes/ethyl acetate, 4/1 to 2/1) to give the title compound as a colorless oil (19.8 g, 
73%).  
1H NMR (400 MHz, CDCl3): δ = 3.63 (t, J = 6.6 Hz, 2H), 3.40 (t, J = 6.9 Hz, 2H), 1.88 – 1.80 (m, 
2H), 1.60 – 1.51 (m, 2H), 1.46 – 1.24 (m, 13H) ppm. 13C NMR (100 MHz, CDCl3): δ = 63.2, 
34.2, 32.92, 32.89, 29.6, 29.49, 29.48, 28.9, 28.3, 25.8 ppm. IR (film): ṽ = 3328, 2924, 2853, 
1463, 1437, 1371, 1352, 1256, 1242, 1129, 1055, 899, 756, 722, 644, 562, 505, 465, 445, 428, 
417 cm−1. MS (EI): m/z (%) = 164 (2), 162 (2), 150 (10), 148 (10), 137 (4), 135 (4), 111 (4), 110 
(6), 109 (10), 97 (16), 96 (16), 95 (21), 84 (7), 83 (30), 82 (40), 81 (46), 80 (5), 79 (8), 71 (7), 70 
(17), 69 (63), 68 (57), 67 (68), 66 (6), 57 (18), 56 (24), 55 (100), 54 (33), 53 (8), 44 (4), 43 (23), 
42 (14), 41 (58), 39 (14), 26 (3), 31 (11), 29 (11), 27 (10); HRMS (ESI(pos)): m/z calcd. for 
[C10H21BrO+Na]
+: 259.0669, found 259.0668. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[134] 
 
10-Bromodecanal (158) 
[Cu(MeCN)4]PF6 (744 mg, 2.00 mmol, 5 mol%), 2,2`-
bipyridine (312 mg, 2.00 mmol), TEMPO (312 mg, 
2.00 mmol) and N-methyl-imidazole (328 mg, 4.00 mmol) were added sequentially to a 
solution of 10-bromo-1-decanol EP10 (10.0 g, 42.0 mmol) in acetonitrile (200 mL) in an open 
flask. The dark red mixture was vigorously stirred open to air for 14 h at room temperature, 
after which time the solution had turned blue. The reaction mixture was filtered through a 
plug of silica, the solvent was evaporated, and the residue was purified by flash 
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chromatography (silica, hexanes/ethyl acetate, 20/1 to 10/1) to give the title compound as a 
slightly red oil (9.00 g, 91%).  
1H NMR (400 MHz, CDCl3): δ = 9.77 (t, J = 1.8 Hz, 1H), 3.42 (t, J = 6.8 Hz, 2H), 2.44 (td, J = 7.4, 
1.8 Hz, 2H), 1.90 – 1.81 (m, 2H), 1.68 – 1.59 (m, 2H), 1.47 – 1.37 (m, 2H), 1.36 – 1.27 (m, 
8H) ppm. 13C NMR (100 MHz, CDCl3): δ = 202.7, 43.9, 33.9, 32.8, 29.21, 29.18, 29.1, 28.7, 
28.1, 22.1 ppm. IR (film): ṽ = 2926, 2854, 2716, 1723, 1463, 1409, 1390, 1245, 1111, 846, 
723, 643, 560 cm−1. MS (EI): m/z (%) = 192 (15), 190 (25), 150 (23), 148 (24), 137 (19), 135 
(12), 111 (32), 109 (36), 95 (52), 83 (18), 82 (37), 81 (69), 71 (14), 70 (10), 69 (100), 68 (35), 
67 (48), 57 (57), 56 (15), 55 (89), 54 (18), 53 (11), 45 (11), 44 (51), 43 (31), 42 (15), 41 (78), 39 
(22), 29 (21), 27 (16); HRMS (ESI(pos)): m/z calcd. for [C10H19BrO+Na]
+: 257.0510, found 
257.0512. 
The analytical and spectroscopic data are in agreement with those reported in the 
literature.[135] 
 
(R)-13-Bromotridec-2-yn-4-ol (159) 
NEt3 (3.90 mL, 27.9 mmol) was added dropwise to a 
suspension of Zn(OTf)2 (10.1 g, 27.9 mmol) and (+)-N-
methylephedrine (5.00 g, 27.9 mmol) in toluene (120 mL) 
at ambient temperature. After stirring for 2 h, the reaction mixture was cooled to −78 °C and 
liquid propyne (ca. 4 mL) was added via cannula at −78 °C. The resulting mixture was allowed 
to warm to ambient temperature. After 1 h, a solution of aldehyde 158 (5.48 g, 23.3 mmol) 
in toluene (10 mL) was added dropwise over 4 h. The mixture was stirred for 14 h at room 
temperature before the reaction was quenched with aq. sat. NH4Cl (20 mL). The aqueous 
layer was extracted with ethyl acetate (3 × 150 mL). The water layer was acidified to pH 2 by 
addition of 2 M HCl and was extracted with ethyl acetate (150 mL). The combined extracts 
were dried over MgSO4, the solvent was evaporated, and the residue was purified by flash 
chromatography (silica, hexanes/ethyl acetate, 10/1) to give the title compound as a 
colorless oil (4.15 g, 65%, 94% ee, determined by chiral HPLC: 150 mm Chiralcell OD-3 
(Ø 4.6 mm), n-heptane/2-propanol 99:1, 1.0 ml/min, 6.5 MPa, 298 K: Rt(minor enantiomer) = 
11.84 min, Rt(major enantiomer) = 12.92 min)). 
[α]
: −0.8 (c = 1, CHCl3). 
1H NMR (400 MHz, CDCl3): δ = 4.35 – 4.29 (m, 1H), 3.42 (t, J = 
6.9 Hz, 2H), 1.85 (d, J = 2.1 Hz, 3H), 1.89 – 1.80 (m, 2H), 1.72 – 1.60 (m, 3H), 1.47 – 1.36 (m, 
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4H), 1.35 – 1.25 (m, 8H) ppm. 13C NMR (100 MHz, CDCl3): δ = 81.1, 80.6, 62.9, 38.3, 34.2, 
33.0, 29.6, 29.5, 29.4, 28.9, 28.3, 25.3, 3.7 ppm. IR (film): ṽ = 3434, 2924, 2854, 2219, 1734, 
1674, 1454, 1441, 1352, 1323, 1260, 1200, 1135, 1119, 1076, 1022, 988, 904, 868, 811, 723, 
543, 428 cm−1. MS (GC-MS): m/z (%) = 192 (1), 190 (1), 150 (1), 148 (1), 137 (1), 135 (2), 133 
(1), 125 (1), 123 (1), 121 (2), 119 (1), 112 (1), 111 (3), 110 (2), 109 (4), 107 (4), 97 (9), 93 (6), 
84 (23), 83 (6), 82 (9), 81 (14), 79 (10), 71 (6), 70 (8), 69 (100), 68 (15), 67 (16), 66 (5), 57 (8), 
55 (19), 43 (7), 41 (16), 40 (5), 39 (8); HRMS (ESI(pos)): m/z calcd. for [C13H23BrO+Na]
+: 
297.0825, found 297.0826. 
 
(R)-((13-Bromotridec-2-yn-4-yl)oxy)(tert-butyl)dimethylsilane (160) 
TBSCl (2.86 g, 19.0 mmol) was added to a solution 
of alcohol 159 (3.60 g, 13.1 mmol) and imidazole 
(2.66 g, 39.0 mmol) in CH2Cl2 (100 mL) at 0 °C. The 
resulting mixture was stirred at ambient 
temperature for 2 h. The reaction was quenched with aq. sat. NH4Cl (30 mL) and the 
aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined extracts were dried over 
MgSO4, the solvent was evaporated, and the residue was purified by flash chromatography 
(silica, hexanes/ethyl acetate, 50/1) to give the title compound as a colorless oil (4.57 g, 
90%). 
[α]
: +24.5(c = 1, CHCl3). 
1H NMR (400 MHz, CDCl3): δ = 4.36 – 4.28 (m, 1H), 3.40 (t, J = 6.9 
Hz, 2H), 1.82 (d, J = 2.1 Hz, 3H), 1.88 – 1.81 (m, 2H), 1.65 – 1.55 (m, 2H), 1.46 – 1.34 (m, 4H), 
1.33 – 1.24 (m, 8H), 0.90 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): 
δ = 81.3, 79.9, 63.3, 39.1, 34.2, 33.0, 29.6, 29.5, 29.4, 28.9, 28.3, 26.0, 25.4, 18.4, 3.7, −4.3, 
−4.9 ppm. IR (film): ṽ = 2927, 2855, 2238, 1716, 1586, 1463, 1389, 1360, 1341, 1250, 1154, 
1075, 1005, 939, 834, 775, 723, 666, 647, 563 cm−1. MS (EI): m/z (%) = 389 (2), 387 (1), 375 
(4), 373 (4), 334 (11), 333 (53), 332 (11), 331 (50), 207 (11), 205 (10), 184 (10), 183 (58), 177 
(28), 137 (15), 135 (36), 127 (32), 123 (10), 121 (44), 109 (23), 107 (53), 98 (11), 97 (100), 95 
(68), 93 (55), 83 (15), 81 (54), 79 (23), 75 (65), 67 (23), 55 (20); HRMS (ESI(pos)): m/z calcd. 
for [C19H37BrOSi+Na]
+: 411.1691, found 411.1689. 
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(2S,13R)-13-(tert-Butyldimethylsilyloxy)hexadec-14-yn-2-ol (151) 
A mixture of magnesium turnings (250 mg, 
10.3 mmol) and I2 (20 mg) was vigorously 
stirred for 14 h at 90 °C. THF (5 mL) was added 
and the mixture was stirred at reflux 
temperature for 1 h before a solution of bromide 160 (2.00 g, 5.14 mmol) in THF (2 mL) was 
added over 2 min. The mixture was stirred at reflux temperature for 1 h before it was cooled 
to −40 °C and Li2CuCl4 (0.1 M in THF, 2 mL, 0.2 mmol, 4 mol%) was added. (S)-Propylene 
oxide (407 mg, 7.00 mmol, 490 µL) was added over 5 min and the reaction mixture was 
allowed to reach room temperature over 14 h. The reaction was quenched by adding aq. sat. 
NH4Cl (5 mL). The aqueous layer was extracted with ethyl acetate (3 × 50 mL). The combined 
extracts were dried over MgSO4, the solvent was evaporated and the residue was purified by 
flash chromatography (silica, hexanes/ethyl acetate, 50/1 to 20/1) to give the title 
compound as a colorless oil (1.35 g, 71%). 
[α]
: +32.6 (c = 1, CHCl3). 
1H NMR (400 MHz, CDCl3): δ = 4.32 – 4.25 (m, 1H), 3.84 – 3.74 (m, 
1H), 1.82 (d, J = 2.1 Hz, 3H), 1.65 – 1.55 (m, 2H), 1.49 – 1.33 (m, 5H), 1.32 – 1.23 (m, 14H), 
1.18 (d, J = 6.2 Hz, 3H), 0.90 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): 
δ = 81.3, 79.9, 68.4, 63.4, 39.5, 39.1, 29.8, 29.7, 29.4, 26.0, 26.0, 25.9, 25.4, 23.6, 18.5, 3.7, 
−4.3, −4.9 ppm. IR (film): ṽ = 3355, 2925, 2854, 1744, 1463, 1407, 1389, 1361, 1341, 1250, 
1083, 1005, 939, 834, 775, 721, 666, 559 cm−1. MS (EI): m/z (%) = 312 (11), 311 (43), 272 
(19), 271 (88), 219 (22), 184 (12), 183 (75), 163 (10), 159 (10), 153 (21), 149 (19), 145 (15), 
143 (26), 137 (14), 135 831), 127 (16), 123 (35), 121 (25), 115 (17), 109 (68), 107 (29), 105 
(12), 97 (76), 95 (93), 93 (36), 83 (33), 81 (68), 79 (17), 75 (100), 73 (46), 67 (32), 57 (11), 55 
(25), 45 (12); HRMS (ESI(pos)): m/z calcd. for [C22H44O2Si+Na]
+: 391.3000, found 391.3003. 
7.5.2 Synthesis of Acid Fragment 152 
Ethyl-(E)-hex-2-en-4-ynoate (156) 
[Pd(MeCN)2]Cl2 (60.8 mg, 210 µmol, 4 mol%) was added to a solution 
of ethyl-(E)-3-iodoacrylate[136] (1.20 g, 5.00 mmol) and tributyl(prop-
1-yn-1-yl)stannane (1.71 g, 5.20 mmol) in DMF (10 mL). The mixture 
was stirred at room temperature for 14 h. Aq. KF (20 mL, 0.5 M) and ethyl acetate (20 mL) 
were added to the mixture and stirring was continued for 2 h. The mixture was filtrated and 
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the aqueous layer was extracted with ethyl acetate (3 × 30 mL). The combined extracts were 
dried over MgSO4, the solvent was evaporated, and the residue was purified by flash 
chromatography (silica, hexanes/ethyl acetate, 50/1 to 20/1) to give the title compound  as a 
colorless oil (630 mg, 91%).  
1H NMR (400 MHz, CDCl3): δ = 6.72 (dq, J = 15.8, 2.5 Hz, 1H), 6.13 (dd, J = 15.8, 0.6 Hz, 1H), 
4.20 (q, J = 7.1 Hz, 2H), 2.02 (dd, J = 2.5, 0.6 Hz, 3H), 1.29 (t, J = 7.1 Hz, 3H) ppm. 13C NMR 
(100 MHz, CDCl3): δ = 166.3, 129.4, 126.2, 96.3, 77.2, 60.8, 14.3, 4.9 ppm; MS (EI): m/z (%) = 
138 (19), 110 (27), 95 (12), 93 (100), 82 (14), 66 (10), 65 (41), 63 (14), 39 (24); HRMS 
(ESI(pos)): m/z calcd. for [C8H10O2+Na]
+: 161.0575, found 161.0573. 
The spectroscopic data (1H NMR) is in agreement with the literature.[137] 
 
(E)-Hex-2-en-4-ynoic acid (152) 
Ester 156 (950 mg, 6.88 mmol) was added to a suspension of LiOH 
(479 mg, 20.0 mmol) in a mixture of THF (10 mL), water (10 mL), and 
ethanol (2 mL). The resulting mixture was stirred for 1 h at room 
temperature. The reaction was quenched with aq. sat. NH4Cl (10 mL).The pH of the aqueous 
layer was adjusted to 2 by addition of 2 M HCl. The aqueous layer was extracted with ethyl 
acetate (3 × 50 mL). The combined extracts were dried over MgSO4 and the solvent was 
evaporated to give the title compound as a colorless solid (690 mg, 91%).  
M.p. = 175 − 177 °C. 1H NMR (400 MHz, CDCl3): δ = 11.92 (bs, 1H), 6.82 (dq, J = 15.8, 2.5 Hz, 
1H), 6.14 (d, J = 15.8 Hz, 1H), 2.05 (d, J = 2.5 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ = 
171.7, 129.0, 128.6, 98.6, 77.1, 5.1 ppm. IR (film): ṽ = 2925, 2582, 2216, 1674, 1614, 1452, 
1421, 1310, 1279, 1210, 1172, 1033, 962, 921, 865, 677, 539, 422 cm−1; MS (EI): m/z (%) = 
110 (100), 93 (12), 82 (40), 81 (13), 65 (26), 63 (16), 39 (36); HRMS (ESI(neg)): m/z calcd. for 
[C6H5O2]
−: 109.0295, found 109.0295. 
7.5.3 Completion of the Formal Total Synthesis 
(2S,13R)-13-((tert-Butyldimethylsilyl)oxy)hexadec-14-yn-2-yl-(E)-hex-2-en-4-ynoate (150) 
Alcohol 151 (1.50 g, 4.07 mmol) and DCC 
(887 mg, 4.30 mmol) were successively added to 
a solution of acid 152 (473 mg, 4.07 mmol) in 
CH2Cl2 (10 mL) at 0 °C. DMAP (10 mg, 
OH
O
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0.82 mmol) was added and the resulting mixture was stirred for 2 h at this temperature. The 
mixture was filtered through a plug of silica, which was carefully rinsed with CH2Cl2. Aq. sat. 
NH4Cl (5 mL) was added to the filtrate and the aqueous layer was extracted with CH2Cl2 (2 × 
20 mL). The combined extracts were dried over MgSO4, the solvent was evaporated, and the 
residue was purified by flash chromatography (silica, hexanes/ethyl acetate, 100/1 to 50/1) 
to give the title compound as a colorless oil (1.75 g, 93%). 
[α]
: +35.9 (c = 1, CHCl3). 
1H NMR (400 MHz, CDCl3): δ = 6.71 (dq, J = 15.8, 2.4 Hz, 1H), 6.12 
(d, J = 15.8 Hz, 1H), 5.00 – 4.90 (m, 1H), 4.32 – 4.25 (m, 1H), 2.02 (d, J = 2.4 Hz, 3H), 1.81 (d, 
J = 2.1 Hz, 3H), 1.66 – 1.54 (m, 3H), 1.54 – 1.24 (m, 17H), 1.23 (d, J = 6.3 Hz, 3H), 0.90 (s, 9H), 
0.11 (s, 3H), 0.09 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ = 166.0, 130.1, 125.9, 96.1, 81.3, 
79.9, 77.3, 71.6, 63.4, 39.1, 36.1, 29.70, 29.66, 29.59, 29.4, 26.0, 25.5, 25.4, 20.1, 18.4, 4.9, 
3.7, −4.4, −4.9 ppm. IR (film): ṽ = 2926, 2854, 2222, 2120, 1712, 1463, 1359, 1300, 1256, 
1180, 1164, 1078, 1005, 961, 835, 776, 720, 667, 516 cm−1. MS (EI): m/z (%) = 404 (2), 403 
(7), 209 (3), 187 (3), 186 (7), 185 (53), 183 (10), 169 (6), 168 (14), 167 (100), 153 (3), 135 (2), 
127 (3), 125 (2), 123 (3), 121 (2), 111 (3), 109 (5), 107 (2), 99 (2), 97 (12), 95 (8), 93 (16), 83 
(2), 81 (5), 79 (2), 75 (8), 73 (7), 69 (3), 67 (3), 55 (4); HRMS (ESI(pos)): m/z calcd. for 
[C28H48O3Si+Na]
+: 483.3266, found 483.3265.  
 
(7R,18S,E)-7-((tert-Butyldimethylsilyl)oxy)-18-methyloxacyclooctadec-3-en-5-yn-2-one 
(149a). 
Diyne 150 (500 mg, 1.09 mmol) was added to a suspension of MS 
5 Å (8 g) in toluene (800 mL) and the mixture was stirred for 1 h at 
room temperature. The mixture was heated to 110 °C and a 
solution of complex 28 (110 mg, 106 µmol, 10 mol%) in toluene 
(2 mL) was added over 2 min. The mixture was stirred for 10 min at 110 °C before it was 
filtered through a plug of Celite®, which was carefully rinsed with ethyl acetate (50 mL). The 
solvent was evaporated and the residue was purified by flash chromatography (silica, 
hexanes/ethyl acetate, 100/1 to 50/1) to give the title compound as a colorless oil (400 mg, 
91%). The product contained ca. 8% of the dimeric macrocycle 149b and was used without 
further purification for the next step.  
1H NMR (400 MHz, CDCl3): δ = 6.75 (dd, J = 15.8, 2.1 Hz, 1H), 6.21 (d, J = 15.8 Hz, 1H), 5.06 – 
4.93 (m, 1H), 4.54 (ddd, J = 7.5, 4.8, 2.1 Hz, 1H), 1.77 – 1.62 (m, 3H), 1.61 – 1.17 (m, 17H), 
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1.23 (d, J = 6.3 Hz, 3H), 0.92 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): 
δ = 165.5, 131.8, 124.9, 101.2, 82.1, 72.8, 63.6, 37.6, 34.2, 29.9, 29.8, 29.5, 29.2, 28.6, 25.9, 
25.8, 25.5, 23.8, 20.3, −4.5, −4.8 ppm. IR (film): ṽ = 2927, 2855, 1715, 1619, 1462, 1360, 
1299, 1254, 1178, 1153, 1125, 1083, 1006, 982, 960, 940, 835, 777, 717, 669 cm−1. MS 
(ESI(pos)) m/z (%) = 429.3 (100 [M+Na]+); HRMS (ESI(pos)): m/z calcd. for [C24H42O3Si+Na]
+: 
429.2799, found 429.2795. 
 
(7R,18S,E)-7-Hydroxy-18-methyloxacyclooctadec-3-en-5-yn-2-one (162a) 
TBAF (1.0 M in THF, 2.00 mL, 2.00 mmol) was added to a solution 
of macrocycle 149a (400 mg, 980 µmol) in THF (5 mL) at 0 °C. The 
mixture was warmed to room temperature and stirred for 2 h 
before the reaction was quenched with aq. sat. NH4Cl (1 mL) and 
water (1 mL). The aqueous layer was extracted with ethyl acetate (3 × 30 mL). The combined 
extracts were dried over MgSO4, the solvent was evaporated, and the residue was purified 
by flash chromatography (silica, hexanes/ethyl acetate, 20/1 to 4/1) to give the title 
compound as a colorless solid (243 mg, 85%).  
M.p. = 62 − 63 °C. [α]
: +61.1 (c = 1, CHCl3). 
1H NMR (400 MHz, CDCl3): δ = 6.75 (dd, J = 15.9, 
2.1 Hz, 1H), 6.24 (d, J = 15.9 Hz, 1H), 5.04 – 4.94 (m, 1H), 4.61 – 4.54 (m, 1H), 2.05 – 1.16 (m, 
24 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 165.3, 132.3, 124.4, 99.9, 82.8, 72.9, 63.1, 36.6, 
34.2, 29.8, 29.7, 29.5, 29.2, 29.1, 28.5, 25.4, 23.9, 20.2 ppm. IR (film): ṽ = 3266, 2922, 2850, 
2215, 1702, 1622, 1611, 1460, 1378, 1351, 1302, 1271, 1188, 1155, 1128, 1107, 1077, 1021, 
979, 871, 755, 719, 585, 499, 410 cm−1. MS (ESI(pos)): m/z (%) = 291.2 (100 [M+Na]+); HRMS 
(ESI(pos)): m/z calcd. for [C18H28O3]
−: 291.1668, found 291.1966. 
 
(3E,5E,7R,18S)-7-Hydroxy-18-methyl-6-(tributylstannyl)oxacyclooctadeca-3,5-dien-2-one 
(163a) 
A solution of tributyltin hydride (163 mg, 0.56 mmol) in CH2Cl2 
(1 mL) was added over 5 min to a stirred solution of enyne 162a 
(150 mg, 0.51 mmol) and [Cp*RuCl4] (10 mg, 9.0 µmol, 2 mol%) in 
CH2Cl2 (2.5 mL) at room temperature. The resulting mixture was 
stirred for 2 h at room temperature before all volatile materials were evaporated. 
Purification of the residue by flash chromatography (silica, hexanes/ethyl acetate, 20/1 to 
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10/1) afforded the title compound as a pale yellow oil (196 mg, 66%). A second isomer 163b 
was isolated (8 mg, 3%). 
[α]
: −31.7 (c = 1, CHCl3). 
1H NMR (400 MHz, CDCl3) δ = 7.25 (dd, J = 15.1, 11.5 Hz, 1H), 6.81 
(d, J = 11.6 Hz, JSn–H = 54.8 Hz, 1H), 5.78 (d, J = 15.0 Hz, 1H), 5.05 (dqd, J = 9.3, 6.3, 2.9 Hz, 1H), 
4.31 (dt, J = 9.3, 3.4 Hz, JSn–H = 26.1 Hz, 1H), 1.71 – 1.58 (m, 2H), 1.54 – 1.38 (m, 9H), 1.35 – 
1.06 (m, 22H), 1.05 – 0.91 (m, 9H), 0.84 (t, J = 7.3 Hz, 9H) ppm. 13C NMR (100 MHz, CDCl3): 
δ = 167.7, 166.8, 144.5, 137.0, 123.2, 80.3, 71.3, 36.1, 35.2, 29.9, 29.8, 29.5, 29.28, 29.25, 
29.01, 28.96, 27.6, 25.2, 23.9, 20.6, 13.8, 11.8 ppm. 119Sn NMR (186 MHz, CDCl3) δ = 
−56.0 ppm. IR (film): ṽ = 3464, 2953, 2922, 2852, 1707, 1688, 1619, 1565, 1460, 1376, 1354, 
1258, 1186, 1125, 1072, 1019, 976, 903, 863, 757, 716, 666, 595, 536, 504 cm−1; MS (EI): m/z 
(%) = 531 (15), 529 (16), 528 (25), 527 (89), 526 (40), 525 (68), 524 (30), 523 (37), 513 (17), 
511 (18), 510 (28), 509 (100), 508 (44), 507 (75), 506 (33), 505 (40), 251 (11), 179 (12), 177 
(19), 175 (15); HRMS (ESI(pos)): m/z calcd. for [C30H56O3Sn+H]
+: 585.3329, found 585.3324. 
 
Stereoisomer 163b: 
1H NMR (400 MHz, CDCl3) δ = 7.51 (ddt, J = 15.2, 11.0, 3.3 Hz, 
1H), 6.33 (dd, J = 11.2, 1.6 Hz, JSn–H = 30.8 Hz, 1H), 5.81 (d, J = 
15.0 Hz, 1H), 5.18 (ddp, J = 9.5, 6.3, 3.1 Hz, 1H), 5.03 (t, J = 7.3 
Hz, JSn–H = 32.0 Hz, 1H), 1.65 – 1.11 (m, 37H), 0.99 – 0.92 (m, 
5H), 0.89 (t, J = 7.3 Hz, 9H) ppm. 13C NMR (100 MHz, CDCl3) δ = 167.5, 166.5, 138.7, 134.6, 
121.2, 72.2, 69.6, 37.8, 36.0, 29.8, 29.2, 28.7, 28.4, 27.7, 27.6, 26.6, 25.3, 24.2, 21.0, 13.9, 
10.9 ppm. 119Sn NMR (186 MHz, CDCl3) δ = −40.2 ppm. IR (film): ṽ = 3500, 2953, 2923, 2854, 
1710, 1691, 1569, 1460, 1419, 1376, 1357, 1337, 1268, 1186, 1125, 1072, 1021, 979, 893, 
876, 845, 804, 769, 722, 665, 596, 548, 505, 435, 408 cm−1. HRMS (ESI(pos)): m/z calcd. for 
[C30H56O3Sn+Na]
+: 607.3148, found 607.3143. 
 
(3E,5E,7R,18S)-7-Hydroxy-18-methyloxacyclooctadeca-3,5-dien-2-one (132) 
CuTC (65 mg, 340 µmol) was added to a solution of stannane 
163a (100 mg, 171 µmol) in DMF (2 mL). The mixture was stirred 
for 1 h at room temperature before H2O (5 mL) was added. The 
aqueous layer was extracted with ethyl acetate (3 × 10 mL). The 
combined extracts were dried over MgSO4, the solvent was evaporated, and the residue was 
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purified by flash chromatography (silica, hexanes/ethyl acetate, 10/1 to 4/1) to give the title 
compound as a colorless oil (42 mg, 83%). 
[α]
: +14.2 (c = 1, CHCl3). 
1H NMR (400 MHz, CDCl3): δ = 7.24 (dd, J = 15.4, 10.9 Hz, 1H), 6.32 
(dd, J = 15.2, 10.9 Hz, 1H), 6.07 (dd, J = 15.2, 7.9 Hz, 1H), 5.85 (d, J = 15.4 Hz, 1H), 5.02 (dqd, J 
= 9.4, 6.3, 3.2 Hz, 1H), 4.27 (td, J = 8.3, 3.7 Hz, 1H), 1.82 – 1.73 (m, 1H), 1.69 – 1.54 (m , 4H), 
1.50 – 1.37 (m, 2H), 1.28 (d, J = 6.3 Hz, 3H), 1.33 – 1.12 (m, 14H) ppm. 13C NMR (100 MHz, 
CDCl3): δ = 166.6, 145.1, 143.6, 128.4, 122.6, 73.3, 71.5, 35.5, 35.4, 29.7, 29.14, 29.10, 29.05, 
28.8, 24.8, 23.4, 20.6 ppm. IR (film): ṽ = 3412, 2925, 2854, 1701, 1644, 1618, 1460, 1355, 
1296, 1260, 1178, 1124, 999, 910, 883, 730, 647, 411 cm−1. MS (EI): m/z (%) = 294 (40), 276 
(10), 221 (17), 195 (32), 191 (11), 177 (27), 163 (13), 150 (14), 149 (17), 142 (17), 137 (14), 
135 (22), 128 (11), 127 (10), 125 (12), 124 (23), 123 (14), 121 (28), 111 (21), 110 (31), 109 
(30), 108 (14), 107 (20), 99 (100), 98 (12), 97 (40), 96 (26), 95 (51), 94 (15), 93 (16), 91 (11), 
84 (11), 83 (37), 82 (54), 81 (64), 80 (13), 79 (21), 71 (14), 69 (45), 68 (12), 67 (32), 57 (20), 55 
(71), 54 (12), 53 (18), 43 (27), 41 (40), 29 (10); HRMS (ESI(pos)): m/z calcd. for 
[C18H30O3+Na]
+: 317.2087, found 317.2087. 
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7.6 Peptide Reactions 
General 
The peptides utilized in this work were synthesized by P. Cromm according to standard 
Fmoc-chemistry for SPPS using HCTU (O-(6-Chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyl-
uronium hexafluorophosphate) and COMU (1-[(1-(Cyano-2-ethoxy-2-oxoethyliden-
aminooxy)-dimethylaminomorpholino)]-uroniumhexafluorphosphate) as coupling reagents. 
The resin bound peptides were dried prior to use in toluene over MS 5 Å for four days while 
exchanging the solvent daily. The resin was stored in a Schlenk tube under argon. The 
reactions were generally done with 5 mg of the resin bound peptides. The products were 
cleaved from the solid support and analyzed by analytical LC-MS. 
 
Ring Closing Alkyne Metathesis 
The resin was suspended in toluene (0.15 mL) together with MS (5 Å, sticks). A stock solution 
of the catalyst 28 (2 mg/mL, 1.5 equiv) in toluene was added and the reaction mixture was 
stirred at 40 °C for 3 h. The resin was filtered off, washed with toluene (3×), CH2Cl2 (3×), and 
dried to constant weight. 
 
Gold Catalyzed Hydratisation 
The resin (5 mg, 15.9 µmol/g, 0.08 µmmol of peptide 182b) was suspended in MeOH 
(0.1 mL). A solution of 1,3-bis-(2,6-di-isopropylphenyl)-imidazol-2-yliden-gold(I) (186) 
(15 equiv) in toluene (0.2 mL) was added and the reaction mixture was stirred at 60 °C for 
2 h. Complex 186 (7 equiv) was added and stirring was continued for 14 h at 60 °C. Complex 
186 (7 equiv) was added and stirring was continued for 2 h at 60 °C The resin was filtered off, 
washed with toluene (3×), CH2Cl2 (3×), and dried to constant weight. 
 
Click Chemistry 
The resin was suspended in toluene (0.3 mL) before chloro-(1,5-cyclooctadiene)-
(pentamethylcylopentadienyl)-ruthenium(II) (190) (1 mg/mL in toluene, 3 equiv) was added. 
The azide was introduced (4-20 equiv) and the reaction mixture was stirred for 14 h at room 
temperature. The residue was filtered off, washed with CH2Cl2 (2×), MeCN/H2O (1×), MeCN 
(1×), CH2Cl2 (3×), and dried to constant weight. 
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Cleavage off the Resin 
The dry resin was treated with a mixture of TFA/TIPSH/H2O (95/2.5/2.5, v/v/v, 100 µL) for 
1 h at room temperature. The solvent was evaporated and the crude material was 
suspended in Et2O. The mixture was cooled with liquid N2 until it froze before it was 
centrifuged (2 min, 10.000 rpm). The supernatant was removed and the crude product was 
dissolved in H2O/MeCN (1/1, v/v, 0.5 mL).  
Table 8.1: Overview over peptides synthesized in this work. 
Entry Sequence Modification 
HPLC 
(tR, [min])
 
HRMS 
Calc. 
MS 
(found) 
1 L Y2 I F L Y1 V Ketone 182c 2.88[a] 1106.6542 1106.85 [m+H]+ 
2 L Y2 I F L Y1 V Benzyl 182d 2.63[a] 1221.7076 1221.60 [m+H]+ 
3 L Y2 I F L Y1 V Sugar 182e 5.86[a] 1433.7608 1433.65 [m+H]+ 
4 L Y2 I F L Y1 V PEG 182f 3.70[a] 1343.7631 1343.75 [m+Na]+ 
5 L Y2 I F L Y1 V Biotin 182g 4.84[a] 1532.8591 1532.60 [m+H]+ 
6 C M W H Y2 A D Q Y1 F R S H L K RCAM 176b 11.15[b] 1071.5137 1071.52 [m+2H]2+ 
7 C M W H Y2 A D Q Y1 F R S H L K Ketone 176c 10.09[b] 1080.5076 1080.40 [m+2H]2+ 
 
[a] 50 mm Zorbax Eclipse Plus C18, 1.8 μm, MeCN/H2O, 0.1% TFA = 75/25, 0.5 ml/min, 308 K, 109 bar 
[b] 50 mm Eclipse Plus C18, 1.8 μm, A: Wasser + 0.1% TFA, B: MeCN + 0.1% TFA, 10% B in 20 min to 80%    
      B, 0.5 ml/min, 308 K, 221 bar 
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8 Appendix 
8.1 List of Abbreviations 
Å Ångström, 1 Å = 10-10 m 
AAC Azide-alkyne cycloaddition 
Ac Acetyl  
ACN Acetonitrile 
ACM Alkyne cross metathesis 
Ar  Aromatic group  
aq. Aqueous 
Bn  Benzyl  
bp Boiling point 
br  Broad  
Bu  Butyl  
Bz  Benzoyl  
calc. Calculated  
cat.  Catalytic  
CI  Chemical ionization  
COD 1,5-Cyclooctadiene 
conc. Concentrated 
conv. Conversion 
COSY Correlation spectroscopy  
δ Chemical shift 
Δ Reflux temperature  
d Day 
d  Doublet  
Da Dalton 1 Da = 1.660539040(20)×10−27 kg 
DAIB (2S)-(−)-exo-(Dimethylamino)isoborneol 
DBU 1,8-Diazabicycloundec-7-ene 
DCC  N,N´-Dicyclohexylcarbodiimide  
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
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DMAP  4-(Dimethylamino)-pyridine  
DME Dimethoxyethane 
DMF  N,N-Dimethylformamide  
DMSO  Dimethyl sulfoxide  
dr  Diastereomeric ratio  
ee  Enantiomeric excess  
EI  Electron ionization  
ent  Enantiomer  
ESI  Electronspray ionization  
Et  Ethyl  
equiv  Equivalents  
eV Electronvolt 
GC  Gas chromatography  
h hour 
hex Hexyl 
HMPA Hexamethylphosphoramide 
HPLC  High pressure liquid chromatography  
HRMS  High resolution mass spectroscopy  
Hz Hertz, 1 Hz = 1 s−1 
i iso 
IPr 1,3-bis(2,6-diisopropylphenyl)-imidazolium 
IR  Infrared spectroscopy  
J Coupling constant 
LICA Lithium N-isopropylcyclohexylamide 
Lit. Literature 
m Meta 
m  Multiplet  
M Molar: mol·l-1 
m/z Mass per charge 
Me  Methyl  
MOM  Methoxymethyl  
Mp.  Melting point  
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MS  Mass spectrometry  
MS  Molecular sieves  
MTBE  Methyl t-butyl ether  
n Normal 
NBS  N-Bromosuccinimide  
n-BuLi n-Butyllithium 
NMI  1-Methylimidazole  
NMO  N-Methylmorpholine-N-oxide  
NMR  Nuclear magnetic resonance  
NOE Nuclear Overhauser effect  
n.r. No reaction 
p  Para  
p-TsOH p-Toluenesulfonic acid 
Pg Protecting group 
Ph  Phenyl  
phen 1,10-Phenanthroline 
ppm  Parts per million  
PPTS Pyridinium p-toluenesulfonate 
py Pyridine 
q  Quartet  
quant.  Quantitative  
R  Organic substituent  
rac  Racemic  
RCAM  Ring closing alkyne metathesis  
RCM  Ring closing olefin metathesis  
rt Ambient temperature  
s Singlet  
sat. Saturated 
sm Starting material 
SPPS Solid phase peptide synthesis 
t Tert 
t  Triplet  
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T Temperature 
Tab. Table 
TBAF  Tetra-n-butylammoniumfluoride  
TBS  tert-Butyldimethylsilyl  
t-BuLi tert-Butyllithium 
TC Thiophene-2-carboxylate 
TEMPO  (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl 
tert Tertiary 
TES  Triethylsilyl  
TFA  Trifluoroacetic acid  
THF  Tetrahydrofuran  
THP Tetrahydropyran 
TLC  Thin layer chromatography  
TMEDA  Tetramethylethylenediamine  
TMS  Trimethylsilyl  
Ts  Tosyl  
  
Amino acid single-letter codes 
A Alanine 
R Arginine 
N Asparagine 
D Aspartic acid 
C Cysteine 
Q Glutamine 
E Glutamic acid 
G Glycine 
H Histidine 
I Isoleucine 
L Leucine 
K Lysine 
M Methionine 
F Phenylalanine 
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P Proline 
S Serine 
T Threonine 
W Tryptophan 
Y Tyrosine 
V Valine 
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8.2 Crystallographic Data 
8.2.1 Crystallographic Data of 97c 
 
Identification code  9856 
Empirical formula  C57 H66 O3 Si3 
Color  colorless 
Formula weight  883.36 g · mol─1   
Temperature  180 K 
Wavelength  0.71073 Å 
Crystal system  MONOCLINIC 
Space group  P21/n, (no. 14)  
Unit cell dimensions a = 15.175(4) Å α = 90°. 
 b = 19.071(5) Å β = 95.910(5)°. 
 c = 22.799(6) Å γ = 90°. 
Volume 6563(3) Å3 
Z 4 
Density (calculated) 0.894 mg · m─3 
Absorption coefficient 0.105 mm─1 
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F(000) 1896 e 
Crystal size 0.187 x 0.110 x 0.067 mm3 
θ range for data collection 2.728 to 26.372°. 
Index ranges ─18 ≤ h ≤ 18, ─23≤ k ≤ 23, ─28 ≤ l ≤ 28 
Reflections collected 133780 
Independent reflections 13393 [Rint = 0.1537] 
Reflections with I>2σ(I) 6269 
Completeness to θ = 25.242° 99.9%  
Absorption correction Gaussian 
Max. and min. transmission 0.99 and 0.97 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 13393 / 0 / 574 
Goodness-of-fit on F2 0.999 
Final R indices [I>2σ(I)] R1 = 0.0599 wR
2 = 0.1462 
R indices (all data) R1 = 0.1475 wR
2 = 0.1947 
Largest diff. peak and hole 0.3 and ─0.3 e · Å─3 
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8.2.2 Crystallographic Data of 100c 
 
Identification code  9064_SCS-SB-263_200_K 
Empirical formula  C21 H30 
Color  colorless 
Formula weight  282.45 g · mol─1   
Temperature  200 K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group  P 21/n,  (no. 14)  
Unit cell dimensions a = 8.9265(16) Å α = 90°. 
 b = 16.393(3) Å β = 106.763(3)°. 
 c = 13.113(2) Å γ = 90°. 
Volume 1837.3(6) Å3 
Z 4 
Density (calculated) 1.021 mg · m─3 
Absorption coefficient 0.057 mm─1 
F(000) 624 e 
Crystal size 0.443 x 0.240 x 0.040 mm3 
θ range for data collection 2.043 to 30.697°. 
Index ranges ─12 h ≤ 12, ─23 ≤  k ≤ 23, ─18≤ l ≤ 18 
Reflections collected 52468 
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Independent reflections 5643 [Rint = 0.0449] 
Reflections with I>2σ(I) 3824 
Completeness to θ = 25.242° 99.9%  
Absorption correction Gaussian 
Max. and min. transmission 0.99757 and 0.97850 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5643 / 0 / 217 
Goodness-of-fit on F2 1.030 
Final R indices [I>2σ(I)] R1 = 0.0554 wR
2 = 0.1502 
R indices (all data) R1 = 0.0859 wR
2 = 0.1716 
Extinction coefficient 0 
Largest diff. peak and hole              0.341 and ─0.222 e · Å─3 
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8.2.3 Crystallographic Data of 105b 
 
Identification code  8687 
Empirical formula  C46 H57 Cl2 Mo N O4 
Color  orange 
Formula weight  854.76 g · mol─1  
Temperature  100 K 
Wavelength  0.71073 Å 
Crystal system  TRICLINIC 
Space group  P1¯, (no. 2)  
Unit cell dimensions a = 12.1447(11) Å α = 60.091(6)°. 
 b = 21.1635(14) Å β = 88.852(8)°. 
 c = 21.1721(18) Å γ = 86.334(7)°. 
Volume 4706.9(7) Å3 
Z 4 
Density (calculated) 1.206 mg · m─3 
Absorption coefficient 0.431 mm─1 
F(000) 1792 e 
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Crystal size 0.18 x 0.10 x 0.02 mm3 
θ range for data collection 2.609 to 30.036°. 
Index ranges ─16 ≤ h ≤ 17, ─29≤ k ≤ 29, ─27 ≤ l ≤ 29 
Reflections collected 69629 
Independent reflections 27332 [Rint = 0.0700] 
Reflections with I>2σ(I) 16106 
Completeness to θ = 25.242° 99.7%  
Absorption correction Gaussian 
Max. and min. transmission 0.99 and 0.95 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 27332 / 0 / 1000 
Goodness-of-fit on F2 1.045 
Final R indices [I>2σ(I)] R1 = 0.0779 wR
2 = 0.1882 
R indices (all data) R1 = 0.1347 wR
2 = 0.2121 
Largest diff. peak and hole 1.2 and ─1.1 e · Å─3 
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